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ABSTRACT 
Lung cancer is the leading cause of cancer-related deaths and has one of the lowest overall survival 
rates. The high mortality rate can be attributed to the fact that a majority of lung cancer patients are 
diagnosed with advanced disease. Low-dose Computed Tomography (LDCT) screening of high-risk 
individuals is emerging as a useful tool for the early detection of lung cancer. Subsequent 
bronchoscopic sampling of the suspect site is required for a tissue-based diagnosis. Almost 40% of 
patients that are unsuitable for surgical resection are diagnosed solely on bronchoscopy-derived 
cytology specimens without additional biopsy material. These formalin-fixed specimens need to 
provide sufficient amounts of material to confirm diagnosis, subtype and stage as well as enable 
molecular testing to guide treatment-based decisions. Effective treatments options for patients with 
metastatic disease are limited. However, the recent development of targeted therapies against 
specific genetic alterations are improving clinical outcomes in a subset of patients with advanced lung 
adenocarcinoma. Immunotherapies such as the Programmed Death 1 (PD-1)/Programmed Death 
Ligand 1 (PD-L1) inhibitors are also improving progression-free survival in non-small cell lung cancer 
(NSCLC) patients irrespective of the subtype.  
PD-L1/PD1 blockade boosts T cell activation and killing of tumour cells. Scoring of PD-L1 
immunohistochemical staining is the only biomarker used to identify patients that are more likely to 
benefit from immunotherapies as first line (>50 % PD-L1 tumour cell staining) or second line treatment 
(>1% PD-L1 tumour cell staining). Whilst immunotherapy has improved survival rates in NSCLC 
patients with elevated PD-L1 expression, this response rate does not exceed 25-30%. Hence 
alternative therapeutic targets are needed to further improve survival rates.  The chronic 
inflammatory environment has been previously identified as enabling tumour development. Patients 
with the chronic obstructive pulmonary disease (COPD) are six times more likely to develop lung 
cancer, yet mechanisms underlying this increased risk have not been fully elucidated. It is known that 
chronic smokers and people with COPD are more likely to develop Squamous cell carcinoma (SCC).  I 
hypothesised that the inflammatory microenvironment is distinct between the major NSCLC subtypes, 
which is driven by smoking history and COPD. This has important implications as strategies that target 
the immune system will be influenced by the function and frequency of immune cells surrounding the 
tumour. 
The role of innate immune cell types including macrophages and neutrophils were investigate using 
retrospectively-collected NSCLC biopsy specimens from resection surgery patients including 
adenocarcinoma (n=48) and squamous cell carcinoma (SCC, n=40). In particular, increased neutrophilic 
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inflammation, observed in both COPD and lung cancer, is a major source of the matrix degrading 
enzyme MMP-9 that contributes to tumour invasion and metastasis. Using RTqPCR profiling of NSCLC 
tumour biopsies and brushings, I simultaneously profiled expression levels of 24 gene transcripts using 
low density TaqManTM arrays from a single small tumour biospecimen. I observed that MMP-9 
expression was highly increased in NSCLC biopsies and its natural inhibitors TIMP2 and TIMP3 were 
significantly decreased. With MMP-9 transcription consistently elevated in early stage malignant 
NSCLC tumours, we demonstrate for the first time the diagnostic potential of the MMP-9:TIMP3 
transcript ratio to discriminate malignant and benign EBUS specimens.  
Next, I developed a novel digital droplet PCR (ddPCR) assay to evaluate the MMP9:TIMP3 ratio as 
ddPCR is a more sensitive and reliable PCR platform that is also suitable for multiplexing targets. This 
allowed for the addition of PD-L1 quantification by ddPCR in the same biospecimen, which revealed 
high concordance between PD-L1 transcription and PD-L1 tumour cell staining, determined by ddPCR 
and immunohistochemistry, respectively. Simultaneous assessment of MMP-9, TIMP3 and PD-L1 
transcripts may have the potential to improve the molecular diagnosis of NSCLC by reducing the time 
and cost associated with identifying suitable candidates for PD-1/PD-L1 inhibitors. Based on our data, 
we proposed an alternative workflow for the preservation of a single-pass EBUS bronchoscopy 
specimen for molecular analysis. This specimen is not only suitable for multiplexing by ddPCR but is 
also highly suitable for mutational analysis, as we detected clinically relevant mutations by performing 
targeted sequencing on the same single cytology specimen. Integration of multiplex ddPCR also 
outperforms RTqPCR in that it requires less starting material to identify malignant tumour biopsies 
with elevated PD-L1 expression and can be used to develop new thresholds or cut-offs for diagnosing 
lung cancer and identify suitable candidates for targeted therapies including immunotherapy. Further 
investigation is warranted in a larger cohort to establish appropriate thresholds and to determine 
whether this approach can be applied to all bronchoscopy-directed specimens. 
Consistent with recent studies, we observed that neutrophils dominate the immune landscape in 
primary NSCLC tumours, especially in SCC. In this study, gene expression analysis of a select panel of 
chemotactic factors suggests that alternative pathways may be involved in driving neutrophilic 
inflammation in each NSCLC subtype. The prognostic potential of the neutrophil-to-macrophage 
(NMR) ratio in patients with early stage SCC was identified. This data demonstrated that a high NMR 
was prognostic of increased survival, to indicate that neutrophils may be protective in early stage SCC, 
but not adenocarcinoma. A limitation of this study is that factors responsible for driving increased 
neutrophilic infiltration in SCC was not yet established. Therefore, further studies are needed to 
evaluate the role of alternative neutrophilic chemotactic factors, including matrikines, in SCC.
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 Lung cancer overview 
Globally, lung cancer is ranked the sixth leading cause of death by the World Health Organisation 3. 
In 2018, lung cancer caused approximately 1.8million deaths, constituting almost 20% of the total 
number of deaths from cancer 4. This number is expected to rise due to the poor five-year survival 
rate of less than 15% 5, which has remained largely unchanged over the last three decades. A 
contributing factor is that a majority of patients still present with an advanced stage of the disease. 
A population-based study of several countries including Australia demonstrated that approximately 
45-60% of patients were diagnosed with stage IV metastatic disease where survival over one year is 
low 6. Impacting prognosis are the significant delays in diagnosis and treatment of lung cancer. 
Patients identified with early stage I-II disease are more likely to survive, with improved survival 
rates of up to 90% 6. However, in Australia it was found that 28% were not staged at the time of 
diagnosis 7. Additionally, 20% of patients did not receive treatment for up to two months following 
diagnosis which can lead to further progression of the disease. The cost of treatment increases with 
disease progression and has contributed to the large economic burden in Australia. Compared to 
other common malignancies including breast and colorectal cancer, lung cancer is associated with 
the largest proportion of patients diagnosed with advanced disease and this has resulted in a 
combined direct and indirect cost of $297.2million on the Australian Health care system 7. One of the 
key initiatives by the Lung Foundation Australia is to improve access to quality diagnostics and care 
for Lung cancer patients, which can only be achieved through the development of better early 
detection methods and targeted therapies 
 Risk Factors 
With tobacco consumption as the major risk factor, lung cancer is regarded as a highly preventable 
disease. A direct link between tobacco consumption and lung cancer incidence was first reported in 
the early 1950s which demonstrated that a greater percentage of heavy smokers developed lung 
cancer in comparison to light- (< 9 smoking pack years) or non-smokers 8. Even today, smoking still 
accounts for approximately 80-90% of lung cancer cases 9. Implementation of successful tobacco 
interventions in several parts of the world have contributed to a decline in lung cancer incidence. 
However, lung cancer rates are expected to rise in countries such as China and Africa, where the 
tobacco epidemic has not yet peaked 10.  
Cigarette smoke is responsible for tumour development because it contains carcinogenic 
components including polycyclic aromatic hydrocarbons and N-nitrosamines 11. These components 
can directly damage DNA leading to microsatellite instability, chromosomal aberrations as well as 
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mutations in important oncogenes and tumour suppressor genes that confer tumour cell growth. 
Direct stimulation of the Lung carcinoma cell line A549 with the PAH benzo[a]pyrene demonstrated 
enhanced cell proliferation and upregulation of genes involved in Epithelial-Mesenchymal transition 
(EMT) which in turn can support tumour invasion 12. Additionally, smoking is a major risk factor for 
COPD, which is a condition associated with abnormal and chronic inflammatory responses 13. COPD 
is characterised by progressive airflow limitation and develops due to persistent inhalation of 
noxious particles and gases such as tobacco smoke. Prolonged exposure to smoke-induced oxidative 
stress damages airway epithelial and endothelial function leading to the dysregulation of normal 
inflammatory processes important for immunity to infection and tissue repair 14. Increased 
activation of pro-inflammatory cells in combination with impaired anti-inflammatory responses can 
promote excessive release of growth factors, survival factors, reactive oxygen species and pro-
angiogenic factors that promote a chronic injury or neoplastic state. Consequently, COPD patients 
are associated with a 6-fold increased risk of Lung cancer development independent of smoking and 
age 15.  
Nevertheless, lung cancer can occur in up to 20% of never smokers. Other risk factors include 
second-hand smoke, diet, alcohol and exposure to air pollutants as well as occupational hazards 
including asbestos, diesel exhaust and silica 16. It has been reported that Taiwanese women, who are 
predominately non-smokers, have an increased risk to lung cancer due to their heavy use of coal 
burning stoves without adequate ventilation 17. Individuals with a family history of the disease are 
also at an increased risk, with a number of susceptibility loci identified that include 5p15 5p25 and 
6p21 16. In addition, underpinning the increased susceptibility for lung cancer in patients with the 
heritable Li-Fraumeni syndrome is the presence of the germline mutation in the tumour suppressor 
TP53 gene 18.  
 Current and emerging procedures for detection and diagnosis  
Almost 75% of lung cancer patients are diagnosed with advanced disease due to the lack of clear 
early signs and symptoms. Regular screening of asymptomatic at-risk populations may improve early 
detection of lung cancer. Currently, Chest X-rays or standard CT are used for the initial examination 
of suspect pulmonary lesions 19. These imaging procedures provide a 2D and 3D visualisation of the 
lung. Upon detection of the suspect lesion they also provide preliminary anatomical description of 
the location, size and spread of the disease prior to obtaining a biopsy or cytology specimen for a 
definitive tissue-based assessment. Chest X-rays and standard CT imaging are not used for routine 
screening of high-risk individuals because they have shown no benefit in reducing overall mortality 
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rates and deliver high levels of radiation that increase the risk of cancer with repeated exposures 20. 
The US National Lung Cancer Screening Trial (NLST) was the first study to detect a reduction in 
overall mortality by LDCT screening 21. In this study a 20% decrease in overall mortality was detected 
in response to annual LDCT screening of high risk individuals aged between 55-74 with a smoking 
history of greater than 30 pack years. Using an average effective dose of 1.5mSV, which is 25% less 
radiation than standard CT, LDCT screening was able to detect a larger proportion of early stage 
tumours compared to the Chest X-ray arm 22. One of the limitations of the study was the high false 
positive rate associated with intrapulmonary lymph nodes and non-calcified granulomas being 
commonly mistaken for possible tumours 21. The Dutch-Belgian Randomised Lung Cancer Screening 
Trial (NELSON), which is the second largest study to assess the potential of LDCT screening, showed a 
significant reduction in the false positive rate by implementing a nodule volume management 
protocol 23. For a subset of patients, additional CT scans were performed within 2 months of the 
initial scan to estimate the nodule volume doubling time in order to identify benign nodules without 
further invasive assessment.  
Patients identified as positive during the initial screen are required to undergo a more invasive 
assessment. Biopsy or cytology specimens are retrieved to perform a tissue-based diagnosis that 
aims to definitively confirm the nature of the suspect lesion. Various techniques may be employed 
including sputum cytology, percutaneous image-guided aspiration/biopsy and bronchoscopic 
sampling. Sputum cytology for the detection of lung cancer is the least-invasive and most cost-
effective procedure, however its diagnostic sensitivity is only approximately 60% 24.  Assessment of 
cytology or biopsy specimens retrieved from malignant pulmonary lesions using percutaneous fine 
needle aspiration achieves the highest diagnostic sensitivity (82-99%) and specificity (86-100%) 25. 
Despite this, positive detection of benign lesions is poor (20-50%) and the procedure is associated 
with a higher rate of complications involving pneumothorax and haemorrhaging. Endobronchial 
Ultrasound (EBUS) guided bronchoscopy is the preferred procedure for lung cancer diagnosis as it is 
minimally invasive and can be performed in the outpatient setting 26. Established as having high 
diagnostic accuracy for the assessment of central pulmonary lesions, evaluation of peripheral 
lesions, tumour invasion and depth has greatly improved with the use of two types of probes 27 
(Depicted in Figure: 1.3.1). Positioned inside a water-inflatable balloon, the radial probe is inserted 
through a working channel of the bronchoscope where it can rotate and achieve a 360° view of the 
bronchial structures. Mediastinal lesions may be evaluated using the linear or convex probe, which 
obtains an oblique 30° view with a depth of 50mm and does not require an inflated balloon if it is in 
close contact with the bronchial surface. Upon detection of the suspect lesion, a biopsy instrument 
(forceps, needle or brush) is inserted through the bronchoscope for tissue sampling. Multiple 
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bronchial brushings, transbronchial needle aspirates and forceps biopsies are retrieved to maximise 
the amount of tissue available for pathological assessment 28. Specimens are subsequently prepared 
as formalin fixed smears or paraffin-embedded cell blocks to assess specific immunohistochemical 
markers which aim to confirm malignancy and tumour subtype. Additionally, radial EBUS 
bronchoscopy combined with rapid-on-site examination (ROSE) by an experienced cytopathologist 
can confirm diagnosis in real time with 76% sensitivity and 96% specificity, which is shown to be 
highly concordant with the final pathological assessment 29.  
 
 
Figure: 1.3.1 Radial or Convex Endobronchial ultrasound (EBUS) bronchoscopy 
While the patient is under conscious sedation, the bronchoscope containing either the radial probe (360° 
view) or convex probe (30° view) is inserted via the oral or nasal cavity and guided towards the suspect 
pulmonary lesion using ultrasound imaging. Upon detection, the probe will either remain (convex) or be 
removed (radial) and a biopsy instrument (forceps, needle, brush) is inserted through the working channel 
of the bronchoscope for tissue sampling. Image adapted from “Endobronchial Ultrasound for the Diagnosis 
and Staging of Lung Cancer”1, 2. 
Radial Probe 
Convex Probe 
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 Classification of Lung Cancer subtypes 
During pathological assessment, lung cancer can be classified into two major histological subtypes 
identified as Non-Small Cell (NSCLC) or Small Cell Lung Cancer (SCLC). The most aggressive subtype is 
SCLC, which accounts for approximately 15% of cases. SCLC is considered morphologically distinct 
appearing as round, oval and spindle shaped tumour cells with vague borders, scant cytoplasm and 
granular nuclear chromatin 30. The aggressive nature of this particular subtype is associated with 
rapidly growing tumour cells, higher vascularity and genomic instability, as well as early metastasis 
31. Despite SCLC patients showing initial responses to first line chemotherapy and radiotherapy, the 
5-year survival rate remains low at approximately 7% due to relapse and multi-drug resistance. In 
comparison, NSCLC is the predominant subtype occurring in approximately 85% of cases 32. 
Historically, NSCLC was poorly classified into three ill-defined subtypes; Adenocarcinoma (Adeno), 
Squamous cell carcinoma (SCC) and large cell carcinoma 33. With the development of targeted 
therapies based on specific histologic and genetic characteristics, greater importance has been 
placed on the accurate classification of NSCLC tumours.  
In 2015, NSCLC was re-classified into two main subtypes; Adeno and SCC 34. Occurring in 40-50% of 
NSCLC cases, Adeno can be further defined as either acinar, papillary, lepidic or micropapillary 35. 
SCC accounts for 20-30% of NSCLC cases and is classified as either keratinising, non-keratinising and 
basaloid. Terms such as bronchioalveolar carcinoma and mixed subtype have been discontinued, 
while the terms large cell carcinoma and Not Otherwise Specified (NOS) are now used to describe 
pulmonary tumours without clear morphology and immunohistochemical differences. The initial 
steps taken to confirm and differentiate NSCLC subtypes include morphological assessment of 
Haematoxylin and Eosin stained specimens as well as immunohistochemical analysis of several 
markers including Thyroid Transcription Factor 1 (TTF-1), p40 and p63 which may be complemented 
by Cytokeratin 5/6 (CK5/6), Napsin A and CK7 in ambiguous cases (Summarised in Figure: 1.4.1). TTF-
1 has been shown to be expressed on 85% of primary adenocarcinomas, with the sensitivity and 
specificity improved using a combination of TTF1, Napsin A and CK7 36. Similarly, a combination of 
p40, p63 and CK5/6 staining has the potential to correctly diagnose SCC tumours. The amount of 
tissue available for these ancillary tests is limited because not all patients are suitable for surgical 
resection and therefore diagnosis may be dependent solely upon cytology and small biopsy 
specimens. Ideally, minimally invasive sectioning is performed so there is sufficient material for both 
confirmatory diagnostic tests as well as mutational testing to guide treatment-based decisions. 
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Figure: 1.4.1 The process of pathological assessment for confirmatory diagnosis and mutational 
analysis of lung tissue specimens 
Formalin fixed lung tissue specimens are prepared usually as 2µm thin sections for H+E staining to confirm 
histological subtype. Differentiation of NSCLC subtypes is achieved by IHC analysis of the common markers 
TTF1, p40 and p63 which may be accompanied by CK5/6, Napsin A and CK7. Remaining tissues specimens 
from Adeno patients are subjected to further mutational profiling to determine patients most suitable for 
targeted therapies. Image taken from Diagnostic procedures for non-small-cell lung cancer (NSCLC): 
recommendations of the European Expert Group 28 
 
  Targeted therapies for the treatment of Lung cancer 
The gold standard treatment for patients with predominantly early stage lung cancer is complete 
surgical resection of the tumour. However, a large proportion of patients, including 40% with 
advanced disease, are inoperable 37. For a period of time, platinum-based chemotherapy, alone or in 
combination with Radiotherapy, were the only treatment options for patients with advanced 
disease. In spite of this, the effectiveness of chemotherapy has plateaued, contributing to the lack of 
improvement in overall survival rates. In the last decade, there has been shift in cancer treatment 
from conventional therapies (chemotherapy, radiotherapy, surgery) to personalised medicine that 
target specific driver mutations in NSCLC (Summarised in Table: 1.5.1Error! Reference source not 
found.). Driver mutations are genetic alterations that confer a growth advantage 38. The first to be 
targeted was the Epidermal Growth Factor Receptor (EGFR), a transmembrane receptor ubiquitously 
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expressed. Belonging to the ERB-B2 family of tyrosine kinases, EGFR is commonly overexpressed in 
40-80% of NSCLC patients. Increased interaction between EGFR and its growth factor ligands can 
lead to enhanced activation of multiple downstream pathways including RAS/MAPK and Akt/PI3K 
important for tumour cell proliferation and survival 39. Gefitinib, a first-generation EGFR tyrosine 
kinase inhibitor (TKI) targeting the ATP cleft, showed an overall objective response in 10.6% of 
patients with chemotherapy-refractory advanced NSCLC 40. The subset of patients associated with 
improved progression-free survival were predominantly non-smoking Asian females diagnosed with 
lung Adeno 41. At a molecular level, the response to Gefitinib was associated with the presence of 
distinct mutations in EGFR largely comprised of an in-frame deletion at exon 19 and the point 
mutations in exon 21 (L858R) and 18 (G719X). Patients that develop acquired resistance to the first 
and second generation TKI, due to the T790M point mutation in exon 20, can be now treated with 
the third generation TKI Osimertinib 42.  
Table: 1.5.1 Frequency of driver mutation  in NSCLC and currently available targeted therapies43 
Gene Alteration Frequency  Available targeted therapies 
EGFR Mutation 10-35% Gefitinib, Erlotinib, Afatanib, Osimertinib 
ALK Rearrangement 3-7% Crizotinib, Alectinib, Brigatinib, Ceritinib 
ROS1 Rearrangement 1% Crizotinib 
MET Amplifications 2-4% Crizotinib 
BRAF Mutation 1-3% Dabrafenib 
ERB-B2/HER2 Mutation 2-4%  
DDR2 Mutation ~4%  
MEK1 Mutation 1%  
RET Rearrangement 1%  
AKT Mutation 1%  
FGFR1 Amplification 20%  
KRAS Mutation 15-25%  
NRAS Mutation 1%  
PIK3CA Mutation 1-3%  
PTEN Mutation 4-8%  
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The success of EGFR TKI in improving clinical outcomes in this subset of patients prompted interest 
in targeting other driver mutations 44. The TKI Crizotinib is now used for the treatment of patients 
harbouring Anaplastic lymphoma kinase (ALK) rearrangements. With an estimated frequency of 3-
7%, the most common rearrangement is the fusion between the receptor tyrosine kinase ALK and 
the echinoderm microtubule -associated protein like 4 (EML4), both of which are located on 
chromosome 2 45.  EML4-ALK fusions promote ligand dependent, constitutive activation of the ALK 
receptor, resulting in the activation of cell proliferation and survival pathways. Treatment with 
crizotinib demonstrated an objective response of 65% in patients with ALK-positive advanced NSCLC 
46. Improved progression-free survival (PFS) of 7.7months was achieved in the crizotinib arm 
compared to 3months PFS in the chemotherapy treated group. Further clinical assessment has led to 
FDA approval of crizotinib against ALK and C-Ros oncogene 1 (ROS1) rearrangements 47.  
Non-smoking patients with adenocarcinoma histology benefit the most from these currently 
available targeted therapies because they harbour specific genetic alterations which often occur 
mutually exclusive of each other. This is not the case for SCC, where a contributing factor to the lack 
of response in SCC patients is that this subtype typically arises in chronic smokers and therefore is 
associated with a higher tumour mutation burden. Revised guidelines by the International 
Association for the Study of Lung Cancer and the Association for Molecular Pathology strongly 
recommend that stand-alone assays for EGFR, ALK, ROS1 and BRAF mutations are routinely tested in 
patients with advanced lung Adeno to identify likely responders 48. With a number of targeted 
therapies currently in clinical development against alternate driver mutations including the 
fibroblast growth factor receptor 1 (FGFR1) and phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA), larger panel sequencing platforms are emerging to assess multiple 
mutations simultaneously.   
 Immunotherapies  
Another class of therapeutic drugs improving clinical outcomes in both lung Adeno and SCC patients 
are immune checkpoint PD-1/PDL1 inhibitors. Among the various immune cell types involved in 
immunosurveillance, activation of cytotoxic T cells plays a crucial role in the recognition and 
elimination of tumour cells. T cell activation is a two-step process involving the interaction between 
the T cell receptor and the major histocompatibility complex (MHC) present on antigen presenting 
cells followed by antigen-independent co-stimulatory signalling that is important for determining T 
cell function and fate 49. In the context of cancer, tumour cells presenting antigen on class I MHC 
molecules are recognised by cytotoxic CD8+ T cells and this interaction promotes cytotoxic killing of 
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malignant cells. Regulating cytotoxic T cell activation are co-Inhibitory T cell receptors such as PD-1 
and cytotoxic T-lymphocyte-associated protein 4 (CTL4) that bind to their respective ligands PD-L1 
and B7-1/B7-2 for T cell inactivation. However, tumour cells can exploit this process and evade T cell 
immunosurveillance by expressing PD-L1. Despite the increased infiltration of CD8+ T cells within the 
intra-tumoural regions of patients with NSCLC, this T cell population was largely inactive due to the 
suppressive function of tumours that express PD-L1 50. PD-1/PD-L1 blockade was shown to restore 
cytotoxic T cell activity by increasing T cell proliferation and cytokine production. The first FDA 
approved PD-1 inhibitor for the treatment of NSCLC was Nivolumab. With a response rate of 
approximately 20%, Nivolumab was shown to significantly improve progression-free survival in 
patients with either lung adenocarcinoma or SCC 51, 52. In particular, SCC patients showed a 41% 
reduced risk in death following nivolumab monotherapy. Additional PD-1 inhibitors Pembrolizumab, 
Durvalumab and the PD-L1 inhibitor Atezolizumab have since been approved as first and second line 
therapies 53. However, with only a subset of patients likely to respond, assessment of PD-L1 tumour 
staining greater than >50% and >1% of the total region of interest has been established as a the only 
valid predictive biomarker to date 54.  Targeting alternative components of the immune cell 
environment may further improve patient outcomes in a larger proportion of NSCLC patients. 
 Defining tumour-associated Inflammation in NSCLC subtypes 
The immune system is an important defence mechanism against tumour development. In response 
to tissue injury or infection, the airway epithelium and tissue resident macrophages become 
activated and initiate cytokine and chemokine signalling which stimulates the trafficking of leukocyte 
subsets into the inflamed site14. Recruitment of the first effector cells, neutrophils, is orchestrated by 
a combination of adhesion molecules (L, P, E-selectins), integrins (α4β1, α4β7), chemotactic factors 
such as the C-X-C and C-C family of polypeptides (CXCL8, CCL2) and matrix degrading proteases. 
There is considerable literature supporting the view that extracellular proteases, such as the matrix 
metalloproteinases (MMPs), mediate tumour promoting changes in the cancer microenvironment. 
The function of MMPs is dependent on the balance between MMP levels and their physiological 
inhibitors, namely TIMP-1, -2, -3, and 4, which form stochiometric complexes with active MMPs to 
inhibit their proteolytic activity. Through their proteolytic activity, MMPs regulate a variety of 
physiological processes and signalling events. For example, Transforming growth factor beta (TGF-β) 
is a tumour-promoting factor and MMP-9 can facilitate the release and conversion of latent TGF-β 
and active TGF-β 55. Activation of EGFR will also result in the upregulation of MMP-9, which in turn 
degrades E-cadherin that influences cancer cell proliferation. In addition, MMP-9 can promote 
tumour angiogenesis by regulating the bioavailability of vascular endothelial growth factor (VEGF), 
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which is a potent inducer of angiogenesis in the tumour microenvironment. MMP-9 produced by 
neutrophils can be particularly potent in inducing angiogenesis as, in contrast to other cell types, 
neutrophil derived pro-MMP-9 is not complexed with TIMP-1. Given the critical and pleotropic roles 
for MMPs in multiple human cancers, they have been considered as drug targets to treat cancer. 
MMP inhibitors have been evaluated in multiple trials with disappointing outcomes 56, which reflects 
poor study design and an incomplete understanding of the complex processes that are regulated by 
MMPs. Determining the role of MMPs including MMP-9 in health and cancer remains important, as 
this family of proteases are critical to oncogenic processes. My thesis will investigate the expression 
and cellular sources of MMPs and TIMPs in greater detail, which has revealed exciting new 
opportunities in developing biomarkers to diagnose NSCLC. 
Temporary breakdown of the extracellular matrix by various proteases such as MMP-9 also enables 
the infiltration of neutrophils and other inflammatory cells including monocytes, eosinophils, mast 
cells and T cells. Neutrophils are primed towards eliminating the immediate threat but can also 
influence tissue repair by secreting pro-inflammatory cytokines (TNFα, IL-6, IL-12, IL-1β), cellular 
growth factors (EGF, FGF) and angiogenic factors (VEGF). Tight regulation of pro-inflammatory 
responses is critical for tissue restitution and involves the induction of anti-inflammatory cytokines 
and chemokines that suppress leukocyte infiltration. In addition, macrophage induced efferocytosis 
of apoptotic neutrophils prevents the inappropriate release of their granular contents 57.  Increased 
expression of the urokinase plasminogen activator receptor on the leading edge of the epithelial 
cells is important for the activation of downstream effector enzymes that degrade the dermal 
collagen layer for incoming re-epithelialisation 58. An effective immune response elicited by CD8+ T 
lymphocytes, CD4+ T helper (Th1) cells and Natural Killer (NK) cells is critical for the recognition and 
elimination of potential tumour cells. However, altered epithelial function and impaired 
immunosurveillance as a result of prolonged smoke exposure can create a chronic inflammatory 
environment that may facilitates tumour growth 59. Among the various types of inflammatory cells 
dominating the immune landscape of primary lung tumours are macrophages and neutrophils 60. It is 
well established that tumour associated macrophages can develop an altered phenotype associated 
with impaired efferocytosis of exhausted neutrophils and excess secretion of immunosuppressive 
cytokines, growth factors and survival factors 61, 62. Interestingly, the role of tumour-associated 
neutrophils (TANs) is not well-understood in NSCLC. TANs are a major source of matrix degrading 
enzymes, pro-angiogenic factors and reactive oxygen species that can promote tumour invasiveness, 
growth and further DNA damage 63. However, recent studies have demonstrated that initial 
recruitment of TANs in early stage lung cancer can promote tumour-suppressing cytotoxic T cell 
responses 64. Elucidating the mechanism responsible for recruiting and polarising TANs in NSCLC 
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remains unresolved. The focus of my thesis is to reveal fundamental insights into the regulation of 
TANs recruitment in NSCLC subtypes. 
 Aims 
The general aim of this thesis is to further characterise the role of tumour-associated leukocyte 
subsets in NSCLC including Adeno and SCC. Exploring key components of the immune landscape 
during early stages of the disease may also identify novel diagnostic and prognostic biomarkers that 
have the potential to further improve overall survival. 
These are the specific aims addressed in each chapter: 
Chapter 2: 
• To investigate shared molecular pathways that may be underpinning the increased risk of 
lung cancer in COPD patients. The matrix degrading enzyme MMP-9 is known to be 
increased in lung cancer and COPD. Loss of PTEN is also a prominent molecular feature of 
lung cancer and COPD.  
• To quantify MMP-9 and PTEN levels using formalin-fixed tissue specimens derived from a 
small cohort of NSCLC patients with concurrent COPD. To identify the cellular sources of 
MMP9 in the patients with lung cancer and co-morbid condition COPD. 
• To determine whether PTEN can regulate the expression of MMP-9 expressed by bronchial 
epithelial by using an siRNA strategy to reduce PTEN levels. To determine whether MMP9 
expression is resistant to the corticosteroid, budesonide 
Chapter 3: 
• To determine whether MMP-9 has utility as a diagnostic marker in NSCLC. There is an 
increasing reliance on cytology specimens to confirm diagnosis as well as provide sufficient 
material for subsequent mutational profiling.  
• To firstly develop a new approach for the preservation of a single pass EBUS-directed 
specimen that provides high quality nucleic acid for large scale molecular and mutational 
profiling.  
• To assess feasibility of quantifying transcript levels of multiple markers including MMP-9, 
TIMP3 and PD-L1 in small bronchoscopy specimens. To validate preliminary findings in a 
larger cohort of NSCLC biopsy specimens derived from resection surgery patients. To 
determine feasibility of also screening for actionable mutations using the same single pass 
bronchoscopy specimen.  
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Chapter 4: 
• To develop a new multiplex digital droplet PCR (ddPCR) that incorporates the quantification 
of MMP-9, TIMP-3 and PD-L1. ddPCR has the potential to improve sensitivity and accuracy 
and streamline the approach for gene expression analysis of EBUS-directed specimens.  
• To determine the concordance between ddPCR and RTqPCR platforms for the assessment of 
the MMP-9:TIMP3 ratio as well as the PD-L1:TIMP3 ratio.  
• To determine whether the MMP9:TIMP3 ratio quantified using ddPCR is predictive of the 
presence of malignant cells in small NSCLC brushings. 
• To determine thresholds or cut-off values for the PD-L1:TIMP3 ratio that can identify NSCLC 
patients with high (>50%) PD-L1 tumour cell staining, which are more suitable for 
immunotherapies as a first line treatment.   
 
Chapter 5: 
• To characterise the innate immune profile of the major NSCLC subtypes. A histological 
approach will be used to quantify the degree of macrophage and neutrophil infiltration in 
Adeno and SCC biopsies. 
• To identify the dominant chemotactic factors involved in the recruitment of neutrophils and 
macrophages according to their NSCLC subtype.  
• To perform survival analysis of the NSCLC biopsy cohort in order to establish whether TANs 
influence prognosis post-surgical resection.  
The overall hypothesis is that molecular profiling of the chronic inflammatory environment in 
patients with NSCLC and co-morbid COPD will reveal distinct immune cell signatures between 
tumour subtypes as well as identify novel diagnostic and prognostic biomarkers. 
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insensitive MMP-9 expression in the chronically inflamed lung microenvironment 
The research reported in this Chapter is largely comprised of experiments published in the journal 
Thorax (Appendix A). This chapter includes an expanded version of the Introduction, Methods and 
Discussion sections of that publication and introduces chronic inflammation as an important 
characteristic underpinning tumour initiation and progression. Covered in the General Introduction 
is the association between COPD and lung cancer. In COPD, there is also an increased number of 
inflammatory cells including macrophages and neutrophils in the airways, which have been shown to 
produce pro-inflammatory cytokines, chemokines and proteases that in turn contribute to 
pathological remodelling. One such metalloproteinase whose tissue and serum expression is 
significantly increased in COPD is MMP-9, which is also known to be increased in lung cancer and can 
contribute to tumour progression. The levels and cellular sources of MMP-9 in lung cancer patients 
with co-morbid COPD have not been well characterised.  In addition, the tumour suppressor gene 
PTEN, which is an important negative regulator of multiple signalling pathways, is commonly 
downregulated in the airway epithelium of COPD and lung cancer patients. This chapter investigates 
the expression profiles and mechanistic links between MMP-9 and PTEN in lung cancer patients with 
concurrent COPD.   
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insensitive MMP-9 expression in the chronically inflamed lung microenvironment 
 Introduction 
The global prevalence of lung cancer and COPD will continue to rise as smoking consumption is yet 
to peak in developing regions 10. Mutagens and free radicals in cigarette smoke damage and 
transform the lung epithelium leading to emergence of a squamous metaplasia phenotype that is 
correlated with the severity of COPD 65. The accumulation of mutations can also manifest into field 
cancerisation where progenitor clones expand to populate broad areas of the injured bronchial 
mucosa 66. Hence, a high proportion of chronic smokers with COPD will accumulate mutations within 
the respiratory epithelium and ultimately die of lung cancer 67. Of significance, individuals with 
emphysema are at increased risk of developing lung cancer, even when adjustments for smoking 
history are made 68-71.These findings indicate that there are shared molecular drivers that contribute 
to the emergence of lung cancer in people with pre-existing COPD 72.  
 
Chronic inflammation has been recognised as an enabling characteristic in cancer where 
inflammatory and metaplastic cells secrete a milieu of growth factors and cytokines to drive 
remodelling processes 59. During inflammation and infection, polarised epithelial cells lose epithelial 
markers such as E-cadherin and dedifferentiate into a mesenchymal phenotype with enhanced 
migratory capacity 73. In addition, squamous metaplastic cells in COPD secrete higher levels of 
inflammatory Interleukin-1eta (IL-1), which induces a fibrotic response in adjacent airway 
fibroblasts via TGF dependent mechanisms 74. One such proteinase known to be elevated in COPD 
is MMP-9, where neutrophils are an important source of corticosteroid resistant MMP-9 activity 75. 
In addition to leukocytes, the number of basal epithelial cells positive for MMP-9 were found to be 
elevated in COPD and current smokers relative to non-smokers 76.  MMP-9 is also known to be 
increased in lung cancer, where it can play multiple roles in tumour progression including 
angiogenesis, establishment of metastatic niche and invasion, inflammation and cellular survival 55. 
Like COPD, the cellular source of MMP-9 is likely to be multi-factorial in lung cancer, including 
inflammatory leukocytes and tumour cells of epithelial origin. A recent systemic review has also 
concluded that overexpression of MMP-9 in lung tumour tissue but not in serum was a risk factor for 
advanced tumour stage and poor outcome 77. 
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insensitive MMP-9 expression in the chronically inflamed lung microenvironment 
In addition to MMP-9, the tumour suppressor gene PTEN has been shown to be altered in COPD and 
lung cancer. The frequent loss of PTEN in many cancers is associated with enhanced activation of 
one or more of these pathways leading to sustained cell proliferation and tumorigenesis. Increased 
PI3K/Akt pathway activation is seen in smokers with dysplastic regions, suggesting that PI3K 
activation is an early event in tumourigenesis 78. In COPD, candidate PTEN SNPs have been identified 
79, its transcript levels have been shown to be progressively downregulated in COPD epithelium 80, 
and in-vitro studies have shown that PTEN expression is reduced when epithelial cells are exposed to 
cigarette smoke condensate 80, 81. There are studies to suggest that PTEN regulatory pathway can 
regulate MMP-9 expression 82, 83 however, a mechanistic link between these two genes has not been 
demonstrated in lung cancer or COPD. In this study, we measured MMP-9 and PTEN transcript levels 
in lung cancer patients with co-existing COPD, where MMP-9 was uniformly increased within the 
tumour region relative to the adjacent tumour-free region. The majority of tumour samples also 
displayed reduced PTEN expression. To mechanistically investigate whether reduced PTEN 
expression can contribute to increased MMP-9 epithelial expression, an siRNA knock-down approach 
was used. Here, we demonstrated that loss of PTEN increased MMP-9 expression in Beas-2B 
bronchial epithelial cells in response to LPS in manner that was resistant to the glucocorticosteroid, 
budesonide. 
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 Methods 
2.2.1 Patient samples  
The studies were approved by the ethics committee of the participating institutions and informed 
written consent was obtained. lung tissue from resection surgery for treatment of a solitary 
peripheral carcinoma was collected from subjects with COPD (n=10; 7 GOLD I stage: 3 GOLD II stage). 
This cohort included 7 males: 3 females; mean age (range) was 71 (63-80) with a mean (range) 
smoking history of 58 (25-140) pack years. Of the 10 resection samples collected, 6 were confirmed 
Adeno and 4 were confirmed SCC.  
2.2.2 Formalin Fixed Paraffin embedded (FFPE) processing for RTqPCR 
Tissue blocks from the tumour site and the adjacent subpleural parenchyma, avoiding areas involved 
by tumour, were fixed in 10% neutral buffered formalin and embedded in paraffin. FFPE sections 
were used for RNA in accordance with the ReliaPrep™ FFPE Total RNA Miniprep System protocol 
(Promega, Madison, WI, USA). Genomic DNA was removed using the DNA-free™ DNA Removal Kit 
(Invitrogen, Carlsbad, CA, USA) and purified RNA was converted to cDNA using the SuperScript IV 
First Strand Synthesis (Invitrogen, Carlsbad, CA, USA). TaqMan® PreAmp Master Mix (Applied 
Biosystems, Foster City, CA, USA) was used to pre-amplify gene-specific targets with pooled Taqman 
primers as per manufacturers’ instructions. Q-PCR was performed on the pre-amplified cDNA for 
gene expression analysis of PTEN and MMP-9 normalised to the reference gene PUM1 validated for 
FFPE lung samples 84. Tumour expression was expressed as a fold change relative to the individuals’ 
tumour free region. 
2.2.3 Haematoxylin and Eosin staining 
FFPE lung biopsies were sectioned at 5µm thickness. Serial sections were deparaffinised in histolenes 
and rehydrated in graded ethanols. Nucleus staining was achieved using Mayers Haematoxylin 
(Amber Scientific, WA, Australia) followed by the bluing reagent Scott’s tap water (0.04M Sodium 
bicarbonate, 0.17M Magnesium sulphate). Cytoplasmic regions were stained with Eosin 1% Aqueous 
solution (Amber Scientific, WA, Australia) and the sections were then cleared in absolute ethanols 
and histolenes before being mounted onto coverslips using entellen. 
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2.2.4 Cluster of Differentiation 68 (CD68) and Myeloperoxidase (MPO) 
Immunohistochemistry 
Serial sections of 5µm thickness were deparaffinised in histolene and rehydrated in a series of 
graded ethanol steps. For heat-induced epitope retrieval, slides were submerged in preheated 
citrate buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0) and incubated at 95°C for 20mins using a 
Decloaking Chamber (Biocare Medical, CA, US). In accordance with the EnVision® + Dual Link System-
HRP kit (Dako, Agilent Technologies, CA, US), endogenous peroxidase activity was quenched using 
the dual enzyme block for 5 mins. Slides were incubated for another 1 hour at room temperature in 
blocking buffer (5% BSA, 10% Horse Serum, 0.4% Triton X-100 in 1x PPBS) to prevent additional non-
specific binding. For the detection of neutrophils and macrophages, a rabbit polyclonal antibody 
against human MPO (Dako #A0398) and a mouse monoclonal antibody against human CD68 (DAKO 
#M0814) was used. Sections were incubated with either a 1:500 dilution of the MPO or 1:100 of 
CD68 antibody in 1x PBS for 1 hour at room temperature. All slides were washed three times in Tris-
EDTA buffer (0.01M Tris amine buffer, 0.04M Tris-HCL, 0.5% Tween 20, pH 7.6), and incubated with 
labelled polymer-HRP (DAKO EnVision kit) for 1-hour at room temperature. Slides were rinsed in 
wash buffers three times prior to incubation with SIGMAFAST 3,3’-Diaminobenzidine (Sigma Aldrich, 
MO, US) for 3-5mins. Following visualisation of MPO and CD68, sections were counterstained in 
Mayer’s Haematoxylin (Trajan Scientific and Medical, VIC, Australia), dehydrated and mounted onto 
slides using entellen mounting medium (Merck, MA, US). To obtain an unbiased analysis of tumour-
infiltrating immune cells with objective data, all immunostained slides were subjected to virtual 
microscope scanning under high-power magnification using the Olympus V120 virtual slide scanner. 
The entire tumour section was captured and the area positive for CD68 or MPO was determined 
using the Olympus CellSens software. The area positive was quantified using the area fraction 
calculated over the Region of Interest 
2.2.5 Beas-2B cell culture    
 Beas-2B human bronchial epithelial cells (ATCC: CRL-9609) isolated from normal bronchial 
epithelium were used as previously described 85. Briefly, cells were cultured in complete media with 
a 1:1 mixture of Keratinocyte-Serum Free Media (Thermofisher Scientific, MA, USA) supplemented 
with 5µg/ml epidermal growth factor and 50µg/ml bovine pituitary extract and Minimum Essential 
Medium (MEM) + Earle Salts supplemented with 10% Fetal Bovine Serum (FBS, Lonza, Basel, 
Switzerland), 2mM L-glutamine, 1.0mM sodium pyruvate, 0.1mM non-essential amino acids, 1.5g/L 
sodium bicarbonate, 25µg/ml gentamicin, 100µg/ml penicillin and 100µg/ml streptomycin. For 
stimulation assays, Beas-2B cells were transferred in a 24 well-plate format at a density of 
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0.25x106cells/well and incubated in low serum media (1%). Cells were treated with media alone 
(vehicle group), 100ng/ml LPS (Sigma-Aldrich, St Louis, MO) 10-7M BUD (Sigma-Aldrich, St Louis, 
MO) or a combination of both BUD/LPS. The treated cells were then collected at 2 time points; 3h 
and 48h and cell pellets were resuspended in RLT buffer (Qiagen, Valencia, CA) and stored at -20⁰C 
in preparation for RTqPCR. 
2.2.6 PTEN siRNA Reverse Transfection and Quantitative Polymerase Chain Reaction 
(qPCR)   
 Beas-2B cells were resuspended in low serum optiMEM media (Life technologies, Grand Island, NY) 
and seeded at a density of 2.5 x105 cells per well in 6 well plate. siPort NeoFx transfection reagent 
(Life Technologies) was combined with Ambion silencer select PTEN or control siRNA (Life 
Technologies) at a final siRNA concentration of 12.5pmol. After a 6hour incubation at 37⁰C this 
media was replaced with complete media (K-SFM and MEM+Earle salts with 10% FBS) and further 
incubated at 37⁰C for a total of 72hours. RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, 
CA) and cDNA was prepared using the High Capacity RNA-to-cDNA synthesis kit previously published 
86. RTqPCR was conducted using ABI Prism 7900HT sequence detection system (Applied Biosystems, 
Foster City, CA) with each assay containing validated Taqman probes/primer sets. Relative 
Expression above the vehicle was established using the delta delta cycle threshold (2-ΔΔCT) method, 
where values where normalised to the house keeping gene, GAPDH. 
2.2.7 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 5.02. All fold change data is 
presented as Tukey boxplots which show the median, interquartile range [1.5x IQR(distance 
between the 25th and 75th percentiles)] and inner fences (Quartile1 – 1.5xIQR, Quartile3 – 1.5xIQR). 
Data points outside the boxplot > 1.5x IQR are expressed as outliers.  In all cases, n represents the 
number of independently conducted experiments and p<0.05 is considered statistically significant. 
Data obtained from RTqPCR were analysed using either paired t-test, spearman correlation, one-way 
or two-way ANOVA in combination with multiple comparison. 
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 Results 
2.3.1 Increased MMP-9 transcript levels within tumour region relative to adjacent 
tumour free region 
Increased tissue expression of MMP-9 commonly occurs in various cancer types and is associated 
with poorer prognosis. Figure 2.3.1.1A-B are representative images of H&E stained tissue sections of 
the intra-tumour region and the adjacent tumour-free site from a COPD subject with histologically 
confirmed squamous cell carcinoma. MMP-9 transcription was significantly higher within tumour 
sample relative to the adjacent control tissue (Figure 2.3.1.1B, mean 4.6 ± 1.5 SEM fold increase, 
p<0.01). Stratification by tumour histology revealed no significant difference between tumour type 
(Figure 2.3.1.1D; Adeno 5.5 ± 2.4 vs. SCC 3.1± 0.9-fold increase).    
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2.3.2 Assessment of CD68+ macrophages and MPO+ neutrophils in the matched lung 
cancer specimens 
Immunohistochemical staining of the archival specimens revealed varied localisation of CD68+ 
macrophages and MPO+ neutrophils in the malignant specimens. CD68+ macrophages were shown to 
be located within the stromal regions surrounding the tumour (Figure 2.3.2.1A). In contrast, MPO+ 
neutrophil staining was predominantly detected within the tumour nests (Figure 2.3.2.1B). The 
Figure 2.3.1.1 MMP-9 transcript expression is increased within tumour region in COPD patients 
A Representative image of the H&E stained tissue section at the tumour site (A) and the adjacent subpleural 
parenchyma that was histologically free of tumour (B) was obtained from the archival specimens (n=10). RNA 
extracted from FFPE section of tumour region and adjacent control section were subjected to Taqman 
RTqQPCR and normalised to the housekeeping gene PUM1. MMP-9 levels were expressed as fold change 
relative to individuals control sample (C, 2.9-fold increase, **p<0.01), Wilcoxon matched-pairs signed rank 
test). Levels of MMP-9 within tumour were grouped on basis of NSCLC tumour type, demonstrating no 
difference in expression (D).  
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percentage area of positive staining for CD68+ macrophages and MPO+ neutrophils revealed no 
significant difference in tissue accumulation of either leukocyte (Figure 2.3.2.1C-D), although there 
was a trend towards increased numbers of tumour associated neutrophils (Figure 2.3.2.1D, 2.7 ± 
0.7% positive area) relative to adjacent control tissue (1.4 ± 0.2% positive area).  
Spearman correlation revealed no association between MMP-9 expression and macrophage staining 
(Figure 2.3.2.2A, r= -0.42, p = 0.23), whereas a closer association between MMP-9 expression and 
tumour associated neutrophils was observed (Figure 2.3.2.2B, r= 0.63, p = 0.05). There was no 
association between neutrophils and MMP-9 expression in adjacent control tissues (Figure 2.3.2.2C, 
r= 0.350, p = 0.35). Consistent with this finding, immunohistochemistry for MMP-9 positive cells 
using serial tumour sections identified intensely staining neutrophils in the tumour tissue relative to 
macrophages with moderate staining (Figure 2.3.2.2D). There was also some evidence for MMP-9 
reactivity in cells of epithelial origin (Figure 2.3.2.2E). 
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 Figure 2.3.2.1 Localisation and quantitative analysis of neutrophil and macrophage expression 
Macrophage and neutrophil expression were assessed in the archival specimens (n=10) by performing CD68 
and MPO immunohistochemical staining. Figure A is a representative image (20x magnification) of CD68+ 
macrophage staining, found predominantly in the tumour surrounding stroma. MPO+ neutrophil expression 
shows localisation mainly within the tumour site (B, 20x magnification). Quantitative analysis of CD68+ 
expression found no significant difference within the tumour and matched tumour-free regions (C). Similarly, 
there was no significant difference in the percentage positive area of MPO+ staining in the matched 
specimens despite an increasing trend in the tumour region (D) 
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Figure 2.3.2.2 Increased MMP-9 expression is found in tumour associated neutrophils and 
malignant lung epithelium 
The source of MMP-9 expression was assessed in the matched lung specimens (n=10). Spearman correlation 
demonstrated no association between CD68+ macrophages and MMP-9 expression (A). A closer association 
was detected between MPO+ neutrophils and MMP-9 transcription in the tumour sections (B) which was not 
observed in the adjacent controls (C). Representative tumour sections stained for MMP-9 identified intense 
immuno-reactivity within tumour associated neutrophils (C, 20x magnification, open arrows), but not 
macrophages (D, black arrows). MMP-9 immuno-reactivity was also detected in tumour cells of epithelial 
origin (E) 
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2.3.3 Reduced PTEN transcript expression within tumour region relative to adjacent 
tumour free region.  
Molecules released by necrotic and cancer cells can activate Toll-like receptors (TLRs) expressed on 
hematopoietic cells, including macrophages. These activated cells can then release inflammatory 
cytokines and proteases including MMP-9, which lead tumour progression and metastasis. TLR2 
recognises a wide range of microbial products and damage associated molecular patterns (DAMPs). 
Lewis lung carcinoma cells (LLC) are known to produce mediators that activate TLR2 on myeloid cells, 
which strongly enhances LLC metastatic growth 87. Assessment of the expression of the leukocyte 
pathogen recognition receptor, TLR2 revealed heterogeneity in transcript levels within the tumour 
region with no significant change in expression relative to the individuals’ tumour free region (Figure 
2.3.3.1A). Furthermore, analysis by spearman correlation demonstrated no relationship between 
TLR2 and MMP-9 levels to indicate that increased expression of MMP-9 within the tumour region is 
not related to the expression of TLR2 in NSCLC (Figure 2.3.3.1B). PTEN expression was reduced by 2-
fold within the tumour region (Figure 2.3.3.1, p<0.01), with 7/9 tumours expressed at least 40% 
lower PTEN transcript levels. Stratification of tumour histological type revealed no significant 
difference in PTEN expression between tumour subtype (Figure 2.3.3.1C).   
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Figure 2.3.3.1 PTEN transcript levels are down-regulated in tumour region in COPD patients 
Transcript levels of the pathogen recognition receptor TLR2 and the tumour suppressor gene PTEN were 
measured by RTqPCR in the archival specimens (n=10). While heterogeneity in TLR2 expression was detected 
at the tumour site, there was no significant change relative to the adjacent tumour-free region (A). In 
addition, TLR2 transcription was not associated MMP-9 gene expression (B). PTEN levels were assessed and 
demonstrated a significant reduction in expression at the tumour site relative to matched tumour-free 
control sections (C, **p <0.01, Wilcoxon matched-pairs signed rank test). Assessment by tumour subtype 
demonstrated no significant difference in PTEN expression. 
 
2.3.4 PTEN knockdown in lung epithelial Beas-2B cells selectively increased MMP-9 
expression in a budesonide resistant manner 
To investigate whether PTEN can regulate the levels of MMP-9 cell of epithelial origin, control and 
PTEN knockdown (PTEN KD) BEAS-2B cells were stimulated with the TLR4 bacterial agonist LPS. IL-6 
transcript levels were measured to characterise a classic inflammatory response. At 3 hours, IL-6 
transcript levels increased approximately 20-fold (Figure 2.3.4.1A) following LPS stimulation, with 
expression returning to baseline by 48hours (Figure 2.3.4.1B). These timepoints were chosen to 
represent the peak (3hours) and resolution (48hours) of inflammatory responses. No significant 
difference was observed between control and PTEN KD cells. Budesonide significantly reduced peak 
LPS-induced IL-6 levels in control cells (Figure 2.3.4.1A, 70% reduction; ANOVA, *p < 0.05 control 
 28 
Chapter 2 – Tumour associated neutrophils and loss of epithelial PTEN can promote corticosteroid 
insensitive MMP-9 expression in the chronically inflamed lung microenvironment 
cells LPS vs. BUD-LPS). Budesonide proved to be less effective in reducing peak IL-6 levels in PTEN KD 
cells (Figure 2.3.4.1B, 54% reduction; p > 0.05 PTEN KD cells LPS vs. BUD-LPS). 
Since Mitogen-activated protein kinase phosphatase-1 (MKP-1) contains consensus glucocorticoid 
response elements within its promoter, this gene was measured as a control for steroid exposure. 
Budesonide-induced levels of MKP-1 were not altered in PTEN KD cells at 3hours, hence steroid 
receptor engagement and nuclear translocation is maintained (Figure 2.3.4.1C). Preliminary 
assessment of MMP-9 expression at 3hours demonstrated no increase in MMP-9 levels in either 
control or PTEN KD cells (data not shown). At the later 48hour time-point, LPS stimulation of control 
cells did not significantly alter baseline MMP-9 expression. In contrast, PTEN KD cells responded to 
LPS by increasing MMP-9 expression (Figure 2.3.4.1D, 4.7±0.5-fold increase, 2-way ANOVA, #p <0.05, 
control vs. PTEN KD cells).  LPS-induced expression of MMP-9 was not inhibited by budesonide in 
PTEN KD cells (Figure 2.3.4.1D, 4.7±0.8-fold increase; BUD-LPS treated control vs. PTEN KD cells, 2-
way ANOVA, #p <0.05). 
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Figure 2.3.4.1 Effect of epithelial PTEN knockdown on inflammation and MMP-9 expression 
Beas-2B cells transfected with control or PTEN siRNA were stimulated with 100ng/mL LPS and 10-7M 
budesonide (n=5). Interleukin-6 (IL-6) levels were measured at 3hours (A) and 48hours (B).  LPS-induced IL-6 
expression at 3hours was significantly reduced by Budesonide pre-treatment in control but not PTEN KD cells 
(C, *p< 0.05, one-way ANOVA of LPS vs. BUD-LPS). As a control for steroid exposure, MKP-1 levels were 
elevated 3hours post treatment and demonstrated no difference between control and PTEN KD cells (C). At 
the 48hr timepoint, MMP-9 expression was determined, demonstrating a significant increase in LPS-
stimulated PTEN KD cells but not control cells and this response was not inhibited by budesonide (F, #p<0.05, 
two-way ANOVA and Bonferroni multiple comparison post hoc test). 
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 Discussion 
MMP-9 is normally released from inflammatory and stromal cells during acute inflammation and 
infection, where it degrades extracellular matrix components to facilitate leukocyte migration and 
tissue regeneration at the site of injury 88. However, MMP-9 is chronically elevated in COPD where it 
correlates with the degree of neutrophilic inflammation and contributes to destruction of alveolar 
attachments due to excessive degradation of collagen and elastin fibres 75, 89. There is also evidence 
to suggest that the chronic injured epithelium is transformed in COPD where expression of epithelial 
and mesenchymal markers including cytokeratin, N-cadherin and MMP-9 are increased 76.  In this 
study, we specifically addressed whether MMP-9 is further increased in lung cancer patients with co-
existing COPD and demonstrate that MMP-9 transcript levels are highest within the tumour region. 
Tumour associated neutrophils represent an important source of MMP-9 in NSCLC and loss of 
epithelial PTEN may further augment steroid insensitive expression. 
Expression of the PTEN tumour suppressor gene has also been shown to be downregulated in COPD 
epithelium 80, and we have shown that PTEN transcript levels were further reduced in the majority of 
tumours tested. Mutations or deletions of the PTEN gene are observed in around 5-10% lung cancers 
and higher rates (30-35%) of  PTEN promoter hypermethylation have been reported in NSCLC 90. 
Microsatellite DNA Instability and loss of heterozygosity have also been shown to occur in COPD 
epithelial cells, where they accumulate as a consequence of chronic inflammation and excessive 
oxidative burden 91. Oxidative stresses can also directly influence the activity of the PTEN protein, 
which is susceptible to oxidative modification that inhibits its enzymatic activity leading to increased 
PIK3CA/Akt signalling 92. Hence, loss of PTEN function by post translational modification caused by 
reactive carbonyls represents an alternative pathway to maintaining tumour promoting PIK3CA 
/Akt/mTOR signalling in COPD-lung cancer patients. 
There are studies that associate PTEN and MMP-9 expression in cancer 82, 83 and our findings 
demonstrate that PTEN can directly regulate epithelial expression of MMP-9. We chose to stimulate 
Beas-2B bronchial epithelial cells with LPS as a surrogate for gram negative bacterium, which are 
frequently isolated from colonised and exacerbating COPD patients 93. We demonstrate that LPS 
potently stimulated inflammatory cytokine expression in a budesonide sensitive manner in Beas-2B 
cells. We have previously shown that the Activator protein 1 (AP-1) transcription factor was 
markedly increased in this cell line in response to LPS relative to the NF-B transcription factor, 
which was modestly activated 94. The promoter region of human MMP-9 contains binding sites for 
multiple transcription factors including NF-B and AP-1 subunits 95. In this study, LPS failed to 
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increase MMP-9 expression; hence an AP-1 high/ NF-B low transcriptional profile was not sufficient 
to induce MMP-9. This is consistent with the AP-1 site being indispensable but not sufficient for the 
induction and requires synergistic cooperation with the NF-B and other transcription factor sites 95. 
The knock-down of PTEN specifically increased MMP-9 in a steroid resistant manner at the later 
48hour LPS time-point. This indicates that MMP-9 is not being directly induced by LPS ligation of the 
TLR4 signalling pathway, but rather induced by secondary events in bronchial epithelial Beas-2B 
cells. Our data demonstrates that inflammatory cytokine IL-6 is induced by LPS stimulation but 
remained 6-fold higher than vehicle treated cells following Budesonide treatment. IL-6 interacts with 
Glycoprotein 130, which is phosphorylated upon ligand binding leading to JAK/Stat pathway 
activation and subsequent gene expression. PTEN is known to be an important negative regulator of 
the Stat3 transcription factor 96. It has already been shown that the functional cooperation of the 
Stat3 and AP-1 transcription factors plays a crucial role in the transcription of MMP-9 gene through 
engagement of juxtaposed Stat3/AP-1 element 97. The loss of PTEN expression during IL-6 mediated 
activation of gp130 can lead to increased activation of Stat3 and our data supports this proposed 
mechanism leading to elevated MMP-9 epithelial expression. PTEN is also an important negative 
regulator of EGFR transactivation, and pharmacological augmentation of PTEN expression 
suppresses pathological processes mediated by EGFR amplification 81. EGFR is also indirectly 
transactivated in response to viral and bacterial agonists in bronchial epithelial cells 85, 98, where TLR 
agonists initiates a cascade that promotes release and activation of latent EGFR ligands including 
TGF. Since PTEN is a critical negative regulator of the EGFR pathway, loss of PTEN can augment 
EGFR-dependent signalling that regulates inflammation and mucus production. It has been 
previously suggested that the EGFR pathway may play an important role in NSCLC invasion via 
specific up-regulation of MMP-9 99. Furthermore, it has been shown that EGFR receptor is not 
inhibited by corticosteroids, but rather increased in response to EGF stimulation in the presence of 
dexamethasone in bronchial epithelial cells 100. 
In summary, tumour associated neutrophils in NSCLC were most strongly associated with MMP-9 
expression in our study.  Neutrophils can be transformed by the malignant microenvironment, 
leading to divergent phenotypes that release pro-angiogenic factors such as MMP-9 101. We also 
propose that reduced expression of epithelial PTEN may activate an alternative transcriptional 
network to stimulate steroid insensitive epithelial expression of MMP-9. A limitation of the study 
was that this shared molecular pathway was investigated in a small cohort of NSCLC patients with 
co-morbid COPD (n=10). Lacking from our cohort, were patients with severe COPD (GOLD stage III-
IV) which would provide greater insight into the changes in the chronic inflammatory environment 
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during metastasis. Wang et al have shown in a total cohort of 2,222 lung cancer patients, 32.6% of 
patients had concurrent COPD, however only 1.3% were diagnosed with severe COPD as they are 
associated with significantly worse overall survival 102. Additionally, tumour biopsies are very difficult 
to obtain from patients with severe COPD who are at an inoperable stage. Nonetheless, our study 
suggests that increased MMP-9 expression in early stage disease may be a useful marker of 
malignancy which will be further assessed in chapter 3. Novel strategies aimed at reducing tumour 
associated neutrophils and restoring epithelial PTEN expression should be considered. 
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In the previous chapter, we identified that MMP-9 transcription is significantly upregulated at the 
tumour site in NSCLC patients. While MMP-9 is commonly upregulated in cancer due to its role in 
promoting tumour migration and invasion, this specific increase in transcripts at the tumour site 
suggests its utility as a potential diagnostic biomarker. Comprehensive gene expression analysis for 
biomarker discovery as well as large panel sequencing to guide clinicians in the use of targeted 
therapies is emerging but has limited use in cytology and biopsy specimens that have been formalin 
fixed for preservation and analysis.  The results presented in Chapter 3 have been reported in full in 
a manuscript published in the Journal of Molecular diagnostics (Appendix B). Here, we propose a 
new workflow for preserving cytology specimens that are suitable for large panel gene expression 
and mutational profiling. The results section has been expanded to compare and validate the 
diagnostic potential of several MMPs and their TIMP inhibitors. In addition, our new workflow can 
easily integrate assessment of PD-L1 transcription as a possible alternative to assessing PD-L1 status 
to guide immunotherapies.  
 
 
 
 
 
 
 
 
 
  
 35 
Chapter 3 – A novel approach to detect PD-L1 status and multiple tumour mutations using a single 
NSCLC bronchoscopy specimen 
 Introduction 
Radial probe endobronchial ultrasound (EBUS) is a minimally invasive procedure that improves 
localisation of peripheral pulmonary lesions. Cytology samples of the suspect lesion site collected by 
radial EBUS bronchoscopy provides good diagnostic sensitivity estimated at 73% 103, where histology 
does not definitely diagnose malignancy in about 20% cases 104, 29. When this procedure is combined 
with rapid on-site examination (ROSE) of cytological samples, shorter procedure times are achieved 
due to real time assessment of specimens 29. In addition to improving diagnosis and/or staging of 
lung cancer, small specimens collected by EBUS-guided procedures are being evaluated for their 
utility to identify molecular drivers of the disease. EBUS-transbronchial needle aspiration (TBNA) 105, 
EBUS-guided fine needle aspirates (FNA) 106 and bronchoscope cytology brush tip washings can 
provide adequate material for both immunohistochemical studies 107 and mutation sequencing of 
EGFR, KRAS, and BRAF genes 108.  
There is increasing demand on molecular and sequencing technology to adapt with limited amounts 
of fixed tumour tissue, which are becoming the most commonly used samples for diagnostic and 
molecular pathology. However, fixed tumour tissue may not be optimal in all settings or for all 
downstream analyses. For example, it is generally accepted that unfixed frozen tumour tissue 
produces a high yield of DNA that is of higher integrity, whereas fixatives are known to fragment 
DNA and artificially incorporate mutations in the tumour genome 109. Another limitation is that the 
majority of NSCLC patients do not harbour oncogenic mutations such as EGFR, hence checkpoint 
inhibitors are increasingly being used to treat advanced NSCLC. As not all individuals benefit from 
immunotherapy, biomarkers are being developed to identify patients that are most likely to 
respond. Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1), 
which significantly increased progression-free and overall survival compared to platinum-based 
chemotherapy in patients with at least 50% PD-L1 tumour cell expression 110. In a more recent study, 
the combination of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) was particularly effective in 
increasing progression-free survival in patients with a high tumour mutational burden (at least 10 
mutations per megabase DNA) relative to chemotherapy 111. 
In this study, we aim to significantly advance the diagnostic utility of EBUS-guided bronchoscopy 
specimens for the molecular testing of lung cancer patients. We have firstly evaluated the 
expression of matrix metalloproteinase-9 (MMP-9) and its endogenous inhibitor (TIMP3) by RT-
qPCR, which are implicated in cancer matrix remodelling, angiogenesis, cancer cell migration and 
signalling 55. We demonstrate for the first time the ratio of MMP9:TIMP3 can accurately differentiate 
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malignant from non-malignant tissue specimens without the need to fix tissue for histological 
assessment. Using high quality nucleic acid from the same single bronchoscopy specimens, we were 
able to quickly and accurately evaluate PD-L1 transcript levels and detect multiple oncogenic 
mutations. Furthermore, we demonstrate excellent concordance between PD-L1 transcript levels 
and PD-L1 immunohistochemical tumour staining. 
 Materials and Methods 
3.2.1 Collection of EBUS bronchial brushings   
EBUS bronchoscopy brushings were obtained from a total of 28 patients enrolled at the Royal 
Melbourne Hospital under conscious sedation, as previously described 29. Final diagnosis was based 
on clinic-radiologic findings as well as histologic results, as per ATS/ERS guidelines for assessment of 
interstitial lung disease. For the malignant brushings (n=15/28), radial EBUS bronchoscopy was 
combined with rapid on-site examination (ROSE) by a medically trained cytopathologist to confirm 
the malignant nature of the lesion site (Table 3.3.1.1). This was immediately followed by an 
additional single pass brush at the same lesion site for molecular processing. For the control 
bronchoscopy specimens (n=13/28), patients were considered for inclusion based on clinic-
radiologic diagnosis of benign interstitial lung disease as summarised in Table 3.3.1.2. With all brush 
specimens, the brush tip was immediately placed in RLT buffer (Qiagen, Hilden, Germany) containing 
β-mercaptoethanol and the samples were stored at -80°C prior to molecular analysis. 
3.2.2 Frozen lung biopsy specimens 
Snap frozen lung biopsies were obtained from the Victorian Cancer Biobank (VCB) under RMIT 
university ethics approval (Ethics ID: SEHAPP 09-17). The VCB biobank included 100 donors and the 
patient characteristics are summarised in Table 3.3.5.1. Macro-dissection was performed by a 
pathologist to enrich for tumorous material and 88 out of 90 FFPE blocks contained at least 50% 
tumour content as determined by microscopic analysis. The control group (n=20) included lung 
specimens obtained from 10 patients without malignant disease (Table 3.3.5.2). Additionally, 
matching control specimens comprised of adjacent tumour-free tissue were obtained from 10/50 
Adeno patients and used for pair-wise analysis of gene expression changes. 
3.2.3 Assessment of gene expression by RT-qPCR 
Total RNA and DNA was isolated from biopsy specimens using the AllPrep DNA/RNA/miRNA 
Universal kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. For the discovery 
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cohort, up to 30mg of frozen lung tissue was homogenised in RLT lysis buffer containing β-
mercaptoethanol using the TissueLyser LT (Qiagen, Hilden, Germany) prior to extraction. For the 
EBUS-guided brush specimens, RNA and DNA was extracted from each single pass brush sample 
without the requirement for homogenisation. The NanoDrop™ One Microvolume UV-Vis 
Spectrophotometer (Thermo Fisher Scientific, MA, US) was used to measure the concentration and 
quality of purified RNA. Up to 2ug of total RNA was converted to cDNA using the Superscript IV VILO 
kit (Thermo Fisher Scientific, MA, US). Quantitative PCR was performed on the QuantStudio 7 
(Applied Biosystems, CA, US) using validated Taqman primers formatted in a Taqman Low Density 
Array (TLDA) card to assess gene expression of MMP-9, MMP-7, MMP-3, TIMP-1, TIMP-2, TIMP-3, 
PD-L1, MET, PTEN, TBP and PUM1. Threshold cycle values (Ct) were normalized to the geometric 
mean of the reference genes TBP and PUM1 reported to be stable in NSCLC tissue specimens 84. The 
comparative (2-ΔΔCt) method was used to present gene expression as fold change relative to a control 
sample within the EBUS bronchoscopy brushing and biopsy cohort.  
3.2.4 Targeted next generation sequencing of EBUS-guided brush specimens 
The TruSight Tumour 15 panel (Illumina, San Diego, CA) was used to screen ROSE confirmed 
malignant EBUS bronchial brushings for somatic tumour variants in 15 commonly mutated genes 
(AKT1, GNA11, NRAS, BRAF, GNAQ, PDGFRA, EGFR, KIT, PIK3CA, ERBB2, KRAS, RET, FOXL2, MET, 
TP53). Isolated DNA was assessed for quantity and quality using the GeneRead DNA QuantiMIZE 
Assay Kit (Qiagen, Hilden Germany). Samples with passed QC scores containing an amplifiable 
concentration greater than 2ng/μl were considered suitable for library preparation. For each sample, 
20ng of DNA in combination with two complementary oligo pools was used in the initial 
amplification step. Each library was PCR amplified with a unique index sequence and purified 
according to manufacturer’s instructions. DNA library concentration was measured on the 
fluorometric qubit system using the Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific, MA, US) 
and normalised to 5ng/μl. Using a 1.5% agarose gel, each library was assessed for an optimal 
product size of approximately 300bp. Samples were excluded from sequencing if the library failed to 
generate the correct product size. Targeted sequencing was performed on the Illumina Miseq (San 
Diego, CA, US) using the Miseq v3 kit. Libraries were combined, denatured and diluted to a final 
concentration of 10pM for optimal cluster density. As a quality control measure for cluster density 
and alignment PhiX (10nM) was spiked in at 5%. Sequencing achieved a minimum read depth of 
1000x with a Q score >30. Resulting VCF files were extracted and analysed using the VariantStudio 
Analysis Software (Illumina, San Diego, CA, US). Confirmatory sequencing testing on a subset of 
tumour specimens was performed by the NATA-accredited anatomical pathology laboratory at St 
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Vincent’s Hospital Melbourne using the Ion AmpliseqTM Colon and lung Cancer Panel V2 
(ThermoFisher, USA) run on the Ion Torrent Personal Genome Machine sequencer and analysed with 
the Ion Reporter software v5.4 (ThermoFisher, USA). Variant calls were manually inspected using the 
Integrative Genomics Viewer (Broad Institute, University of California, USA). 
3.2.5 PD-L1 immunohistochemical staining on matching FFPE biopsies. 
Matching FFPE blocks, prepared from the same resected site as the frozen tumour biopsies, were 
collected and sections of 5µm thickness were prepared for PD-L1 immunohistochemical staining. 
The Anatomical Pathology laboratory at the Royal Melbourne Hospital stained SCC slides (n=40) 
using the human PD-L1 (SP263) rabbit monoclonal antibody (Ventana) with the aid of the Benchmark 
Ultra automatic staining instrument (Ventana,Tuscan, AZ, USA), according to manufacturer’s 
instructions. Visualisation was achieved using the OptiView DAB IHC detection kit (Ventana) and 
sections were counterstained in haematoxylin. The slides were captured using the Olympus VS120 
virtual slide scanner and the area positive for PD-L1 staining across the entire tumour section was 
determined using the Olympus CellSens software. In addition, scoring of the percentage of PD-L1 
tumour and immune cell staining was blindly performed by an experienced pathologist as previously 
described 112. 
3.2.6 Statistical analysis 
All graphs were generated using Graphpad prism 7.02 (Graphpad Software Inc, San Diego, CA). All 
fold change data is expressed as Tukey boxplots as previously described (Section 2.2.7) with outliers 
shown as data points outside the boxplot > 1.5x IQR. Mann-Whitney two-tailed t-tests were 
performed to compare gene expression changes between unpaired NSCLC vs Control groups. Paired 
groups were assessed using the Wilcoxon signed rank test. The fold change between multiple groups 
was compared using the Kruskal Wallis test followed by Dunn’s multiple comparison post hoc test. In 
all cases, n represents the number of independently conducted experiments and p<0.05 is 
considered statistically. To assess the diagnostic accuracy of MMP-9 and TIMP-3, a receiver 
operating characteristic (ROC) curve was generated and the area of the curve (AUC) was calculated. 
Sensitivity and specificity values generated from the ROC curve were used to determine the best fold 
change cut-off value.  
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 Results 
3.3.1 Patient characteristics and Nucleic acid yields of the EBUS cohort 
The EBUS cohort comprised of 15 NSCLC patients and 13 control patients. Following an examination 
of additional bronchoscopy specimens, the final pathology-based diagnosis of the malignant 
brushings included Adeno (n=10) and SCC (n=5) as summarised in Table 3.3.1.1. In conjunction with 
the clinic-radiologic findings, the control specimens were diagnosed with either benign or 
inflammatory conditions (Table 3.3.1.2).  The male to female ratio was 8M:7F for the malignant 
specimens and 7M:6F for the control specimens. Median age of the malignant cohort was 73.7 (± 
10.8) while the median age for the controls were 62.8 (±12) years old. Total RNA yield from the 
control single-pass EBUS-guided brush specimens (Table 3.3.1.2, median 5.2; range 1.0-5.8 µg) was 
significantly higher than the malignant brush specimens (Table 3.3.1.1, median 2.1; range 0.2-7 µg). 
All malignant EBUS-guided brush specimens were found suitable for genomic sequencing and 
generated total amplifiable DNA (Table 3.3.1.1; median 1.9; range 0.3-9.6 µg).  In one case, the initial 
EBUS guided bronchoscopy specimen was determined to be non-malignant based on cytology (post-
inflammatory benign lesion), however a secondary EBUS specimen collected nine months later 
identified the presence of malignant cells and is therefore described as a stand-alone case study 
(Figure 3.3.2.2). 
 
Table 3.3.1.1 Patient Characteristics of the NSCLC brushings specimens 
Sample Age (Yrs) Sex M/F NSCLC subtype Total RNA (µg) Total DNA (µg) 
1 73 Female Adenocarcinoma 1.7 3.2 
2 64 Male Squamous (SCC) 1.6 3.8 
3 67 Female Squamous (SCC) 3.0 3.8 
4 89 Female Adenocarcinoma 2.5 1.3 
5 76 Female Adenocarcinoma 1.4 0.3 
6 73 Male Adenocarcinoma 2.2 1.9 
7 58 Female Adenocarcinoma 1.8 0.8 
8 90 Male Adenocarcinoma 1.8 1.4 
9 64 Male Adenocarcinoma 6.0 4.7 
10 79 Female Adenocarcinoma 0.2 1.6 
11 89 Male Adenocarcinoma 2.1 2.1 
12 68 Male Squamous (SCC) 4.8 1.5 
13 60 Female Squamous (SCC) 6.3 9.6 
14 70 Male Squamous (SCC) 7.0 2.9 
15 86 Male Adenocarcinoma 1.0 0.5 
Median 
Age±SD 
73 ± 10.8  Median yield ± 
range 
2.1 ± 0.2-7 1.9 ± 0.3-9.6 
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Table 3.3.1.2 Patient characteristics of the control EBUS specimens with benign or inflammatory 
conditions 
Sample Age 
(Years) 
Gender 
(M/F) 
Diagnosis  Total RNA 
(µg) 
Total DNA 
(µg) 
1 60 Male Hypersensitivity Pneumonitis 1 2.0 
2 64 Male Chronic Aspiration Pneumonia 3.3 1.1 
3 57 Female Interstitial Lung Disease 10 7.0 
4 51 Female Sarcoidosis 10.3 7.2 
5 61 Female Pneumonia 4.1 3.2 
6 57 Female Normal (no radiologic abnormality) 9 3.1 
7 74 Male Idiopathic Pulmonary Fibrosis  4 2.2 
8 69 Male Non-specific interstitial pneumonia  6.4 2.5 
9 37 Male Drug reaction 15.8 4.6 
10 77 Female Hypersensitivity pneumonitis 4.9 3.6 
11 74 Female Hypersensitivity pneumonitis 4 2.7 
12 71 Male Non-specific interstitial pneumonia  6.2 3.8 
13 49 Male Respiratory bronchiolitis interstitial lung disease  5.2 1.8 
Median 
Age±SD 
61 ± 11.6 Median yield ± range 5.2 ± 
1.0-15.8 
3.1 ±  
1.1-7.2 
 
 
3.3.2 Assessment of MMP-9 and TIMP3 transcript levels strongly distinguishes malignant 
from control EBUS bronchial brushings 
MMP-9 gene expression was significantly increased in malignant specimens relative to the control 
brushings (Figure 3.3.2.1A; 23-fold increase, p < 0.0001). TIMP3 levels were significantly reduced in 
the malignant tissue specimens (Figure 3.3.2.1B, 3-fold reduction, p = 0.0004). The MMP9:TIMP3 
ratio was also markedly increased in NSCLC specimens collected by EBUS bronchoscopy (Figure 
3.3.2.1C, 137-fold increase, p < 0.0001). ROC curve analysis of the MMP9:TIMP3 ratio generated an 
AUC value of 0.980 (Figure 3.3.2.1D, 95% CI;0.93-1.0, p<0.0001). Using a cut-off of 10.4, the 
MMP9:TIMP3 ratio was highly sensitive (93%, CI 68-99%) and specific (92%, CI 64-98%) for 
discriminating non-malignant from malignant EBUS-guided specimens. In one case that was initially 
considered non-malignant by pathology [path(-)], elevated levels of MMP-9 and reduced levels of 
TIMP3 were detected (Figure 3.3.2.2A-B). The MMP9:TIMP3 ratio was well above the 10-fold cut-off 
(Figure 3.3.2.2C, 311-fold increase), to indicate that the specimen was malignant. A subsequent 
EBUS specimen collected 9 months later confirmed malignancy by pathology and the MMP9:TIMP3 
ratio remained well above the 10-fold cut-off (73-fold above control specimens).       
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Figure 3.3.2.1 MMP-9:TIMP3 ratio differentiates control and malignant EBUS brushings 
Following ROSE confirmation, MMP-9 and TIMP3 transcript levels were determined by RT-qPCR in control (n=13) 
and malignant (n=15) EBUS bronchoscopy brush specimens. MMP-9 levels were significantly increased in NSCLC 
specimens (A; ****P<0.0001, Mann-Whitney t test), whereas TIMP-3 levels were significantly reduced (B; 
***P<0.001). The ratio of MMP-9:TIMP3 expression was significantly increased in the NSCLC specimens relative 
to the controls (C; ****P<0.0001). ROC curve analyses of the MMP-9:TIMP3 ratio demonstrated its accuracy to 
differentiate control and NSCLC specimens by generating an area under the curve (AUC) value of 0.98 (D; 95%CI; 
0.9-1.0, ****P<0.0001). 
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Figure 3.3.2.2 A case study demonstrating the ratio of MMP-9:TIMP3 can confirm malignancy 
Assessment of MMP-9 and TIMP3 transcript levels, by Taqman RT-qPCR, was performed on one case with a 
suspect lesion. The lesion was initially classified as control (  Path-) following cytological analysis, however 
it was re-identified as malignant (  Path+) 9 months later. Gene expression analysis detected a significant 
increase in MMP-9 and a reduction in TIMP3 transcript levels in both Path- and Path+ EBUS brushings (A-B). 
Moreover, the ratio of MMP-9:TIMP3 remained well above the 10-fold cut off value in both the Path- and 
Path+ specimens (C), highlighting the potential of MMP-9:TIMP3 to improve the diagnostic accuracy of EBUS 
brushings 
 
3.3.3 Targeted sequencing detects somatic variants in malignant EBUS brushings 
Using the TruSight tumour panel the most frequently mutated gene was TP53 with 13 alterations in 
10/15 (67%) patients (summarised in Table 3.3.3.1). KRAS single nucleotide variants (Q61H and 
G12C) were detected in 2/15 (13%) of patients with lung adenocarcinoma. Additionally, two Adeno 
patients harboured EGFR variants, which included the common single nucleotide variant L858R and 
the exon 19 deletion-insertion E746_T751>IP. A single nucleotide variant in MET was detected in 
one patient with SCC and an insertion of p.A775_G776insSVMA was detected within exon 20 of 
ERBB2/HER-2 in one patient with Adeno. This insertion occurred within the exon 20 hotspot region 
previously identified as the most commonly mutated site in HER2 in NSCLC 113. Confirmatory analysis 
using the Ion Ampliseq panel detected identical variants in EGFR, MET and ERBB2/HER-2 in the same 
patients. The Ion Ampliseq panel detected an additional TP53 variant (D148fs) in one patient with 
SCC (Table 3.3.3.1: sample 12) as well a variant in CTNNB1 which is not covered by the TruSight 
tumour panel. 
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Table 3.3.3.1 Genetic variants detected in individual malignant EBUS bronchial brushings 
No. 
NSCLC 
Subtype Gene 
Variant 
Type 
Variants detected by TruSight tumour 
Illumina panel 
Variants detected by Ion Ampliseq 
panel 
CDS Amino Acid VAF (%) CDS Amino Acid VAF (%) 
1 Adeno TP53 SNV c.856G>T p.E286* 5.1    
 
 KRAS SNV c.183A>C p.Q61H 4.4    
2 
SCC TP53 Insertion 
c.834_835 
dupT 
p.G279fs*27 39.7    
 
  SNV c.722C>G p.S241C 37.8    
3 SCC TP53 Deletion c.602delT p.L201fs*46 33.2    
4 ADENO   No Variants    
5 ADENO   No Variants    
6 ADENO EGFR SNV c.2573T>G p.L858R 9.1    
7 
ADENO TP53 Deletion 
c.529_546d
el18 
p.P177_C182
delPHHERC 
10.6 
c.529_546 
del18 
p.P177_C18
2delPHHER
C 
12.9 
 
 EGFR Deletion 
c.2235_225
1delinsATTC 
p.E746_T751>
IP 
40 
c.2235_225
1delinsATTC 
p.E746_T75
1>IP 
40.2 
8 
ADENO TP53 Insertion 
c.537_538 
dupT 
p.E180fs*6 10.2    
 
 KRAS SNV c.34G>T p.G12C 26.1    
9 ADENO TP53 Deletion c.463delA p.T155fs*15 35.4    
 
  SNV c.461G>C p.G154A 35.2    
10 
ADENO ERBB2 Insertion 
c.2324_232
5insCTCCGT
CATGGC 
p.A775_G776i
nsSVMA 
34.5 
c.2324_232
5insCTCCGT
CATGGC 
p.A775_G77
6insSVMA 
33.9 
  *CTNNB1 SNV    c.98C>T p.S33F 28.8 
11 
ADENO TP53 MNP 
c.741_742d
elCCinsTT 
p.R248W 8.1 
c.741_742 
delCCinsTT 
p.R248W 5.5 
 
  SNV c.298C>T p.Q100* 7.9 c.298C>T p.Q100* 7.5 
12 SCC MET SNV c.3393C>G p.N1131K 38.5 c.3393C>G p.N1131K 40.5 
 
 *TP53 Deletion    
c.443_470 
del28 
p.D148fs 21.5 
13 SCC TP53 SNV c.314G>T p.G105V 82.7 c.314G>T p.G105V 83.7 
14 SCC TP53 SNV c.623A>T p.D208V 52    
15 ADENO TP53 SNV c.830G>T p.C277F 8.9    
* Refers to additional genetic variants detected by the Ion AmpliseqTM Colon and Lung Cancer Panel V2 
(ThermoFisher) that were not detected or covered by the TrusSight tumour panel (Illumina) 
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3.3.4 Assessment of the oncogenic drivers PD-L1, MET and PTEN in the EBUS cohort  
Using the same EBUS-brush specimen, we also evaluated gene expression of a panel of genes 
implicated as oncogenic drivers in NSCLC including PD-L1, MET and PTEN by RT-qPCR. Gene 
expression analysis identified distinct gene expression changes. Significantly higher PD-L1 transcript 
levels (Figure 3.3.4.1A; p=0.029) were detected in NSCLC brushings, where 4/15 samples were above 
the highest control specimen. Whilst MET expression was not significantly altered in NSCLC, we did 
detect two NSCLC specimens with markedly amplified levels of MET gene expression (> 8-fold 
increase, Figure 3.3.4.1B).  PTEN transcript levels were not significantly altered in NSCLC brushings, 
however we did detect 3/15 specimens that were reduced by at least 40% (Figure 3.3.4.1C).  
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Figure 3.3.4.1 Gene expression of PD-L1, MET and PTEN in the EBUS specimens by RT-qPCR 
Further analysis of the same EBUS specimens by Taqman RTq-PCR was performed to evaluate gene expression 
changes of PD-L1, MET and PTEN in NSCLC. PD-L1 transcript levels were significantly higher in the malignant 
EBUS specimens (A; *P<0.05, Mann-Whitney t-test). MET gene expression was not significantly altered in the 
NSCLC biopsies, however elevated transcripts levels that are indicative of MET gene amplification was 
detected in 2 NSCLC specimens (B). Similarly, PTEN transcript levels were not significantly different in the 
NSCLC specimens, however 4/15 were reduced by at least 2-fold relative to the median control levels (C). 
 
3.3.5 Patient characteristics of the biopsy cohort 
The larger biopsy cohort (n=110), comprised of 90 NSCLC specimens and 20 control specimens, is 
summarised in Table 3.3.5.1. Subclassification of the NSCLC group confirmed 50 Adeno specimens 
with a mean age 67 ± 8.6 yrs and a M:F ratio of 26:24. The SCC subtype comprised of 40 patients 
with a mean age of 69.0 ± 9.6 yrs and a M:F ratio of 33:7. Assessment of smoking status in the Adeno 
group determined 24% were current smokers, 56% were former smokers and 20% were never-
smokers. However, nearly all SCC patients were either current (27.5%) or former (67.5%) smokers. 
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COPD status was confirmed in 68/90 NSCLC patients. The proportion of Adeno and SCC patients with 
concurrent COPD was 18/50 (36%) and 17/40 (42.5%), respectively.  A majority of the malignant 
specimens were from patients with early stage I (36/90) and stage II (46/90) disease, with only 8/90 
with advanced stage III. In comparison, the control group comprised of 10 non-malignant specimens 
(Table 3.3.5.1; mean age of 52.4 ± 17.6 yrs; M:F ratio of 6:4) and 10 Adeno matched specimens 
obtained from the adjacent normal region.  The final diagnosis of the non-malignant controls is 
summarised in Table 3.3.5.2. 
 
Table 3.3.5.1 Patient characteristics of the biopsy cohort 
 Controls NSCLC 
 Non-malignant 
Adjacent tumour-
free tissue Adeno SCC 
Number of patients 10 10 50 40 
Age (mean yrs ± SD) 52.4 ± 17.6 71.0 ± 11.5 67.0 ± 8.6 69.0 ± 9.6 
Sex        
Male 6 6            26 33 
Female 4 4 24 7 
Smoking status        
Current Smoker 2 3            12 11 
Ex-smoker 5 7 28 27 
Never-Smoker 3 - 10 1 
Unknown - - - 1 
COPD status        
Yes 2 4            18 17 
No 6 5 19 17 
Unknown 2 1 13 6 
Tumour Stage        
    I - -            21 15 
II - - 27 19 
III - - 2 6 
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Table 3.3.5.2 Patient characteristics of the biopsy non-malignant control cohort 
Sample Age (Years) Gender (M/F) Diagnosis 
1 65 Male Necrotic Bullitis (benign) 
2 73 Female Bronchiolitis Obliterans with Organizing 
Pneumonia (BOOP) 
3 40 Female Bronchiectasis 
4 63 Male Pulmonary Hamartoma (benign) 
5 60 Male Progressive atypical mycobacteria infection 
6 60 Female Granuloma 
7 29 Female Schwannoma (Benign) 
8 71 Male Haematoma 
9 26 Male Chronic inflammation and fibrosis 
10 37 Male Foreign material bronchopneumonia and 
scarring 
 
 
 
3.3.6 Assessment of MMP transcript levels in the biopsy specimens 
The total RNA yield was high in the normal biopsy specimens (median 11.5; range 4.0 – 33.1 µg) and 
in the tumour biopsies (median 36.3; range 2.0 - 93 µg). Assessment of MMP-9 transcript expression 
showed that it was significantly increased in the biopsies derived from NSCLC patients relative to the 
control specimens (Figure 3.3.6.1A, 9.0-fold increase, p < 0.0001). MMP9 was further increased in a 
sub-analysis restricted to the ten matched specimens (Figure 3.3.6.1B, 27.3-fold increase, p<0.01). 
MMP-9 expression based on histological type revealed no significant difference between Adeno and 
SCC (Figure 3.3.6.1C).  The expression of MMP-7 was not significantly altered in NSCLC and no 
difference was observed across histological type (Figure 3.3.6.1D-F). Assessment of MMP-3 
expression demonstrated that this metalloproteinase was significantly increased in NSCLC (Figure 
3.3.6.1G, 4.3-fold increase, p<0.05), however MMP-3 transcription was not consistently detected in 
this archive (23% of specimens were below the limit of detection). The matched tissue analysis 
revealed no significant difference in MMP-3 expression (Figure 3.3.6.1H). MMP-3 was increased 
when assessed based on histological type, where transcript levels were significantly higher in SCC 
(Figure 3.3.6.1I, 7.5-fold increase, p<0.05). 
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Figure 3.3.6.1 Evaluation of MMP-9, MMP-7 and MMP-3 transcript levels in the biopsy 
specimens 
The biopsy cohort was used to assess MMP-9, MMP-7 and MMP-3 transcript levels by RTqPCR in NSCLC 
specimens (n=90) compared to non-malignant controls (n=10) and control adjacent tumour-free specimens 
matched to 10/50 Adeno patients. MMP-9 transcript levels were significantly increased in NSCLC specimens 
relative to unmatched (A; 9.0-fold increase, ****p<0.0001, Mann-Whitney t test) and matched controls (B; 
27.3-fold increase, **p<0.01 Wilcoxon’s paired t test), however no difference was observed between tumour 
types (C). MMP-7 transcript levels remained unchanged in NSCLC specimens relative to unmatched and 
matched controls (D-E) and similarly there was no difference across tumour subtypes (F). Despite MMP-3 
expression not detected in 23% of the specimens, a significant increase in MMP-3 transcription was detected 
in the unmatched specimens (G, 4.3-fold increase, p<0.05) but not in the matched cohort (H). This increase 
was specific to patients with SCC relative to the control group (I, 7.5-fold increase, p<0.05).  
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3.3.7 Evaluation of the natural TIMP inhibitors in the biopsy cohort 
Analysis of the TIMP1 family member in the same biopsy cohort demonstrated a significant increase 
in NSCLC biopsies (Figure 3.3.7.1A, 1.6-fold increase, p<0.05), although levels were not uniformly 
increased in the matched specimens (Figure 3.3.7.1B). The increase in TIMP1 expression was 
predominately driven by an increase in Adeno and not SCC (Figure 3.3.7.1C, 1.9-fold increase, 
p<0.01). TIMP2 levels were significantly lower in NSCLC biopsies (Figure 3.3.7.1D, 2.5-fold decrease, 
p<0.0001), however the decline was not uniformly observed in the matched analysis with 3/10 
specimens unchanged or increased (Figure 3.3.7.1E). A significant reduction in TIMP2 expression was 
detected in both Adeno and SCC, with the greatest reduction observed in SCC (Figure 3.3.7.1F). 
There was a 5.1-fold reduction in median TIMP3 transcript levels (Figure 3.3.7.1G, p < 0.0001) which 
were also significantly lower in the matched tissue analysis (Figure 3.3.7.1H, 6.4-fold decrease, 
p<0.01). TIMP3 transcription were significantly reduced in both Adeno and SCC biopsies, with the 
greatest decline detected in SCC (Figure 3.3.7.1I, 9.2-fold decrease, p<0.0001).     
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Figure 3.3.7.1 Transcript levels of the natural MMP inhibitors TIMP1, TIMP2 and TIMP3 in the 
biopsy specimens 
Taqman RTqPCR was performed to assess TIMP1, TIMP2, TIMP3 transcript levels in the NSCLC specimens 
(n=90) compared to non-malignant controls (n=10) and matched control specimens (n=10). TIMP1 gene 
expression was elevated in the NSCLC specimens relative to controls (A, 1.6-fold increase, *p<0.05, Mann 
Whitney t test) but not in the matched specimens (B). The increase in TIMP1 transcription was observed 
specifically in Adeno relative to controls (C, 1.9-fold increase, **p<0.01). Reduced TIMP2 transcript levels 
were detected in the NSCLC specimens relative to controls (D, 2.5-fold decrease, ****p<0.0001) but not in 
the matched specimens (E). A stepwise decrease in TIMP2 transcription was found in Adeno and SCC relative 
to controls (F). In addition, TIMP3 transcript levels were significantly reduced in the unmatched (G, 5.1-fold 
decrease, ****p<0.0001) and matched specimens (H, 6.4-fold decrease, **p<0.01). A comparison between 
tumour subtypes showed that TIMP3 transcription was significantly reduced in Adeno (I, 3.9-fold decrease, 
***p<0.001) and further reduced in SCC (I, 9.2-fold decrease, ****p<0.0001) relative to controls. 
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3.3.8 The diagnostic potential of the MMP-9:TIMP3 ratio in discriminating malignant 
lung specimens 
To assess the diagnostic potential of MMP and TIMP gene expression to differentiate non-malignant 
from malignant lung tissue specimens, ROC curve analysis was performed. MMP-9 expression in 
control vs. NSCLC biopsies generated an AUC value of 0.854 (Figure 3.3.8.1A, 95% CI;0.76-0.95, 
p<0.0001), whereas TIMP2 generated an AUC of 0.794 (Figure 3.3.8.1B, 95%CI; 0.69-0.90, 
****p<0.0001). TIMP3 revealed superior performance for TIMP3 with an AUC value of 0.872 (Figure 
3.3.8.1C, 95% CI;0.79-0.95, p<0.0001). In addition, we evaluated the ratio of MMP9:TIMP2 transcript 
levels, which was significantly increased in the total NSCLC biopsies relative to controls (Figure 
3.3.8.1D, 15.3-fold increase, p <0.0001) as well as in tumour region of the matched specimens 
samples (Figure 3.3.8.1E, 28.8-fold increase, p<0.01). ROC curve analysis of the MMP9:TIMP2 ratio 
generated an AUC of 0.925 (Figure 3.3.8.1F, 395% CI;0.79-0.95, p<0.0001) and achieved a best 
sensitivity (89%, CI 81-95%) and specificity (84%, CI 60-97%) pair using a fold change cut-off of >3.3. 
The MMP9:TIMP3 ratio was also markedly increased in NSCLC biopsies (Figure 3.3.8.1G, 35.2-fold 
increase, p<0.0001) and levels were uniformly increased across all the matched specimens (Figure 
3.3.8.1H, 118.0-fold increase, p<0.01). ROC curve analysis of the MMP9:TIMP3 ratio generated the 
greatest AUC value of 0.933 (Figure 3I, 95% CI;0.86-1.0, p<0.0001). Using a cut-off of >7.6, the 
MMP9:TIMP3 ratio was highly sensitive (88%, CI 79-94%) and specific (89%, CI 67-98%) for 
discriminating non-malignant from malignant tissue biopsies. 
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Figure 3.3.8.1 ROC curve analyses of MMP-9, TIMP2 and TIMP3 in the biopsy specimens 
The diagnostic potential of MMP-9, TIMP2 and TIMP3 were assessed in the biopsy specimens (n=110) by ROC 
curve analysis. MMP-9 alone generated and area under the curve (AUC) value of 0.854 (A, 95%CI; 0.76-0.95, 
****p<0.0001) and TIMP2 alone generated a lower AUC of 0.794 (B, 95%CI; 0.69-0.90, ****p<0.0001). 
However TIMP3 alone generated a higher AUC of 0.871 (C, 095%CI; 0.79-0.95, ****p<0.0001). Assessment 
of the ratio of MMP9:TIMP2 transcript detected a significant increase in the unmatched NSCLC specimens 
relative to controls (D, 15.3-fold increase, ****p<0.0001, Mann Whitney t test). The same ratio was 
significantly increased in the matched specimens (E, 28.8-fold increase, **p<0.01, Wilcoxon’s paired test). 
ROC curve analysis of the MMP-9:TIMP2 ratio generated an AUC of 0.925 (F, 95%CI; 0.85-1.0, ****p<0.0001) 
and a best sensitivity (89%) and specificity (84%) pair using >3.3-fold cut off. Additionally, the MMP-9:TIMP3 
ratio was significantly elevated in the NSCLC specimens (G, 35.2-fold increase, ****p<0.0001) as well as in 
the matched specimens (H; 118.0-fold increase, **p<0.01). ROC curve analysis showed that the MMP9:TIMP3 
ratio generated the highest AUC of 0.933 (E, 95%CI; 0.86-1.0, ****p<0.0001) with the best sensitivity (88%) 
and specificity (89%) pair using >7.6-fold cut off. 
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3.3.9 Assessment of the oncogenic drivers PD-L1, MET and PTEN in the biopsy cohort 
In addition to measuring MMP9 and TIMP3 transcript levels, we also assessed gene expression of 
multiple markers involved in tumour progression by RT-qPCR. PD-L1 transcription was detected in all 
the biopsies analysed and there was a broad range of expression levels (0.13 to 5-fold changes) 
within the groups analysed (Figure 3.3.9.1A). Using a 2-fold increase above median control levels as 
a cut-off, we observed that 2/50 (4%) Adeno displayed elevated PD-L1 transcript levels. Using the 
same criteria, there were a greater number of SCC biopsies that expressed increased PD-L1 
transcript levels (8/40 or 20%). MET transcription was detected in all the biopsies tested and there 
was no significant difference across the groups (Figure 3.3.9.1B). When using a 2-fold increase cut-
off relative to the median control levels, we found that 12/50 (24%) Adeno and 2/40 (5%) SCC 
biopsies expressed higher levels of MET transcript. PTEN transcription was detected in all the 
biopsies tested and there was a significant reduction in Adeno biopsies, with levels being further 
reduced in SCC biopsies (Figure 3.3.9.1C). When using a 2-fold decrease cut-off relative to the 
median control levels, we found that 15/50 (30%) Adeno and 18/40 (45%) SCC biopsies expressed 
reduced levels of PTEN transcript.  
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Figure 3.3.9.1 Gene expression of PD-L1, MET and PTEN in the biopsy cohort 
Taqman RTqPCR was performed to assess the same oncogenic drivers in the biopsy archival specimens. PD-
L1 trancript levels were not significantly different relative to control biopsies (A). Using a 2-fold increase cut-
off value, 2/50 (4%) Adeno and 8/40 (20%) displayed elevated PD-L1 transcipt levels. MET transcript levels 
were not significantly different across the groups (B), however when using a 2-fold increase cut-off value, 
12/50 (24%) Adeno and 2/40 (5%) SCC biopsies expressed higher levels of MET transcript. PTEN transcript 
were significantly reduced in Adeno and SCC biopsies and when using a 2-fold decrease cut-off value, 15/50 
(30%) Adeno and 18/40 (45%) SCC biopsies expressed reduced PTEN transcript levels (C; *P<0.05 and 
****P<0.0001, Kruskal Wallis test). 
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3.3.10 PD-L1 transcript levels is strongly associated with PD-L1 tumour staining and 
clinically relevant cut-offs  
In order to validate gene expression against current protocols to evaluate PD-L1 status, we 
performed PD-L1 immunohistochemistry on matching FFPE tumour slides obtained from biopsies 
derived from the SCC patients (n= 40). As current clinical biomarker requirements for anti-PD-1 
therapies involve quantitation of PD-L1 tumour membrane staining by a pathologist, this was blindly 
performed on the SCC tumour sections. In addition, infiltrating PD-L1–positive immune cells were 
also scored. Heterogeneity in PD-L1 immunoreactivity across the SCC tumour blocks was detected 
and shown in Figure 3.3.10.1. In our SCC tumour sections, we observed that 24/40 (60%) had <1%, 
9/40 (22.5%) had between 1-49% and 7/40 (18%) had >50% PD-L1 positive tumour cells. 
Representative images are shown in Figure 3.3.10.1A-C.  The percentage of PD-L1 positive immune 
cell staining was variable and did not exceed 20% (Figure 3.3.10.1D-E). In order to determine 
whether PD-L1 transcript levels could be predictive of PD-L1 immunohistochemistry, we directly 
compared PD-L1 staining as determined by the Olympus CellSens software with transcript levels. 
Using non-parametric Spearman correlation, we observed a positive association with PD-L1 staining 
and PD-L1 transcript levels (Figure 3.3.10.1F, Spearman r = 0.803, p < 0.0001).  
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Figure 3.3.10.1 Tumour vs immune cell PD-L1 immunohistochemical staining in SCC  
PD-L1 immunohistochemical staining was performed on matched SCC FFPE tumour slides (n=40) using the 
SP263 antibody. Representative images (20x magnification) demonstrate the heterogeneity in PD-L1 staining 
within the tumour and immune cell environment. In relation to the clinically relevant cut-offs, patients with 
PD-L1 staining <1% (A), between 1-49% (B) or >50% in tumour cells were detected. In addition, the 
percentage of PD-L1 staining in the immune cell (IC) environment was assessed. The IC% of PD-L1 detected 
was either < 1% (D) or between 1-49% (E). PD-L1 staining across the entire section was compared with PD-L1 
transcript levels in matching SCC specimens, where a strong positive association was observed (F; Spearman 
r = 0.0.803, ****P<0.0001). 
 
The relationship between PD-L1 tumour/immune cell staining and PD-L1 mRNA levels were analysed 
by non-parametric Spearman correlation and summarised in Table 3.3.10.1. A strong positive 
association was observed between PD-L1 mRNA levels and PD-L1 tumour staining (r = 0.636, 
p<0.0001), whereas a weaker association was detected with immune cell staining (r = 0.316, p = 
0.05). The levels of PD-L1 mRNA were significantly higher (10-fold higher) in biopsies that contained 
>1% PD-L1 positive tumour cells (Figure 3.3.10.2A, p<0.0001). ROC curve analysis generated an AUC 
value of 0.857 (<1% vs >1% PD-L1 tumour staining), and using a cut-off of >0.423, RTqPCR was 69% 
sensitive and 92% specific in identifying tumours with >1% PD-L1 tumour staining (Figure 3.3.10.2B, 
p<0.001). The levels of PD-L1 mRNA were also significantly higher (12-fold higher) in biopsies that 
contained >50% PD-L1 positive tumour cells (Figure 3.3.10.2C). ROC curve analysis generated an AUC 
value of 0.948 (<50% vs. >50% PD-L1 tumour staining), and using a cut-off of >0.878, RTqPCR was 
F 
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100% sensitive and 91% specific in identifying tumours with >50% PD-L1 tumour staining (Figure 
3.3.10.2D). 
Table 3.3.10.1 Relationship between PD-L1 mRNA and staining 
   
PD-L1 IHC staining 
  % total area % tumour % immune cell 
PD-L1 mRNA 
(fold change) 
Spearman r 0.803 0.636 0.316 
95% CI 0.65 – 0.89 0.40 – 0.80 0 – 0.58 
P value p < 0.0001 p < 0.0001 P = 0.05 
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Figure 3.3.10.2 PD-L1 transcript levels strongly discriminate clinically relevant IHC cut-off values 
PD-L1 transcript levels were significantly higher in tumours with >1% tumour cell membrane staining (A; 
****P<0.0001, Mann-Whitney test). ROC curve analysis generated an AUC= 0.857 and using a cut-off of 
>0.423-fold increase, PD-L1 mRNA expression was 69% sensitive and 92% specific in identifying tumours with 
>1% PD-L1 tumour staining using (B). Using a higher threshold of <50% vs. >50% PD-L1 positive tumour cell 
membrane staining, PD-L1 transcript levels were significantly higher in tumours with >50% staining (C; 
****P<0.0001, Mann-Whitney test). ROC curve analysis generated an AUC = 0.948 and using a cut-off of 
>0.878-fold increase, PD-L1 mRNA expression was 100% sensitive and 91% specific in identifying tumours 
with >50% PD-L1 tumour staining (D). 
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 Discussion 
To the best of our knowledge, this is the first study to demonstrate that the MMP9:TIMP3 transcript 
ratio is markedly increased in NSCLC tissue specimens and can accurately discriminate between 
control and malignant specimens. We have also generated preliminary findings to suggest that the 
MMP9:TIMP3 ratio may be more sensitive than cytology in detecting the presence of malignant cells 
in small bronchoscopy specimens. In one of the EBUS cases that was initially considered non-
malignant by pathology, the MMP9:TIMP3 ratio was markedly increased (311-fold increase), to 
indicate that the specimen was malignant. A subsequent EBUS specimen collected 9 months later 
confirmed malignancy by pathology and the MMP9:TIMP3 ratio remained elevated (73-fold above 
control specimens). Our observation in one patient would indicate that the assessment of 
MMP9:TIMP3 ratio may detect malignancy in EBUS specimens that were defined as cytologically 
normal, however a larger trial is needed to confirm this observation.       
MMP-9 is known to contribute to pathological processes including angiogenesis and establishment 
of a metastatic niche. Immunohistochemical staining for MMP-9 in resected primary lung tumours 
has identified a significant association between MMP-9 expression and shortened patient survival 
114. Furthermore, we have shown that MMP-9 transcript levels were highly elevated within resected 
primary NSCLC tumour specimens relative to the adjacent tumour-free tissue, where MMP-9 
immunoreactivity localised to tumour cells and tumour infiltrating neutrophils 115. TIMP3 has broad 
inhibitory MMP activity 116, where it forms tight structures with the catalytic domains of MMP-9, -7 
and 3. Hence, loss of TIMP3 expression and/or activity can contribute to tumour progression by 
releasing active MMPs in the tumour microenvironment. In addition to its inhibitory function, TIMP3 
has been shown to induce apoptosis of cancer cells 117 and can inhibit angiogenesis by directly 
blocking the action of VEGF on endothelial cells 118. Our findings show a marked reduction in TIMP3 
gene expression in NSCLC localised to the tumour, with more prominent suppression in SCC. TIMP3 
expression has been shown to be repressed in NSCLC cells at an epigenetic level which promotes 
tumour cells invasion 119. Immunohistochemical analysis also showed that low TIMP3 protein 
expression in NSCLC was more common in tumours with epigenetic alterations within the TIMP-3 
gene/promoter 120.  
Our high yield of intact nucleic acid also allowed for reliable measurement of multiple targets by RT-
qPCR and NGS including genes implicated as potential oncogenic drivers in lung cancer. Programmed 
death-1 (PD-1) is a negative costimulatory T cell receptor and binding PD-L1 can inhibit cytotoxic T-
cell responses. The response rate to PD-1 inhibition with pembrolizumab in NSCLC was reported to 
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double when patients were selected on the basis of PD-L1 expression 121. PD-L1 expression in the 
majority of lung cancers is reflective of an important pathway of adaptive immune evasion by the 
tumour, as there is limited evidence for CD274/PD-L1 gene amplification in this setting 122, 123. 
Importantly, we have identified a strong positive association between PD-L1 tumour cell membrane 
staining and transcript levels in SCC. Our data strongly suggest that PD-L1 mRNA levels within 
tumour biopsies are predominately dictated by tumour cells and not immune cell or alveolar 
macrophage PD-L1 levels, hence reinforcing mRNA expression as a potential predictive biomarker. 
 The key advantage of measuring PD-L1 by RT-qPCR is that the technique is relatively rapid (within 
24hours of biopsy), highly quantitative and can be readily multiplexed with many other potentially 
actionable oncogene targets such as MET and PTEN. Indeed, we readily detected gene expression 
alterations in both MET and PTEN expression levels. Such changes may contribute to the further 
refinement of biomarkers for the selection of patients that are most likely to respond to immune 
checkpoint inhibitors. Our high yield of unfixed nucleic acid would also allow for reliable 
measurement of oncogenic fusions by RT-qPCR or NGS, and ROS1 testing is strongly recommended 
on advanced-stage lung Adeno patients, irrespective of clinical characteristics 124. Whilst IHC and 
FISH assays are routinely used to detect ALK and ROS1 rearrangements, RT-qPCR and NGS 
approaches have shown comparable performances 124. Therefore, our laboratory workflow has the 
capacity to incorporate detection of important oncogenic fusions. 
In addition to detecting gene expression changes by RT-qPCR, all our EBUS specimens generated 
DNA that was highly suitable for targeted mutation sequencing and accordingly, we detected 
mutations in the majority of EBUS tumour specimens. The TP53 gene was most frequently mutated 
with 13 alterations in 10/15 EBUS specimens. A recent study has identified a greater frequency of 
PD-L1high tumours in NSCLC patients harbouring TP53 mutations 125 and in our EBUS specimens, 6/10 
(60%) p53 mutated specimens were classified as PD-L1high, whereas 1/5 (20%) wild-type TP53 
specimens were graded PD-L1high. The total mutation burden has recently been proposed as an 
alternative biomarker for PD-1 immunotherapy, where response rates were higher in patients with 
>10 mutations per megabase DNA 111. Since our processing of small tumour brushings and biopsies 
does not require fixation to confirm malignancy, we were able to generate a high quantity and 
quality of amplifiable DNA that could be readily assessed for total mutation burden.  
The flow chart in Figure.3.3.10.1 summarises our streamlined approach where an EBUS 
bronchoscopy specimen (brush or biopsy) is collected and placed directly in nucleic acid stabilisation 
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buffer following rapid onsite evaluation (ROSE) of the malignant site. RNA and DNA are isolated from 
the single specimen and a multi-panel RT-qPCR assay is performed to quantify MMP-9, TIMP3 and 
PD-L1 transcript levels, which can be readily achieved within 24 hours of EBUS bronchoscopy. 
Following confirmation of malignant cell content, achieved using the MMP9:TIMP3 ratio, genomic 
DNA from the same specimen can be deemed suitable for targeted next generation mutation 
sequencing or potentially for assessment of tumour mutation burden. A key advantage of our 
technique is that PD-L1 status can also be achieved within 24hours and there is an excess amount of 
nucleic acid that can be used for multiple downstream molecular profiling including total mutational 
profiling, which are emerging as integral biomarkers to guide immunotherapy.  
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Figure.3.3.10.1 A flow chart depicting our streamlined approach for comprehsive molecular 
profiling of bronchial specimens 
We propose a new approach to enable large scale molecular and mutational profiling of a single EBUS 
bronchial specimen. As shown in the flow chart, a single EBUS specimen (brush or biopsy) is collected in 
stabilisation buffer following rapid onsite evaluation (ROSE) of the malignant site. Nucleic acid integrity is 
preserved for adequate isolation and subsequent assessment of MMP-9, TIMP-3 and PD-L1 transcript levels 
through multi-panel RT-qPCR, which can be achieved in a 24-hr time frame. Following confirmation of the 
malignant cell content using the MMP-9:TIMP3 ratio, genomic DNA from the same specimen is suitable for 
multi-panel targeted next generation sequencing to potentially assess the mutational burden and therefore 
guide the clinical use of targeted and immunotherapies. 
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In the previous chapter, a new workflow was developed to comprehensively assess an increasing 
panel of molecular markers in a single bronchoscopy specimen by RTqPCR. Gene expression analysis 
of select MMPs and TIMPs demonstrated that the ratio of MMP-9:TIMP3 was consistently 
upregulated in malignant lung tumours, which may improve the molecular detection of lung cancer. 
In addition, PD-L1 transcription can be simultaneously assessed, providing an alternative measure 
for PD-L1 status that maybe more efficient than determining PD-L1 positive tumour staining. In 
Chapter 4, the results of experiments which aimed to streamline this approach using ddPCR are 
reported. This technique was used to enable the absolute quantification of MMP-9, TIMP3 and PD-
L1 transcripts to allow accurate generation of clinically relevant cut-offs for the detection of lung 
cancer and inform the use of immunotherapies. This chapter incorporates the published manuscript 
“Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy 
specimens” (Appendix C). The results section has been expanded to include a detailed analysis of 
multiplex ddPCR. 
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 Introduction 
Immune checkpoint inhibitors that target programmed cell death 1 (PD-1) or programmed cell death 
ligand 1 (PD-L1) are currently changing the approach to treatment of NSCLC patients. Since not all 
NSCLC patients respond to immunotherapy, biomarkers have been developed to improve patient 
selection. The Ventana PD-L1 (SP263) immunohistochemical assay is an FDA approved test for the 
detection of PD-L1 expression in formalin fixed, paraffin embedded (FFPE) specimens. 
Demonstration of high levels of PD-L1 expression by immunohistochemistry on FFPE specimens is 
associated with improved response rates in NSCLC treated with PD-1 inhibitors such as 
pembrolizumab and nivolumab (Keynote-024, Keynote-010, Checkmate 017, Checkmate-057). 
Pembrolizumab is now approved as first line therapy for NSCLC patients with PD-L1 expression in 
>50% of tumour cells, and as second line therapy for those demonstrating PD-L1 expression >1% 126 
The current evaluation of PD-L1 expression is dependent on availability of FFPE tumour specimens. 
When available, FFPE tumour slides will firstly be used to evaluate presence of malignant cells, 
identify histological type of NSCLC and if warranted, screen for specific EGFR mutations and ALK and 
ROS1 rearrangements that are predictive of clinical response to tyrosine kinase inhibitors 28. Hence, 
the assessment of PD-L1 expression is dependent on how much FFPE tumour tissue is left and the 
integrity of this fixed tissue specimen. We have recently taken an alternative approach to determine 
PD-L1 expression in small biopsy specimens using RTqPCR 127. Utilising minimally-invasive 
bronchoscopy and archived biopsy specimens, we identified the MMP:9:TIMP3 mRNA ratio as a 
molecular marker for presence of malignant cells in NSCLC. We also quantified PD-L1 gene 
expression by RTqPCR and demonstrated excellent concordance with the Ventana PD-L1 (SP263) 
Assay in identifying tumours with >1% and >50% tumour cell staining 127. 
In this study, we have significantly advanced our approach by developing a droplet digital PCR 
(ddPCR) assay to accurately and rapidly assess multiple biomarkers within the same specimen. 
ddPCR is an emerging molecular technique with increased sensitivity to detect driver mutations such 
as EGFR activating mutations. It has been shown to accurately detect and quantify EGFR variants in 
both tissue biopsies and plasma with greater sensitivity than amplification-refractory mutation 
system (ARMS) and may be more useful in monitoring disease progression 128. ddPCR is also suitable 
for higher order multiplexing and is particularly sensitive at detecting low abundant variants 129. 
Furthermore, ddPCR can address some significant limitations associated with RTqPCR, as it allows for 
absolute quantification of mRNA copy number, is less reliant on suitability of housekeeping genes 
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and does not need to be normalised to a control specimen. We have specifically developed a 
multiplex ddPCR assay incorporating MMP9, TIMP3 and PD-L1 that generated absolute cut-off 
values, accurately identified presence of malignant cells in small NSCLC biopsies and quantified PD-
L1 expression in a single assay. 
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 Methods 
4.2.1 Patient Characteristics 
Matching snap frozen and FFPE specimens were provided by the Victorian Cancer Biobank with 
ethics approval (Ethics ID: SEHAPP 09-17) as previously detailed in Chapter 3 (Section 3.2.2). The 
specimens were obtained from surgically resected tumour tissue from patients with stage IA-IIIA 
NSCLC (n=88) at the Royal Melbourne Hospital pathology department and included reclassified 
Adeno (n=48) and SCC (n=40) subtypes. A 1-2cm sample of tumour tissue excess to diagnostic 
requirements was obtained from the fresh resection specimen and bisected, with one piece of tissue 
snap frozen and one piece formalin-fixed and paraffin embedded as per standard laboratory 
protocols. Control tissue resection specimens (n=20) were obtained from patients without malignant 
disease (n= 10) and adjacent tumour-free region of Adeno patients (n=10), as previously described in 
Chapter 3 (Section 3.2.2).  
4.2.2 Gene expression determined by RTqPCR  
Total RNA was isolated from the biopsy specimens using the Allprep DNA/RNA/miRNA universal kit 
(Qiagen, Hilden, Germany), as previously described in Chapter 3 (Section 3.2.3) 127. Briefly, RNA was 
converted to cDNA using the Superscript IV VILO kit (Thermo Fisher Scientific, MA, US) and RTqPCR 
was performed on the QuantStudio 7 (Applied Biosystems). MMP-9, TIMP3 and PD-L1 gene 
expression levels were normalised to the stable housekeeping reference genes (TBP and PUM1) and 
the comparative (2-ΔΔCt) method was used to determine fold changes relative to a control biopsy.  
4.2.3 Scoring of PD-L1 immunohistochemical staining 
FFPE tissue sections at 5µm thickness were prepared from resected NSCLC tumours adjacent to the 
frozen tissue biopsy specimen (n=88). PD-L1 immunohistochemical was performed by the 
Anatomical Pathology Laboratory at the Royal Melbourne Hospital using the human PD-L1 (SP263 CE 
IVD) rabbit monoclonal antibody (Ventana) and the Benchmark Ultra automatic staining instrument 
(Ventana, Tuscan, AZ, USA), as previously described 127. The scoring of PD-L1 tumour staining was 
blindly performed by an experienced pathologist 112. 
4.2.4 Direct quantification of gene expression by multiplex ddPCR 
The QX200 Droplet Digital PCR System (Bio-Rad Laboratories, CA, US) was used for direct 
quantification of MMP-9, TIMP3, PD-L1 and PUM1 in the biopsy specimens (n=110). A duplex or 
 66 
Chapter 4 – Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer 
biopsy specimens 
 
triplex ddPCR reaction was developed using TaqMan primer and probe sets for each target sequence 
at a final concentration of 900nM primer and 250nM probe (Thermofisher MA, US). Summarised in 
Table 4.2.4.1 are the FAM/VIC dye combinations used to determine the ratio of MMP-9:TIMP3, PD-
L1:PUM1 and PD-L1:TIMP3. Individual 20µl duplex reactions combined a FAM-labelled probe, a 
second VIC-labelled probe, ddPCR Supermix (Bio-Rad laboratories, CA, US) and 1-25ng of input 
cDNA. Each triplex reaction comprised a third target sequence derived from a 50:50 mixture of FAM- 
and VIC- labelled probes.  
The wells of a DG8 cartridge were loaded with 20µl of reaction mix and 70µl of droplet generation 
oil for probes (Bio-Rad Laboratories, CA, US). Using the QX200 Droplet Generator (Bio-Rad 
Laboratories, CA, US) each reaction was partitioned into 20,000 droplets before being transferred to 
a semi-skirted 96-well PCR plate. The plates were sealed using the PX1 PCR plate sealer (Bio-Rad 
Laboratories, CA, US). Endpoint PCR was performed using the C1000 Touch 96-deep well Thermal 
Cycler (Bio-Rad Laboratories, CA, US) at a ramp rate of 2°C/s under the following conditions: 95°C for 
10mins, 40 cycles of 94°C for 30sec and 60°C for 1min, followed by 98°C for 10mins. Upon 
completion, the plate was read using the QX200 Droplet Reader (Bio-Rad Laboratories, CA, US). 
Adequate droplet number and absolute transcript levels were assessed using the QuantaSoft 
Analysis Pro software v 1.0 (Bio-Rad Laboratories, CA, US).  
Table 4.2.4.1 Summary of Taqman assays and reporter dye combinations used in a duplex or triplex assay 
 20X Taqman 
Assay 
Duplex assay Triplex assay 
MMP-9 Hs00957562_m1 MMP-9:TIMP3 MMP-9VIC 
TIMP3FAM   
MMP-
9:TIMP3 
PD-L1:TIMP3 
MMP950%FAM: 50%VIC 
TIMP3FAM 
PD-L1VIC 
TIMP3 Hs00165949_m1 
PD-L1 Hs01125301_m1 PD-L1:PUM1       PD-L1VIC  
PUM1FAM PUM1 Hs00472881_m1  
 
 
4.2.5 Statistical Analysis 
The two-dimensional (2D) amplification plots were produced on the QuantaSoft Analysis Pro 
Software v 1.0 (Bio-Rad Laboratories, CA, US). All graphs were generated using Graphpad prism 7.02 
(Graphpad Software Inc, San Diego, CA). The Spearman correlation coefficient was determined to 
measure the association between two variables. Mann-Whitney two-tailed t-tests were performed 
to compare gene expression changes displayed as Tukey boxplots between unpaired NSCLC vs 
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Control groups. Paired groups were assessed using the Wilcoxon signed rank test. The Kruskal Wallis 
test followed by Dunn’s multiple comparison post hoc tests were used to compare multiple groups 
and statistical significance was determined by p values less than 0.05. A Receiver Operating 
Characteristic (ROC) curve was generated and the area of the curve (AUC) was calculated to assess 
the diagnostic accuracy of the MMP-9:TIMP3 ratio as well as the potential for PD-L1:PUM1 or PD-
L1:TIMP3 to discriminate positive PD-L1 tumour staining. Sensitivity and specificity values generated 
from the ROC curve were used to determine the best fold-change cut-off values. 
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 Results 
4.3.1 Direct quantification of MMP-9 and TIMP3 identifies malignant NSCLC specimens  
The duplex ddPCR assay, used to determine absolute copy number for MMP-9 and TIMP3, identified 
three distinct populations representing amplified FAM-labelled TIMP3, VIC-labelled MMP-9 and a 
population positive for both MMP-9 and TIMP3 (Figure 4.3.1.1).  A significant increase in the ratio of 
MMP-9:TIMP3 copies/µL was detected in the NSCLC specimens relative to control biopsies (Figure 
4.3.1.2A, 42.5-fold increase, p<0.0001). The median MMP-9:TIMP3 ratio value for the control 
biopsies is 0.01 copies/µL, demonstrating that there is 100-fold more TIMP3 transcript relative to 
MMP-9 transcript. This ratio increases to 0.50 copies/µL in the NSCLC biopsies, hence there was only 
2-fold more TIMP3 relative to MMP9 transcript levels in the NSCLC biopsies. The MMP-9:TIMP3 ratio 
was also significantly increased within the tumour region relative to the patients matched adjacent 
tumour-free biopsy specimen (Figure 4.3.1.2B, 91.6-fold increase, p<0.0001).  
 
Figure 4.3.1.1 A 2D amplification plot of MMP-9 and TIMP3 measured by duplex ddPCR 
Direct quantification of MMP-9 and TIMP3 was assessed in the NSCLC (n=90) and control (n=20) biopsy 
specimens. A 2D amplification plot of MMP-9 and TIMP-3 is displayed showing four distinct clusters. With 
negative droplets in grey, amplified FAM-labelled TIMP3 is identified as a single-positives cluster (blue) in 
channel 1 and amplified VIC-labelled MMP-9 is identified as a single-positive cluster (green) in Channel 2. 
Double positives (orange) for both target sequences were included in the final analysis. 
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A direct comparison of conventional RTqPCR with our newly developed duplex ddPCR assay shows 
very high concordance between these two molecular techniques (Figure 4.3.1.2C, r=0.95, p<0.0001). 
A ROC curve analysis used to evaluate the diagnostic potential of the MMP-9:TIMP3 ratio obtained 
by duplex ddPCR generated an area under the curve (AUC) of 0.943 (Figure 4.3.1.2D, 95% CI; 0.88-
1.0, p<0.0001). Using a new cut-off value of >0.036 generated by ddPCR, the ratio of MMP9:TIMP3 
was found to be 98% (95% CI; 92.2-99.7) sensitive and 80% (95% CI; 56.3-94.3) specific in 
distinguishing malignant NSCLC biopsy from non-malignant biopsy specimens.  
C o n tro l N S C L C
0 .0 0 1
0 .0 1
0 .1
1
1 0
M
M
P
9
/T
IM
P
3
(R
a
ti
o
 c
o
p
ie
s
/
l)
* * * *
C o n tro l T u m o u r
0 .0 0 1
0 .0 1
0 .1
1
1 0
M
M
P
9
/T
IM
P
3
(R
a
ti
o
 c
o
p
ie
s
/
l)
* * * *
0 .1 1 1 0 1 0 0 1 0 0 0 1 0 0 0 0
0 .0 0 1
0 .0 1
0 .1
1
1 0
q P C R
d
d
P
C
R
* * * * r  =  0 .9 5
0 5 0 1 0 0
0
5 0
1 0 0
1 0 0 %  -  S p e c if ic ity %
S
e
n
s
it
iv
it
y
%
     Area 0.9433
A
D
B
C
 
Figure 4.3.1.2 A duplex ddPCR assay identified malignant NSCLC biopsies using the MMP-
9:TIMP3 ratio. 
The ratio of MMP-9:TIMP3 was determined by duplex ddPCR in the NSCLC specimens (n=90), non-malignant 
controls (n=10) and adjacent tumour-free controls matched to Adeno patients (n=10). The ratio of MMP-
9:TIMP3 transcript levels was significantly increased in NSCLC specimens relative to unmatched (A, 
****p<0.0001, Mann-Whitney t test) and matched controls (B, ****p<0.0001). A comparison of two 
platforms showed that the ratio of MMP-9:TIMP3 determined by RTqPCR when normalised to the geomean 
of two house-keeping genes PUM1 and TBP, was highly concordant to the ratio of MMP-9:TIMP3 obtained by 
duplex ddPCR, generating a correlation coefficient of 0.95 (C, ****p<0.0001, Spearman correlation). To 
evaluate the diagnostic potential of the MMP-9:TIMP3 ratio generated by ddPCR, a ROC curve analysis was 
performed and obtained an area under the curve (AUC) value of 0.94 (D, 95%CI; 0.88-1.0, ****p<0.0001). 
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4.3.2 Direct quantification of PD-L1 by duplex ddPCR is highly consistent with PD-L1 
detection by RT-qPCR  
Our previous study also revealed that PD-L1 transcript levels detected by RTqPCR and normalised to 
the reference genes PUM1 and TBP strongly associated with PD-L1 immunohistochemical staining in 
SCC biopsies 127. Assessment of the ratio of PD-L1:PUM1 by duplex ddPCR generated three distinct 
populations representing FAM-labelled PUM1, VIC-labelled PD-L1 and a ddPCR population that was 
positive for both PUM1 and PD-L1 (Figure 4.3.2.1 is a representative 2D amplification plot).  
 
Figure 4.3.2.1 A 2D amplification plot of PD-L1 and PUM1 measured by duplex ddPCR 
Absolute copy number of PD-L1 transcript relative to the reference gene PUM1 were assessed by duplex 
ddPCR in the NSCLC (n=90) and control (n=20) biopsy specimens. The following 2D amplification plot shows 
four distinct clusters used to assess the ratio of PD-L1:PUM1. Negative droplets are shown in grey while 
amplified FAM-labelled PUM1 is identified as a single-positives cluster (blue) in channel 1 and amplified VIC-
labelled PD-L1 is identified as a single-positive cluster (green) in Channel 2. Double positives (orange) for both 
target sequences were included in the final analysis. 
 
The PD-L1:PUM1 ratio generated by ddPCR demonstrated very high concordance with PD-L1 gene 
expression detected by RT-qPCR (r=0.95, p<0.0001). Using clinically relevant thresholds for PD-L1 IHC 
staining, the ratio of PD-L1:PUM1 generated by ddPCR was significantly increased in the SCC biopsies 
with >1% PD-L1 positive tumour staining (Figure 4.3.2.2A, 8.9-fold increase, p<0.0001). A ROC curve 
analysis generated an AUC value of 0.87 (95% CI; 0.75-0.99) and demonstrated that PD-L1:PUM1 
produced the best sensitivity and specificity pair of 87.5% and 66.7%, respectively, when using a cut-
off of >0.053 (Figure 4.3.2.2B, p<0.0001). The ratio of PD-L1:PUM1 was also significantly elevated in 
tumours with >50% positive PD-L1 staining (Figure 4.3.2.2C, 10-fold increase, p<0.0001). The 
resulting AUC value was 0.95 (95%CI; 0.88-1.0) following a ROC curve analysis, demonstrating that 
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the ratio of PD-L1:PUM1 was 100% sensitive and 90.9% specific when using a cut off >0.167 (Figure 
4.3.2.2D, p<0.001).  
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Figure 4.3.2.2 PD-L1 gene expression determined by duplex ddPCR strongly correlates with PD-
L1 tumour cell immunohistochemical staining 
The ratio of PD-L1:PUM1 was assessed by duplex ddPCR in the NSCLC specimens (n=90), non-malignant 
controls (n=10) and adjacent tumour-free controls matched to Adeno patients (n=10). Quantification of PD-
L1 gene expression by RTqPCR was obtained by normalising to the geomean of two reference genes, PUM1 
and TBP. The ratio of PD-L1:PUM1 transcript levels by ddPCR was increased in SCC biopsies with >1% PD-L1 
positive tumour staining (A, ****p<0.0001, Mann-Whitney t test) and ROC curve analysis generated an AUC 
value of 0.87 (B, 95%CI; 0.75-0.99, ****p<0.0001) A comparison of <50 % vs. >50% PD-L1 positive staining 
showed that the ratio of PD-L1:PUM1 transcript levels was significantly increased in tumours with >50% 
staining (C, ****p<0.0001) and ROC curve analysis generated an AUC value of 0.95 (D, 95%CI; 0.88-1.0, 
***p<0.001). 
 
 
 
 72 
Chapter 4 – Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer 
biopsy specimens 
 
4.3.3 The MMP9:TIMP3 ratio detects biopsies with malignant cells. 
The feasibility of measuring MMP-9, TIMP3 and PD-L1 transcript levels using a triplex ddPCR assay 
was next assessed. A representative 2D plot shows the generation of seven distinct clusters using a 
combination of FAM and VIC labelled probes for the quantification of three target sequences (Figure 
4.3.3.1). FAM labelled TIMP3 is identified as a single positive cluster in channel 1 (TA, burgundy) 
while VIC labelled PD-L1 is identified as a single-positive cluster in Channel 2 (TB, purple). Using a 
50:50 mixture of FAM and VIC labelled probes, MMP-9 is identified as a single positive cluster in 
both channels (TC, yellow). The generation of double-positive (TA, TB, TC) and triple-positive (TABC) 
clusters demonstrates the detection of 2 or more target sequences within the same droplet.   
 
Figure 4.3.3.1 A 2D amplification plot of MMP-9, TIMP3 and PD-L1 assessed by triplex ddPCR 
A triplex ddPCR reaction was performed for direct quantification of MMP-9, TIMP-3 and PD-L1 (n=110) 
simultaneously. Displayed is a representative image of a 2D amplification plot showing 7 distinct clusters with 
each Target sequence (T) identified as either a single-positive, double-positive or triple-positive cluster. FAM-
labelled TIMP-3 is identified in Channel 1 (TA; burgundy) and VIC-labelled PD-L1 is identified in Channel 2 (TB; 
purple). The third target sequence, MMP-9, derived from a 50:50 mixture of FAM- and VIC- labelled probe is 
identified as a single positive cluster in both channels (TC; yellow). Included in the final analysis are the double 
and triple positives for each target combination (TAB; beige, TBC; pink, TAC; blue, TABC; orange). Negative 
droplets are shown in grey. 
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The triplex assay generated data that was consistent with RTqPCR and the duplex ddPCR data, where 
the ratio of MMP-9:TIMP3 was significantly increased in the NSCLC specimens relative to control 
biopsies (Figure 4.3.3.2A, 43.7-fold increase, p<0.0001). The comparison between matched adjacent 
tumour-free control and NSCLC biopsies also identified a significant increase in tumour biopsies 
(Figure 4.3.3.2B, 118.2-fold increase, p<0.01). ROC curve analysis of the MMP9:TIMP3 ratio obtained 
using the triplex assay generated and AUC value of 0.945 (Figure 4.3.3.2C, 95%CI; 0.88-1.0, 
p<0.0001), which is consistent with our previous published RTqPCR data 127. A cut-off value of >0.028 
in the triplex assay generated a sensitivity of 99% (95% CI; 94-100) and specificity of 80% (95% CI 
56.3-94.3), in discriminating malignant and control biopsies, demonstrating excellent diagnostic 
performance using our triplex assay. 
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Figure 4.3.3.2 Assessment of the MMP-9:TIMP3 ratio using a triplex ddPCR assay shows 
potential for NSCLC diagnosis 
The ratio of MMP-9:TIMP3, assessed in the biopsy specimens (n=110) by triplex ddPCR, was consistent with 
the results obtained by duplex ddPCR. The ratio of MMP-9:TIMP3 was significantly elevated in the NSCLC 
specimens relative to the unmatched controls (A, ****p<0.0001, Mann-Whitney t test) and matched controls 
(B, **p<0.01). A ROC curve analysis of the MMP-9:TIMP3 ratio produced an AUC value of 0.945 (E, 95%CI; 
0.88-1.0, ****p<0.0001). 
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4.3.4 The PD-L1:TMP3 ratio identifies PD-L1 positive tumours 
Assessment of PD-L1 by immunohistochemistry demonstrated that 52.1% and 52.5% of the tumours 
showed no tumour cell PD-L1 staining in Adeno and SCC respectively (Figure 4.3.4.1). There were 
proportionally more PDL1-high tumours based on >50% tumour cell staining cut-off in SCC (17%, 
7/40) than in Adeno (6%, 3/48). Consistent with increased PD-L1 immunoreactivity in SCC, the PD-
L1:TIMP3 ratio was only significantly increased in SCC relative to the control biopsy specimens 
(Figure 4.3.4.2A). Despite a subset of patients showing PD-L1high >50% expression in both tumour 
subtypes, there was no significant difference in PD-L1 positive tumour staining (Figure 4.3.4.2B), 
however there were proportionally more PD-L1 high patients in the SCC cohort. The degree of PD-L1 
immune cell staining was also significantly higher in SCC when compared to Adeno (Figure 4.3.4.2C). 
PD-L1 copy number was next expressed as a ratio relative to TIMP3 copy number using the same 
triplex ddPCR assay. A positive association was observed between the PD-L1:TIMP3 ratio and PD-L1 
tumour cell IHC staining performed on matching NSCLC biopsies (Figure 4.3.4.2D; r = 0.539, p< 
0.0001). In contrast, there was no significant association between the PD-L1:TIMP3 ratio and PD-L1 
immune cell IHC staining (Figure 4.3.4.2E; r = 0.122, p = 0.259). 
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Figure 4.3.4.1 A comparison of PD-L1 status in NSCLC subtypes 
The tumour percentage (TC%) of PD-L1 expression was scored in the matched FFPE specimens and 
categorised according to the clinically relevant cut-offs (0%, 1-49% and >50) for each tumour subtype (Adeno; 
n=48, SCC; n=40). Approximately half of the patients had negative PD-L1 tumour expression in both subtypes 
(A-B). A greater proportion (41.7%) of Adeno patients had a PD-L1 TC% between 1-49% compared to SCC 
(32.5%). However, twice as many SCC patients (15%), displayed >50% PD-L1 expression than Adeno (6.3%). 
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Figure 4.3.4.2 Triplex ddPCR: An alternative approach to scoring PD-L1 tumour expression 
Absolute transcript levels of PD-L1 and TIMP3 were assessed in the biopsy specimens by triplex ddPCR. A 
significant increase in the PD-L1:TIMP3 ratio was detected in SCC but not in Adeno when compared to control 
biopsies (A; **p<0.01, Kruskall Wallis test). PD-L1 scoring in the tumour and immune cell environment was 
performed using the PD-L1 immunostained slides (Adeno; n=48, SCC; n=40). The percentage of PD-L1 tumour 
expression was statistically similar between NSCLC subtypes despite a subset of patients showing >50%. 
Scoring of PD-L1 expression in immune cells revealed a significant increase in SCC (C, *p<0.01), however the 
proportion did not exceed 30% in both tumour subtypes. Spearman analysis demonstrated that the ratio of 
PD-L1:TIMP3 transcript correlated directly with PD-L1 tumour expression (D, r=0.518, ****p<0.0001) but not 
PD-L1 immune cell expression (E). 
 
The ratio of PD-L1:TIMP3 was significantly higher in NSCLC biopsies that were graded as >1% PD-L1 
positive tumour cell staining (Figure 4.3.4.3A, 3.3-fold increase, p<0.0001). ROC curve analysis 
generated a modest AUC value of 0.771 (Figure 4.3.4.3B, 95% CI; 0.66-088, p<0.0001) but the ratio 
achieved only 82% (95% CI; 65-93) sensitivity and 45% (95% CI; 32-59) specificity in differentiating 
PD-L1 tumour expression >1%. Using a higher PD-L1 tumour cell staining threshold, the ratio of PD-
L1:TIMP3 was also significantly increased in tumours with >50% staining (Figure 4.3.4.3C, 14.2-fold 
increase, p< 0.0001). ROC curve analysis generated an AUC of 0.942 (Figure 4.3.4.3D, 95% CI; 0.87-1, 
p<0.0001). The PD-L1:TIMP3 ratio was 89% sensitive and 85% specific in determining PD-L1 positive 
tumour staining >50% using a fold cut off > 0.104. 
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Figure 4.3.4.3 The diagnostic utility of PD-L1:TIMP3 ratio by triplex ddPCR in the NSCLC cohort 
The ratio of PD-L1:TIMP3, determined by triplex ddPCR, was assessed in the total NSCLC cohort in relation to 
the PD-L1 IHC thresholds. A significant increase in PD-L1:TIMP3 transcript was detected in the NSCLC patients 
with >1% PD-L1 TC% (A, ****p<0.0001) and the ROC curve analysis generated a modest AUC value of 0.771 
(B, 95%CI; 0.66-0.88, ****p<0.0001). Despite 82% sensitivity, PD-L1:TIMP3 showed poor specificity (45%) in 
differentiating tumours with >1% PD-L1 IHC scores using >0.027 cut off. Furthermore, a significant increase 
in the PD-L1:TIMP3 ratio was detected in the NSCLC patients with >50% PD-L1 TC% (C, ****p<0.0001). ROC 
curve analysis generated an AUC of 0.942 (D, 95% CI; 0.87-1.0, ****p<0.0001) and demonstrated that the 
ratio was 89% sensitive and 85% specific in determining PD-L1 status equivalent to PD-L1 IHC >50%. 
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4.3.5 Assessment of PD-L1 status in each tumour subtype by triplex ddPCR 
The diagnostic utility of the PD-L1:TIMP3 ratio to determine the PD-L1 status equivalent to using IHC 
thresholds was assessed in each NSCLC subtype. In the Adeno biopsies, the ratio of PD-L1:TIMP3 
transcript was significantly higher in patients with >1% PD-L1 positive tumour staining (Figure 
4.3.5.1A, 1.8-fold increase, p<0.0001). ROC curve analysis generated a relatively low AUC value 0.697 
(Figure 4.3.5.1B, 95%CI; 0.53-0.86, p<0.05). Using the cut-off ratio > 0.035 with the greatest 
likelihood, the PD-L1:TIMP3 ratio showed poor sensitivity (67%, 95% CI; 41-87) and specificity (62%, 
95% CI; 43-79) in differentiating Adeno patients with >1% PD-L1 IHC scores. Assessment using higher 
thresholds revealed that the PD-L1:TIMP3 ratio was significantly increased in tumours with >50% PD-
L1 staining (Figure 4.3.5.1C, .2-fold increase, p<0.01) and generated an AUC of 0.926 (D, 95%CI; 0.90-
1.0, *p<0.05) following ROC curve analysis (Figure 4.3.5.1D). Despite a low number of PD-L1high 
patients, the PD-L1:TIMP3 demonstrated 100% (95%CI; 24-100) sensitivity and 78% specificity (95% 
CI; 63-89) using a cut-off ratio >0.0.05 (Figure 4.3.5.1D).  
The ratio of PD-L1:TIMP3 was significantly higher in SCC biopsies with >1% PD-L1 positive tumour 
staining (Figure 4.3.5.2A, 5.9-fold increase, p<0.0001). ROC curve analysis produced an AUC value of 
0.898 (95%CI; 0.80-1.0) and using a cut-off of >0.087, the ratio of PD-L1:TIMP3 was 87.5% sensitive 
and specific in differentiating tumours with >1% PD-L1 positive tumour staining (Figure 4.3.5.2B, 
p<0.0001). Using a higher threshold, the ratio of PD-L1:TIMP3 was shown to be significantly 
increased in tumours with >50% staining (Figure 4.3.5.2C, 13.9-fold increase, p<0.0001). ROC curve 
analysis of PD-L1:TIMP3 generated an AUC value of 0.961 (95%CI; 0.90-1.0) and using a cut off 
>0.104, this ratio was 100% sensitive and 78.8% specific in identifying tumours with >50% PD-L1 
positive staining (Figure 4.3.5.2D, p<0.001).  
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Figure 4.3.5.1 PD-L1 status in Adeno biopsies by triplex ddPCR 
The diagnostic utility of the PD-L1:TIMP3 ratio was assessed specifically in the Adeno biopsies (n=48). The 
ratio of PD-L1:TIMP3 was significantly elevated in specimens identified with PD-L1 tumour score >1% (A, 
*p<0.05). ROC curve analysis generated an AUC of 0.697 (B, 95%CI; 0.53-0.86, *p<0.05) demonstrating the 
poor sensitivity and specificity of the PD-L1:TIMP3 ratio to discriminate PD-L1 status > 1% in the Adeno 
specimens. Using a higher threshold, the ratio of PD-L1:TIMP3 was significantly increased in Adeno specimens 
with >50% tumour cell staining (C, **p<0.01). ROC curve analysis generated an AUC value of 0.926 (D, 95%CI; 
0.90-1.0, *p<0.05). Despite the small sample size, the PD-L1:TIMP3 ratio was 100% sensitive and 78% specific 
in differentiating specimens with a PD-L1 score >50% using a cut-off ratio >0.05. 
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Figure 4.3.5.2 PD-L1 status in SCC biopsies by triplex ddPCR 
The PD-L1:TIMP3 ratio was assessed across the clinically relevant cut-offs in SCC biopsies (n=40) and revealed 
that the ratio was significantly increased in specimens with > 1 % PD-L1 tumour staining. (A, ****p<0.0001). 
ROC curve analysis generated an AUC of 0.898 (B, 95%CI; 0.80-1.0, ****p<0.0001) demonstrating that a PD-
L1:TIMP3 ratio >0.087 was 87.5% sensitive and specific in determining the PD-L1 status equivalent to a PD-
L1 IHC score >1%. Using a higher threshold, the ratio of PD-L1:TIMP3 was significantly increased in SCC 
specimens with >50% tumour cell staining (C, 13.9-fold increase, ****p<0.0001). ROC curve analysis 
generated an AUC value of 0.961 (D, 95%CI; 0.90-1.0, ***p<0.001). A PD-L1:TIMP3 ratio > 0.104 was 100% 
sensitive and 79% specific in distinguishing a PD-L1 IHC score >50%. 
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 Discussion 
As more targeted agents and immunotherapeutic options become available for the treatment of 
cancer, the number of essential predictive biomarkers also increases, putting pressure on 
pathologists and oncologists to make the best use of often limited tissue samples to avoid repeated 
invasive procedures. Some specimen types are particularly problematic, for example endobronchial 
biopsies are often small and crushed making PD-L1 IHC interpretation challenging, while cytology 
specimens often contain insufficient cells in the cell block for reliable PD-L1 IHC. A major advantage 
of our ddPCR workflow is the ability to quantify PD-L1 tumour expression and provide sufficient 
nucleic acid to test for additional targetable mutations in EGFR, ALK and ROS1 from a single small 
specimen. We have previously demonstrated that a single EBUS bronchoscopy specimen is sufficient 
to quantify multiple target genes 127, thereby potentially avoiding the need for repeat biopsy. 
Furthermore, our workflow could be easily integrated into current practices as EBUS specimens are 
routinely collected fresh before fixatives are added. Our fixative approach will specifically stabilise 
and generate high quality and quantity of nucleic acid for multiple molecular tests. Multiplexing 
ddPCR simplified the quantification of our target transcripts by directly and simultaneously 
generating absolute copy number for multiple transcripts. When using an MMP9:TIMP3 ratio cut-off 
of >0.028, our triplex ddPCR assay identified malignant specimens with very high sensitivity and 
specificity, and hence can be used to determine whether the specimen is suitable for additional 
molecular tests including PD-L1 quantification. 
PD-L1 IHC is acknowledged to be an imperfect biomarker, and the three most concordant 
commercially available IHC assays have an agreement of approximately 85% 130. In our study, a 
similar level of concordance was observed between PD-L1 tumour cell IHC and PD-L1 levels 
determined by ddPCR, where 11/88 tumour biopsies identified as PD-L1 high by ddPCR were scored 
negative by IHC based on the <50% IHC score. These specimens included biopsies with increased PD-
L1 tumour cell staining that fell below the 50% threshold (range 5-40%) and biopsies with elevated 
immune cells staining and prominent alveolar macrophage infiltration. Alveolar macrophage 
expression of PD-L1 is a known confounder that particularly affects Adeno compared to SCCs, due to 
tumour architecture. The inability to discriminate the cell type expressing PD-L1 is acknowledged as 
a limitation of this testing method, however the impact of this limitation on the predictive ability of 
the test remains to be fully elucidated. It could be argued that assessment of clinical response to 
anti-PD-1 treatment is really the "gold standard" against which to compare different PD-L1 
biomarker methodologies. Future studies are needed to determine diagnostic ddPCR values that are 
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predictive of clinical response to PD-1/PDL1 immunotherapy before clinical implementation of our 
assay. What has also recently become apparent is that PD-L1 expression on tumour and infiltrating 
immune cells has non-redundant roles in regulating anticancer immunity, where PD-L1 expression 
on both cell types is important for predicting best response to atezolizumab in NSCLC 131. Our data 
demonstrates that whilst PD-L1 tumour expression is the dominant driver of increased PD-L1 
transcript levels in NSCLC, immune cell infiltration can also contribute to absolute PD-L1 mRNA copy 
number.  
Another important advantage is that our triplex ddPCR assay can be automated, performed within 
24-48 hours of specimen collection and only requires standard ddPCR consumable reagents. The 
analysis can be readily adapted into an automated, quantitative process to remove potential inter-
assay and inter-observer variation in the scoring of PD-L1 staining on FFPE sections. A limitation of 
our study is that it remains to be established whether small EBUS-TBNA specimens would be 
adequate for our multiplex ddPCR workflow. However, we have recently shown that a single pass 
snap frozen EBUS-TBNA specimen yielded highly intact DNA (4 micrograms), which is well above the 
minimum threshold for ddPCR or targeted sequencing 132. In summary, we propose the following 
workflow where our triplex ddPCR assay can complement current gold standard protocols. Following 
tumour cell confirmation by rapid on-site evaluation, an EBUS or other endoscopic specimen 
comprising of 3 or more passes should be obtained and formalin-fixed paraffin embedded for lung 
cancer diagnosis and staging as previously described 133. A final single pass EBUS-directed specimen 
from the same site should then be collected and either snap frozen or stored in a nucleic acid 
stabilisation buffer, which will provide a high yield of unfixed nucleic acid for evaluating PDL1 levels 
by ddPCR and allow for additional mutation detection. 
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Figure 4.3.5.1 Workflow for using triplex ddPCR to confirm malignancy and identify NSCLC 
patients suitable for immunotherapies 
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In previous results chapters, neutrophils were identified as an important cellular source of MMP-9 in 
NSCLC and the MMP-9:TIMP3 ratio was characterised as a novel molecular biomarker to confirm 
malignancy in small tumour biospecimens. Previous studies have identified neutrophils as the 
prominent immune cell type in NSCLC, however what is driving tumour associated neutrophil 
infiltration has not been well characterised, particularly in each histological subtype. In this chapter, 
macrophage and neutrophil infiltration was assessed in the biopsy cohort. In addition, the 
association between increasing neutrophils and a panel of chemokines, cytokines and proteases was 
explored to identify whether there are distinct differences in mechanism that drives leukocyte 
trafficking within each tumour subtype.  
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  Introduction 
Surgical resection of early stage lung cancer has the potential of being curative, yet recurrence and 
death occurs in approximately 30-55% of patients 134. An important factor to consider in the 
prognosis of NSCLC is the immune landscape. All tumour types exhibit a degree of leukocyte 
infiltration that is considered to be important for tumour suppression. In recent years, tumour-
infiltrating inflammation has also been recognised as an enabling characteristic for tumour 
progression 59. Identifying unique inflammatory signatures associated with lung cancer prognosis 
and histology will provide fundamental insight into strategies aimed at harnessing the anti-tumoral 
responses of key immune cells. The most prominent immune cell type discovered within the NSCLC 
landscape varies between studies.  T lymphocytes have been reported to constitute approximately 
50% of all tumour-infiltrating CD45+ leukocytes in both lung Adeno and SCC 135.  Cytotoxic T 
lymphocytes, which make up a large proportion, are responsible for tumour recognition and killing. 
Increased levels of tumour-infiltrating cytotoxic T cells in NSCLC patients are associated with 
improved overall survival 136, yet, tumours can evade immunosurveillance by producing PD-L1 that 
inhibit cytotoxic T cell response by binding to its surface receptor PD-1 137. FDA approved PD-1 
inhibitors, nivolumab and pembrolizumab, have shown to improve progression-free survival in 
NSCLC patients 51, 138. However, with a response rate of approximately 20%, it highlights the 
importance of targeting other immune cell subsets. 
Tumour associated macrophages (TAMs) and tumour associated neutrophils (TANs) also dominate 
the immune cell composition in NSCLC 60. It is well established that the phenotype and spatial 
distribution determines whether TAMs are predominantly pro-tumourigenic or anti-tumourigenic. 
Macrophages have a diverse range of functions due to their ability to polarise into distinct 
phenotypes, where the M1 or M2 paradigm represent extreme ends of a spectrum of phenotypes. 
Fluidity between the two phenotypes plays an important role in wound healing. The polarisation of 
macrophages into an M1 pro-inflammatory phenotype can occur in response to several cytokines 
including IFNγ, TNFα and CSF2 139. M1 macrophages produce predominantly pro-inflammatory 
mediators such as IL-23 and IL-12 for pathogen recognition and elimination. In response to 
immunosuppressive cytokines such as CSF1, IL-10 and IL-4, macrophages may then polarise to an M2 
anti-inflammatory phenotype to promote angiogenesis as well as scavenge debris for tissue repair 
and restitution. In cancer, it is well-known that pro-tumourigenic macrophages commonly display a 
variant of the M2 phenotype. As such, these immunosuppressive TAMs support tumour growth by 
inhibiting T cell responses and producing pro-angiogenic factors such as VEGF, and MMP-9 for 
tumour migration and invasion 139. In NSCLC, improved overall survival was found in a subset of 
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patients with increased expression of M1-type macrophages within the tumour islets  140. However, 
survival was reduced in patients with higher TAM infiltration in the tumour-surrounding stroma 
irrespective of phenotype. This suggests that anti-tumoral TAMs infiltrating tumour islets may be 
impaired in NSCLC subpopulations. 
In contrast to TAMs, the role of TAN infiltration in NSCLC is not well understood. Increased TAN 
infiltration in several cancers including renal carcinoma 141 and melanoma 142 have been associated 
with poorer prognosis. However, this is not always the case particularly in gastric cancer where a 
positive association between increased neutrophilic inflammation and better clinical outcome was 
found 143. In advanced NSCLC, neutrophilia in the peripheral blood has been identified as a predictor 
of poorer prognosis 144. In support of this, clinical assessment of the Neutrophil-to-Lymphocyte ratio 
(NLR) is well-established. A systematic review has shown that increased NLR in NSCLC is consistently 
associated with an increased risk of death and poorer progression-free survival 145. Neutrophils are a 
major source of reactive oxygen species (ROS), pro-angiogenic factors and matrix-degrading 
enzymes such as MMP-9 146 that in abundance support tumour initiation, progression and metastasis 
147. In both NSCLC subtypes, Adeno and SCC, increased TAN infiltration has been detected 
predominately within the tumour region relative to the tumour-free distal lung 60. However growing 
evidence supports the view that the presence of tumour-infiltrating neutrophils during early stages 
of NSCLC may have a protective role against tumour progression. Isolated TANs from stage I-II NSCLC 
biopsies were highly activated and were able to stimulate cytotoxic T cell responses whilst retaining 
their capacity to produce ROS and pro-inflammatory mediators 64. The capacity of neutrophils to 
stimulate T cells reduced as the tumour size increased, suggesting that neutrophils may become 
more pro-tumourigenic as the disease progresses. Like macrophages, neutrophils may also switch 
between a pro-tumourigenic N1 phenotype or an anti-tumourigenic N2 phenotype depending on the 
chemokine landscape within the tumour microenvironment.  
There are several chemokines and cytokines that have been implicated in the recruitment of 
neutrophils during acute inflammation. Among these are the classic chemotactic factors derived 
from the C-X-C and C-C family of proteins 148 with Interleukin-8 (IL-8/CXCL8) considered one of the 
most potent neutrophil chemoattractants. Generated by various sources including macrophages, 
epithelial cells and IL-17- producing T cells, IL-8 can induce neutrophil trafficking into the inflamed 
site by binding to its surface receptors CXCR1 and CXCR2 149. Neutrophils are also major source of IL-
8 and can therefore support their own recruitment through autocrine activation 150. Activated 
macrophages may coordinate neutrophil recruitment by producing other chemotactic factors 
including CXCL1, CXCL2 and CCL2 151. Furthermore, cytokines such as GM-CSF (CSF2) and G-CSF 
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(CSF3) can mobilise neutrophil recruitment by stimulating granulopoiesis within the bone marrow 
and increasing the expression of the adhesion molecules on the neutrophil cell surface 152. Another 
important neutrophil chemoattractant to consider is Serum Amyloid A (SAA). In response to tissue 
injury or infection, the hepatic acute phase protein can be upregulated up to 1000-fold in circulation 
to isolate and neutralise invading pathogens 153.  Extrahepatic tissues including colon, kidney and 
skin can also produce SAA where it can influence local responses and modulate inflammation by 
interacting with its receptors on nearby cells 154. Acutely, SAA can promote initial neutrophil and 
monocyte recruitment for pathogen clearance 155. SAA appears to function in a biphasic manner that 
can promote subsequent tissue repair by transforming macrophages into an M2 phenotype for 
effective efferocytosis 156.  
Intriguingly, a marked increase in SAA expression has been detected in several cancers including 
melanoma 157, colon 158 an ovarian carcinoma 159, where SAA was further increased as the tumours 
progressed. More importantly, as a chemotactic factor, SAA has the capacity to influence the 
plasticity of neutrophils to either an N1 or N2 phenotype. In melanoma patients, the increased 
presence of immunosuppressive IL-10 secreting neutrophils was directly modulated by SAA 157. It is 
not known whether SAA expression is increased at the tumour site of NSCLC patients, despite the 
fact that circulating SAA levels are frequently elevated. Proteomic profiling of sera from lung cancer 
patients have identified increased serum SAA as a distinguishable marker of lung cancer patients 
from healthy subjects and is a reproducible predictor of prognosis 160. However, in NSCLC, it is 
unclear whether excess SAA in the peripheral blood may overflow into the local tumour 
environment and whether SAA plays an important role in the recruitment of TANs.   
In this study, we aim to quantify the number of TAMs and TANs in early stage NSCLC using FFPE 
tumour resection biopsies (VCB cohort) and matched serum samples. Whilst the current dogma is 
that classic CXCL chemokines such as IL-8 are driving the recruitment of TANs in NSCLC subtypes, this 
has not been extensively characterised. In this chapter, a comprehensive assessment of various 
inflammatory chemokines was undertaken in order to identify the molecules driving accumulation of 
TANs and determine whether there are distinct differences between histological subtypes. 
Subsequent survival analysis will provide greater insight as to whether recruitment of TANs in early 
stage NSCLC subtypes is a prognostic predictor of overall survival.    
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 Method 
5.2.1 Biopsy cohort 
Patient characteristics of the biopsy cohort (n=100) from the Victorian Cancer Biobank is described 
in Chapter 3.2.2 127. Reclassification of the NSCLC specimens identified 48 Adeno and 40 SCC cases 
(Chapter 4.2.1) with which two case identified as mixed adenosquamous and pleomorphic 
carcinoma were excluded. The control group (n=20) comprised of 10 patients without malignant 
disease and 10 Adeno-matched control specimens from the adjacent tumour-free region.  
5.2.2 Gene expression analysis by RTqPCR 
Total RNA was isolated from the frozen biopsies (n=107) and converted to cDNA, as previously 
described (Chapter 3.2.3). Quantitative PCR was performed on the QuantStudio 7 (Applied 
Biosystems, CA, US) using validated Taqman primer/probes to assess the transcript levels of SAA, IL-
8, CXCL1, CXCL2, CSF1, CSF2, CCL2, MMP-9, MMP-7, ADAM10, ADAM17, TIMP1, TIMP2 and TIMP3. 
Threshold cycle values (Ct) were normalised to the geomean of two stable reference genes TBP and 
PUM1 84. The comparative (2-ΔΔCt) method was used to present gene expression as fold change 
relative to a control sample in the biopsy cohort.  
5.2.3 Direct quantification by ddPCR 
Absolute transcript levels of MMP-9 and TIMP3 were determined by Droplet digital PCR (ddPCR). 
Specimens were prepared for droplet generation and endpoint PCR using the QX200 ddPCR system 
(Bio-Rad Laboratories, CA, US), as previously described (Chapter 4.2.4). The QuantaSoft Analysis Pro 
Software v 1.0 (Bio-Rad Laboratories, CA, US) was used to generate 2D amplification plots to assess 
the copy number ratio of MMP-9:TIMP3.  
5.2.4 Immunohistochemical analysis of CD68, Myeloperoxidase (MPO) and Serum 
Amyloid A (SAA) 
Matched tumour and tumour-free tissue was obtained from the same region as the frozen tissue 
biopsies and prepared as formalin-fixed paraffin embedded (FFPE) tissue blocks. As previously 
described in Chapter 2.2.4, 5µm thick serial sections were deparaffinised, rehydrated and incubated 
in citrate buffer (10mM Citric Acid, 0.05% Tween 20, pH 6.0) at 95°C for 20mins for heat-induced 
epitope retrieval. Using the EnVision® + Dual Link System-HRP kit (Dako, Agilent Technologies, CA, 
US), slides were exposed to the endogenous peroxidase dual enzyme block for 5 mins and incubated 
for another 1 hour (hr) at room temperature (RT) in blocking buffer specific for MPO/CD68 (5% BSA, 
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10% Horse Serum, 0.4% TritonX in 1x PPBS) and SAA (5% HS, 0.4% TritonX in 1x PBS). For the 
detection of neutrophils and macrophages, sections were incubated with either a 1:500 dilution of 
the rabbit polyclonal antibody against human MPO (Dako #A0398) or a 1:100 dilution of the mouse 
monoclonal antibody against human CD68 (DAKO #M0814) in 1XPBS for 1 hr at RT. SAA staining was 
attained using the mouse monoclonal antibody against human Amyloid A (clone mc1; Dako #M0759) 
at a 1:40 dilution in freshly prepared 0.05M Tris-HCL. MPO/CD68 slides were washed three times in 
Tris-EDTA buffer (0.01M Tris amine buffer, 0.04M Tris-HCL, 0.5% Tween 20, pH 7.6), whereas SAA 
slides were washed in 1xPBS. All slides were incubated with labelled polymer-HRP (Envision kit) for 
1hr at RT. Slides were rinsed three times in wash buffer prior to incubation with SIGMAFAST 3,3’-
Diaminobenzidine (Sigma Aldrich, MO, US) for 3-5mins. Following visualisation of MPO and SAA 
staining, sections were counterstained in Mayer’s Haematoxylin (Trajan Scientific and Medical, VIC, 
Australia), dehydrated and mounted onto slides. All immunostained slides were subjected to virtual 
microscope scanning under high-power magnification using the Olympus V120 virtual slide scanner. 
The entire tumour section was captured and the area positive for CD68 or MPO was determined 
using the Olympus CellSens software. An experienced pathologist at St Vincents Hospital determine 
the localisation of SAA staining in the malignant specimens. 
5.2.5 ELISA for the quantification of SAA in serum  
The human SAA sandwich enzyme-linked immunosorbent assay (ELISA) kit (Thermofisher Scientific, 
MA, US) was used to quantify SAA levels in matching serum from patients in the biopsy (n= 97) 
cohort in accordance with the manufacturer’s instructions. Briefly, samples and standards were 
transferred to a 96-well plate pre-coated with a human SAA capture antibody. Biotin conjugate was 
then added to each well and the plate was incubated for 2hrs at room temperature while rotating at 
1000 rpm on a Grant Thermoshaker (Lab Gear, QLD, Australia). Following 3x washes, samples were 
incubated for a further 30mins at 1000rpm in Streptavidin-HRP solution at room temperature. After 
another set of 3x washes, samples were incubated in stabilised chromogen for 10mins until a colour 
change was produced. Stop solution was added and the absorbance was measured at 450nm using 
the CLARIOstar (BMG LABTECH, Ortenberg, Germany). The concentrations of the unknown samples 
were determined using a 4-parameter logistic regression analysis of the standard curve.  
5.2.6 Statistical Analysis 
Data presented as Tukey boxplots or scatterplots were generated using Graphpad prism 7.02 
(Graphpad Software Inc, San Diego, CA). The Mann-Whitney two-tailed t-tests were performed to 
compare two unpaired samples. A comparison of multiple groups was determined using the Kruskal 
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Wallis test followed by Dunn’s multiple comparison post hoc tests. Spearman correlation was 
performed to identify the association between two groups. Two-way Anova was used to assess 
compare relative transcript expression of a select panel of genes between histological subtypes. 
Survival analysis was achieved on SPSS Version 25 (IBM Corp, Armonk, NY). Univariate Cox 
proportional hazards regression was performed to assess the prognostic value of NMR and other 
covariates including age, sex, stage of tumour and smoking status. Cumulative survival curves 
comparing low vs high NMR expression in both NSCLC tumour subtypes were generated by the Cox 
regression tool. Using the forced entry model, categorical groups were compared to the reference 
group using the indicator contrast. Multivariate regression analysis was performed using forward 
stepwise entry to assess whether NMR is an independent or dependent prognostic factor for survival 
in SCC patients. Statistical significance for all analyses were determined by p values less than 0.05. 
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 Results  
5.3.1 The neutrophil to macrophage ratio (NMR) is elevated in NSCLC tumour biopsies 
FFPE control and tumour sections were subjected to immunohistochemical staining for CD68 
positive macrophages and Myeloperoxidase (MPO) positive neutrophils. Virtual whole slide scan 
images were captured and representative images of CD68+ macrophages and MPO+ neutrophils are 
presented in Figure 5.3.2.1A-F. In the control specimens, CD68+ macrophages constituted 2.7% 
(95%CI, 2.2-4.9) of the total tissue area (Figure 5.3.2.1A). CD68 positive macrophages were 
predominantly located around the surrounding tumour stroma in the Adeno biopsies (Figure 
5.3.2.1B) and SCC biopsies (Figure 5.3.2.1C). Very few MPO-positive neutrophils were detected in 
the control sections (Figure 5.3.2.1D). MPO positive tumour-infiltrating neutrophils were diffusely 
detected in Adeno sections (Figure 5.3.2.1E), whereas large clusters of MPO+ neutrophils were 
found within tumour nests in SCC (Figure 5.3.2.1F). Quantification of the area positive for CD68 
staining identified a significant increase in SCC (Figure 5.3.2.1G, 2.2-fold increase, p<0.01) but not 
Adeno relative to controls. The area fraction of MPO positive staining in the controls was a median 
of 0.2% (Figure 5.3.2.1H, 95%CI; 0.1-0.4) of the entire tissue section. Compared to controls, a 
significant percentage increase in MPO staining was detected in Adeno (4.7-fold increase, p<0.01), 
which was further increased in SCC (26.0-fold increase, p<0.0001). In addition, the neutrophil to 
macrophage ratio (NMR) was evaluated, which identified a disproportionate increase in Adeno 
(Figure 1I, 3.5-fold increase, p<0.01), which was further enhanced in SCC (13.4-fold, p<0.0001).  
5.3.2 IL-8, CXCL1 and SAA are associated with tumour infiltrating neutrophils in Adeno 
Expression of the neutrophil chemokines including IL-8, CXCL1 and CXCL2 was assessed by RTqPCR in 
the biopsy specimens. IL-8 and CXCL1 transcript levels were similar between Adeno and control 
specimens (Figure 5.3.2.1A-B), whereas CXCL2 transcripts were significantly reduced in Adeno 
(Figure 5.3.2.1C, 2.8-fold decrease, p<0.01). Nevertheless, a positive association was detected 
between IL-8 transcripts and MPO staining, indicative of neutrophilic infiltration (Figure 5.3.2.2D, r = 
0.50, p<0.001). Similarly, MPO+ staining was found to be positively associated with CXCL1 transcripts 
(Figure 5.3.2.2E, r = 0.46, p<0.01), but did not reach a statistically significant association with CXCL2 
(Figure 5.3.2.2F). Local and systemic SAA expression were assessed in the biopsies and matched 
serum by RTqPCR and ELISA, respectively. Relative to controls, circulating SAA levels was markedly 
increased in the Adeno patients (Figure 5.3.2.3A, 4.3-fold increase, p<0.01). 
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Figure 5.3.2.1 Assessment of macrophage and neutrophil infiltration in the biopsy specimens 
Immunohistochemical staining of CD68 and Myeloperoxidase (MPO) were performed on matched FFPE tissue 
sections from the biopsy cohort (n=110). Representative images show low expression of CD68 (brown) in the 
control tissue (A, magnification) indicative of macrophage and monocyte expression. In the Adeno (B; n=48) and 
SCC specimens (C; n=40), an increase in CD68 expression is observed in the stroma surrounding the tumour. Very 
low MPO staining, indicative of neutrophil expression, is detected in the controls (D). MPO staining is increased 
within and around the tumour cells of the Adeno specimens (E). This was further increased in the SCC specimens 
(F) where large clusters of MPO staining was observed directly within and around the tumour.  Quantification of 
CD68 staining shows a percentage increase in the Area Fraction of the Region of Interest (ROI) specifically in SCC 
relative to controls (G, 2.2-fold increase, **p<0.01) and Adeno specimens (G, **p<0.01). A percentage increase 
in MPO positive staining was detected in Adeno (H, 4.7-fold increase, **p<0.01) which was further increase in 
SCC (H, 26.0-fold increase, *p<0.0001) relative to control specimens. The Neutrophil to macrophage ratio (NMR) 
was evaluated by determining the ratio of MPO:CD68 staining. A significant step-wise increase of NMR was 
detected in the NSCLC subtypes relative to controls (H, **p<0.01, ****p<0.0001). 
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In the tumour biopsies, SAA transcript levels remained unchanged (Figure 5.3.2.3B) and did not 
associate with serum SAA levels (Figure 5.3.2.3C). However, an association was identified between 
SAA transcription and MPO+ neutrophil staining (Figure 5.3.2.3D, r = 0.51, p < 0.001). In addition, SAA 
transcript levels positively associated with the chemotactic factors IL-8 (Figure 5.3.2.3E, r =0.47, 
p<0.001) and CXCL1 (Figure 5.3.2.3F, r = 0.61, p<0.0001). Pathological assessment of SAA expression 
in the Adeno biopsies identified granular cytoplasmic SAA staining in seromucinous glands (Figure 
5.3.2.3G) and alveolar macrophages (Figure 5.3.2.3H). SAA was also expressed in alveolar 
macrophages containing carbon pigment (Figure 5.3.2.3I).  
 
Figure 5.3.2.2 Transcript levels of IL-8 and CXCL1 are associated with increasing tumour 
associated neutrophils in Lung Adeno 
Taqman RTqPCR was performed to assess gene expression changes of IL-8, CXCL1 and CXCL2 in the Adeno 
specimens (n=48) relative to controls (n=20). Transcript levels of IL-8 and CXCL1 remained similar between 
Adeno and control specimens (A-B, Mann Whitney t-test). CXCL2 transcript levels were significantly reduced 
by 2.8-fold in the Adeno biopsies (C, **p<0.01). On the matched FFPE tissue, MPO immunohistochemical 
staining was quantified to assess the level of neutrophilic inflammation in the Adeno Specimens. Spearman 
correlation identified a positive association between IL-8 transcript levels and increasing MPO+ neutrophil 
staining (D, r=0.50, ***p<0.001). Similarly, CXCL1 was found to be positively associated with MP0+ neutrophil 
staining (E, r=0.46, **p<0.01). However, no association was detected between CXCL2 and MPO staining (F). 
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Figure 5.3.2.3 Local SAA transcript levels is associated with increased tumour associated 
neutrophils in Lung Adeno   
ELISA and Taqman RTqPCR was performed to assess systemic and local SAA production in the Adeno specimens 
(n=48) relative to controls (n=20).  Serum SAA level were significantly increased in Adeno (A, 4.3-fold increase, 
**p<0.01, Mann Whitney t-test). SAA transcript levels were similar between Adeno and control specimens (B). 
No association was detected between serum SAA and local SAA transcript levels (C, Spearman correlation). 
However, SAA transcript was found to be positively associated with MPO+ neutrophil staining (D, r=0.51 
***p<0.001), IL-8 transcript (E, r=0.472, ***p<0.001) and CXCL1 transcript levels (F, r=0.61, ****p<0.0001). 
Displayed are representative images of SAA expression in matched Adeno FFPE tissue (20x magnification). SAA 
immunohistochemical staining was detected in normal seromucinous glands (G), tumour associated alveolar 
macrophages (H) and alveolar macrophages containing carbon pigment (I) 
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5.3.3 IL-8, CXCL1, CXCL2 and SAA are not associated with MPO+ neutrophil staining in 
SCC 
Expression of IL-8, CXCL1, CXCL2 and SAA were assessed in the SCC biopsy cohort by RTqPCR. IL-8 
transcript levels were significantly elevated in SCC relative to controls (Figure 5.3.4.1A, 3.3-fold 
increase, p<0.01). Similarly, a significant increase was detected in CXCL1 transcription (Figure 
5.3.4.1B, 2.6, p<0.05), while CXCL2 was significantly reduced in SCC (Figure 5.3.4.1C, 9.3-fold 
decrease, p<0.001). All three chemotactic factors however, did not associate with MPO+ neutrophil 
staining in SCC specimens (Figure 5.3.4.1D-F). As observed in Adeno, serum SAA levels were 
significantly increased in the peripheral blood of SCC patients relative to controls (Figure 5.3.4.1G, 
14.7-fold increase, p<0.001). Moreover, SAA transcript levels was also significantly elevated in the 
local tumour environment (Figure 5.3.4.1H, 8.2-fold increase, p<0.01), however no association was 
detected between SAA transcription and MPO+ staining in SCC (Figure 5.3.4.1I).  
5.3.4 The MMP9:TIMP3 ratio is associated with tumour infiltrating neutrophils in SCC 
A panel of proteases and their inhibitors were assessed by RTqPCR in the biopsy cohort. Relative to 
MMP-7 transcript levels, MMP-9 was similarly expressed in the control specimens while ADAM-17 
and ADAM-10 transcript levels was found to be more abundant (Figure 5.3.4.2A). Post hoc multiple 
comparison’s test showed no statistical difference in MMP-7, ADAM-17 and ADAM-10 transcript 
levels between the NSCLC subtypes and controls. A significant difference was detected in the mean 
fold-change of MMP-9 in the Adeno specimens relative to controls (Figure 5.3.4.2A, 6.8-fold 
increase, p<0.05). The gene expression levels of the corresponding inhibitors TIMP1, TIMP2 and 
TIMP3 were assessed relative to TIMP1 (Figure 5.3.4.2B). In the control specimens, TIMP3 appeared 
to be the most abundant inhibitor. A significant increase in TIMP1 was detected in Adeno relative to 
controls (2.1-fold increase, p<0.05). However, TIMP2 was significantly reduced in Adeno (1.5-fold 
decrease, p<0.05) and even further in SCC (3.3-fold decrease, p<0.0001). A similar step-wise 
reduction in TIMP3 transcript levels was detected in Adeno (2.4-fold decrease, p<0.0001) and SCC 
(5.3-fold decrease, p<0.0001). In comparison to the other proteases and inhibitors MMP-9 and 
TIMP3 gene expression was substantially altered in the NSCLC subtypes. Direct quantification of the 
MMP-9 and TIMP3 transcript by duplex ddPCR detected a significant increase in the ratio of MMP-
9:TIMP3 in Adeno (Figure 5.3.4.3A, 27.5-fold increase, p<0.0001) and SCC (63.5-fold increase, 
p<0.0001) relative to controls. While no association between the MMP-9:TIMP3 ratio and MPO+ 
neutrophil staining was found in Adeno (Figure 5.3.4.3B), a positive correlation was detected in SCC 
(Figure 5.3.4.3C, r = 0.404, p<0.05). 
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Figure 5.3.4.1 Chemotactic factors IL-8, CXCL1, CXCL2 and SAA are not associated with increasing 
tumour associated neutrophils in Lung SCC 
Taqman RTqPCR was performed to assess gene expression changes of IL-8, CXCL1 and CXCL2 in the SCC 
specimens (n=40) relative to controls (n=20). Compared to controls, IL-8 and CXCL1 transcription were 
significantly increased by 3.3-fold (A, **p<0.01, Mann Whitney t-test) and 2.6-fold (B, *p<0.05), in SCC 
respectively. Whereas CXCL2 was significantly reduced in SCC (C, 9.3-fold decrease, ***p<0.001). Spearman 
correlation showed that there was no association between MPO+ neutrophil staining and the chemotactic 
factors IL-8, CXCL1 and CXCL2 (D-F). Serum SAA levels were significantly increased in SCC relative to controls 
(G, 14.7-fold increase, ***p<0.001). While SAA transcript levels was also significantly increased in SCC (H, 8.2-
fold increase, **p<0.01), it was not associated with MPO+ immunohistochemical staining (I). 
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Figure 5.3.4.2 Gene expression of select MMPs and their corresponding inhibitors in the biopsy 
specimens 
Taqman RTqPCR was performed to assess the expression levels of the metalloproteinases MMP-7, MMP-9, 
ADAM-17 and ADAM10 as well as their inhibitors TIMP1, TIMP2 and TIMP3 in the NSCLC subtypes (Adeno; 
n=48, SCC; n=40) and controls (n=20). Figure A shows the gene expression levels of MMP-9, ADAM-10 and 
ADAM-17 relative to a control specimen in the MMP-7 group. A two-way Anova with tukey’s multiple 
comparison test showed no statistical difference in MMP-7 transcription between NSCLC subtypes and 
controls. Baseline transcript levels of MMP-9 and MMP-7 levels were similar in the control specimens, 
however MMP-9 transcription was significantly increased in the Adeno specimens (6.8-fold increase, 
*p<0.05). While ADAM-17 and ADAM-10 transcript levels were more abundant than MMP-7 and MMP-9 at 
baseline, there was no significant change in the tumour subtypes relative to controls. Figure B shows the 
gene expression changes the inhibitors TIMP1, TIMP2 and TIMP2 relative to a single control specimen in the 
TIMP1 group. At baseline, TIMP3 transcription appears to be the most abundant in the control samples. 
Tukey’s multiple comparison’s test detected a significant increase in TIMP1 transcription in the Adeno 
relative to controls (2.1-fold increase, *p<0.05). In contrast, a step-wise reduction in TIMP2 transcription was 
detected in Adeno (1.5-fold decrease, *p<0.05) and SCC (3.3-fold decrease, ****p<0.0001) relative to 
controls. Similarly, TIMP3 transcription was significantly reduced in Adeno (2.4-fold decrease, ****p<0.0001) 
and SCC (5.3-fold decrease, ****p<0.0001).  
 
A 
B 
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Figure 5.3.4.3 The MMP9:TIMP3 ratio is associated with increasing MPO+ neutrophil staining 
Direct quantification of MMP-9 and TIMP3 transcript levels was assessed by duplex ddPCR in the NSCLC 
subtypes (Adeno; n=48, SCC; n=40) relative to controls (n=20). The ratio of MMP-9:TIMP3 was significantly 
increased in Adeno (A, 27.5-fold increase, ****p<0.0001, Kruskall-Wallis test) and SCC (63.5-fold increase, 
****p<0.0001) relative to controls. There was no association between the MMP-9:TIMP3 ratio and MPO+ 
staining in Adeno (B, Spearman’s correlation), whereas a positive association was found in SCC (E, r = 0.404, 
*p<0.05). 
 
5.3.5 Reduced CSF1 transcription is associated with increasing NMR in SCC 
Chemotactic factors CSF1, CCL2 and CSF2 were assessed in the biopsy specimens by RTqPCR. CSF1 
transcription was significantly reduced in SCC relative to controls (Figure 5.3.5.1A, 3.1-fold decrease, 
p<0.0001) and Adeno specimens (2.7-fold decrease, P<0.0001). Quantitative assessment of the ratio 
of neutrophils to macrophages (NMR) staining showed no association between CXCL1 transcription 
and NMR in Adeno (Figure 5.3.5.1B), however a negative association was detected in SCC (Figure 
5.3.5.1C, r = -0.34, p<0.05). In SCC, a significant reduction was detected in CCL2 transcript levels 
(Figure 5.3.5.1D, 3.5-fold decrease, p<0.01) relative to controls, whereas a statistically significant 
association was not observed between CCL2 and NMR in either tumour subtype (Figure 5.3.5.1E-F). 
Like CCL2, CSF1 also showed a 3.8-fold reduction in transcript levels in SCC specimens (Figure 
5.3.5.1G, p<0.05) and was not associated with NMR in both NSCLC subtypes (Figure 5.3.5.1H-I).  
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Figure 5.3.5.1 A loss in CSF1 transcript levels is associated with increased NMR in SCC 
Gene expression CSF1, CCL2 and CSF2 were assessed in the NSCLC biopsy specimens (Adeno; n=48 SCC; n=40) 
relative to controls (n=20) by Taqman RTqPCR. A significant reduction in CSF1 gene expression was detected 
SCC relative to both controls (A, 3.1-fold decrease, ****p<0.0001, Kruskall-Wallis test) and Adeno (A, 2.7-
fold decrease, ****p<0.0001). While there was no association between CSF1 transcript levels and NMR in 
Adeno (B, Spearman correlation), a negative association was found in SCC (C, r= -0.387, *p<0.05). CCL2 was 
significantly reduced in SCC relative to both controls (D, 3.5-fold decrease, **p<0.01) and Adeno (D, 2.7-fold 
decrease, **p<0.01), however no association was found between CCL2 transcript and NMR across both 
NSCLC subtypes (E-F). A significant decrease in CSF2 transcription was detected in SCC when compared to 
controls (G, 3.8-fold decrease, *p<0.05, ***p<0.001), and Adeno specimens (G, 5.9-fold decrease, 
****p<0.0001). Despite this, no association was found between CSF2 transcript and NMR across both NSCLC 
subtypes (H-I). 
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5.3.6 Predictors of survival were not identified in the Adeno subtype 
For both histological subtypes, patients were categorised into two groups based on NMRlow <1 vs 
NMRhigh >1. The prognostic value of NMR on survival, considering age, sex, smoking status and 
pathological stage was assessed by the Cox proportional hazards model in Adeno and SCC 
specimens. Cox regression analysis generated statistically similar survival curves for Adeno patients 
in either the NMRlow or NMRhigh group (Figure 5.3.6.1). The Omnibus Tests of Model Coefficients was 
performed to assess the validity of the Cox regression model to determine whether one or more 
variables were useful predictors of survival in either NSCLC subtype. In the Adeno patients, the 
Omnibus test did not reach statistical significance (Figure 5.3.6.1, p = 0.445) and therefore was not 
applicable to this subtype.   
 
 
 
Figure 5.3.6.1 Cox regression was inadequate in identifying statistically significant predictors of 
survival in the Adeno subtype  
Cox regression was performed to determine whether the independent variables; NMR, Age, Sex, Pathological 
Stage and Smoking status were useful predictors of survival in the Adeno cohort (n=48). The Omnibus tests of 
Model coefficients identified that each variable entered into the model did not achieve statistical significance. 
Overall, cox regression was an inadequate model of fit for the Adeno subtype and the above graph shows that 
the survival curves were statistically similar in Adeno patients with NMRhigh or NMRlow expression.    
Time post-surgery (Years) 
 101 
Chapter 5 – Low NMR is a poor prognostic predictor of survival in Squamous Cell carcinoma 
5.3.7 NMR <1 is predictive of poorer survival in SCC patients 
The Omnibus Tests of Model Coefficients was applied to the SCC cohort and achieved statistical 
significance (Figure 5.3.7.1, p<0.01). This demonstrated the validity of the Cox regression model to 
identify useful predictors of survival in SCC. Univariate Cox regression analysis was performed and 
identified NMR, Smoking status and Pathological stage as potential predictors of survival. Figure 
5.3.7.1 shows a graphical representation of the percentage survival over 5 years post-surgery in SCC 
patients with either NMRlow vs NMRhigh expression. NMRlow patients were associated with a 3.9-fold 
increased risk in death relative to NMRhigh patients (Table 5.3.7.1, 95%CI; 1.4-11.5, p<0.05). In 
addition, current smokers showed a significant increased risk in death relative to former smokers 
(Table 5.3.7.1, HR=6.12, 95%CI; 1.6-22.8, p<0.01) and poorer survival was observed in SCC patients 
with increasing pathological stage. SCC patients with advanced stage IIIA showed a significant 14.2-
fold increased risk in death (Table 5.3.7.1, 95%CI 2.6-78.5) patients with early stage IA. However, age 
and sex were not significantly associated with survival in SCC. 
 
Figure 5.3.7.1 Cox regression identified that SCC patients with low NMR <1 were associated with 
poorer survival 
Cox regression analysis was performed to determine whether the independent variables; NMR, Age, Sex, 
Pathological Stage and Smoking status were useful predictors of survival in the SCC cohort (n=40). The 
Omnibus test of Model Coefficients achieved statistical significance (**p<0.01) and demonstrated the validity 
of the Cox regression model to identify potential predictors of survival in SCC. NMR was identified as a 
potential predictor of survival and the above graph shows that SCC patients with NMR low expression were 
associated with significantly poorer survival 5 years post-surgery than NMRhigh patients. 
 
Time post-surgery (Years) 
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Table 5.3.7.1 Univariable predictors of survival for SCC 
Covariate Hazard Ratio 95% CI P value N 
NMR 3.945 1.4-11.5 0.012 18 (Low) 
19 (High) 
Age (at surgery) 1.004 0.9-1.1 0.902 
 
Sex 0.600 0.1-2.5 0.479 31 (M) 
 6   (F) 
Smoking status 
    
Former 1.00 NA NA 25 
Current 6.120 1.6-22.8 0.007 12 
Stage 
    
IA 1.00 NA NA 11 
IB 3.636 0.6-21.2 0.151 4 
IIA 1.564 0.4-7.0 0.556 11 
IIB 5.052 0.7-34.1 0.097 7 
IIIA 14.219 2.6-78.5 0.002 4 
 
 
5.3.8 NMRlow SCC patients who continue to smoke 5 years post-surgery have the 
greatest risk in death  
Multivariate Cox regression analysis determined that NMR adjusted for smoking status and 
pathological stage was associated with an increased risk in death. An increased hazard ratio of 4.2-
fold was identified in SCC patients with low NMR < 1 (Table 5.3.8.1, 95%CI; 1.5-12.0, p<0.01). To 
determine which covariate NMR was dependent upon, the interaction between each combination 
was assessed by simple effects analysis. A statistically significant interaction was detected between 
NMR and smoking status in SCC, shown in Figure 5.3.8.1. However, the effect of NMR and smoking 
status on survival was independent of pathological stage. The reference category defined as former 
smokers with high NMR >1 were associated with better survival outcomes (Figure 5.3.8.1, blue). 
While a decrease in survival was observed in former smokers with low NMR (Figure 5.3.8.1, red) and 
current smokers with high NMR (Figure 5.3.8.1, green) relative to the reference group, this was not 
statistically significant. In contrast, SCC patients with low NMR who continued to smoke post-surgery 
showed the greatest risk in death (Figure 5.3.8.1, HR = 9.1, 95% CI; 2.2-36.8, p<0.01). 
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Table 5.3.8.1 Multi-variant predictors of survival for SCC 
Covariate Hazard Ratio 95% CI P value 
NMR 4.247 1.5-12.0 0.007 
Smoking status 
   
Former 1.00 NA NA 
Current 5.772 1.6-20.8 0.007 
Stage 
   
IA 1.00 NA NA 
IB 3.408 0.6-19.6 0.169 
IIA 1.894 0.5-7.4 0.360 
IIB 4.941 0.7-33.5 0.102 
IIIA 14.009 2.6-74.4 0.002 
 
 
 
Figure 5.3.8.1 NMR and smoking status are dependent predictors of survival in SCC  
Simple effects analysis identified a significant interaction between the NMR and smoking status in the SCC 
cohort (n=40). The reference category, defined as former smokers with high NMR >1, were associated with 
increased survival 5 years post-surgery (Blue, HR = 1, 95%CI; NA, p = NA). A decline in survival is observed in 
former smokers with low NMR <1 (Red, HR, 2.995, 95%I; 0.9-10.1, p= 0.76) and current smokers exhibiting 
high NMR >1 (Green, HR = 4.055, 95%CI; 0.8-19.5, p= 0.8). Relative to the reference category, SCC patients 
with low NMR <1 who continued to smoke post-surgery were associated with the greatest risk in death over 
the 5 years (Orange, HR = 9.056, 95%CI; 2.2-36.8, **p<0.01) 
  
Time post-surgery (Years) 
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 Discussion 
In our study, we assessed the abundance of TANs and TAMs in stage I-II NSCLC biopsies as well as a 
select panel of chemokines and cytokines to elucidate the dominant mediators driving neutrophil 
recruitment and survival. Immunohistochemical analysis of CD68+ macrophages and MPO+ 
neutrophils established that the accumulation of TAN and TAM infiltrates differs between the major 
NSCLC subtypes. In the control patients with non-malignant disease macrophage density constituted 
2.7% of the total lung tissue region assessed. Neutrophils  were rarely detected or completely absent 
in the airways, which is consistent with the fact that neutrophils normally reside in circulation under 
normal conditions 161. In the NSCLC subtypes we observed that again macrophages predominantly 
infiltrated the tumour-surrounding regions, however compared to control patients, macrophage 
abundance was similar to Adeno and only 2-fold higher in the SCC cohort. A striking result was the 
increased area of neutrophil infiltration relative to macrophage infiltration in both tumour subtypes. 
Compared to control patients, neutrophil staining was 5-fold higher in Adeno and even further 
increased in SCC. Evaluation of the neutrophil-to-macrophage ratio (NMR) demonstrated that TANs 
were disproportionately increased relative to TAMs in a subset of Adeno (15.2%) and SCC (51.4%) 
patients.   
Here, we identified distinct differences in the chemokine landscape between the NSCLC subtypes 
and, for the first time, demonstrate that the ratio of neutrophils to macrophages may serve as a 
prognostic predictor of clinical outcomes in SCC. The gene expression profile of select CXCL 
neutrophil chemoattractants was found to be altered in SCC. An increase in IL-8 and CXCL1 
transcription was accompanied by a significant reduction in CXCL2. Yet, neither of these markers 
were associated with the increasing number of neutrophils, suggesting that the classic chemotactic 
factors may not be involved in TAN recruitment in SCC. In Adeno, CXCL2 transcription was also 
reduced, however the gene expression of IL-8, and CXCL1 was similar between Adeno and controls. 
Further evaluation detected a positive association between IL-8, CXCL1, CXCL2 transcription and 
increasing neutrophilic expression in Adeno. Another potential chemotactic factor driving TAN 
recruitment in Adeno is SAA. Consistent with other studies, we showed a marked elevation of 
circulating SAA in the NSCLC serum samples162, which was not associated with local expression. 
While SAA transcription within the Adeno tumour biopsies were not elevated, a positive association 
with increasing TAN infiltration as well as IL-8 was found. SAA can promote further neutrophil 
recruitment by inducing IL-8 secretion from neutrophils through FPR2/ALX receptor activation. In 
early stage NSCLC, tumour-specific expression of SAA was not detected in the lung resection tissue. 
Localisation of SAA was found primarily in the mucosal glands and alveolar macrophages, showing 
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more intense staining in SCC. In some cases, SAA was found in alveolar macrophages containing 
carbon pigment in patients who were either current or former smokers.  However, the role of SAA 
may be more prominent in later stages of disease as it has been implicated in promoting distant 
metastasis of primary tumours into the lung 163.  
Since classic CXCL chemokines did not associate with neutrophil abundance in SCC, we explored 
alternative pathways involved in the recruitment of neutrophils. Proteases regulating the 
degradation of the extracellular matrix (ECM) can generate matrikines that promote neutrophil 
recruitment. Matrix degrading enzymes, including the zinc dependent endopeptidases, MMPs and 
the transmembrane glycoproteins a disintegrin and metalloproteinase (ADAMS), promote effective 
cell migration during embryogenesis and wound healing 164. Their activity is inhibited in a timely 
manner by the tissue inhibitor enzymes (TIMPs) 165. An excess of proteases combined with a loss of 
TIMP expression has been observed in a number of pathological conditions including cancer because 
it can result in excessive ECM degradation that enable tumour cells to escape and metastasise into 
distant organs 166. Here, assessment of select MMPs and ADAMs implicated in tumour progression 
demonstrate that MMP-9 transcript levels was upregulated in early stage Adeno specimens with a 
trending increase in SCC. This was accompanied by a significant reduction in TIMP2 and TIMP3 
enzymes. Direct quantification of the ratio of MMP-9:TIMP3 was positively associated with 
increasing NMR in SCC alone. In Chapter 1, we established that TANs are a major source of MMP-9 
and therefore increased production of MMP-9 by TANs may promote further neutrophil recruitment 
by degrading ECM components such as collagen. This in turn can release matrikines including the 
elastin peptide (EP) and the N-acetyl-proline-glycine-proline (ac-PGP) that strongly promotes 
neutrophil migration 167. Further investigation is warranted to determine whether expression of EP 
and ac-PGP, are also upregulated in SCC and directly promote TAN recruitment. 
Another alternative factor that may be contributing to the neutrophil influx specifically in SCC is the 
High mobility group box 1 protein (HMGB1) released during necrosis. Abundant in the cell nucleus, 
the primary role of HMGB1 is to stabilise nucleosomes as well as facilitate transcription factor 
binding and DNA repair processes 168. However, HMGB1 may be inappropriately released by necrotic 
cells into the extracellular environment. On release, HMGB1 has been shown to act as a damage-
associated molecular pattern (DAMP) molecule where it can trigger the innate immune response 
through TLR and RAGE activation. An in vivo study demonstrated that the activation of the 
HMGB1/RAGE axis resulted in a 7-fold increase in neutrophilic inflammation following tissue injury 
which was attenuated in Hmgb1-deleted mice 169. Macrophage infiltration was unaffected by the 
loss in HMGB1. In our study, during the qualitative assessment of SAA immunostained biopsy 
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specimens, the blinded pathologist observed necrotic areas in a greater number of SCC specimens 
(7/40) compared to Adeno specimens (3/50). A limitation of the study was that the necrotic areas 
were not further assessed due to time constraints. Future studies are needed to quantitatively 
assess the necrotic tissue and evaluate HMGB1 gene expression by RTqPCR and protein levels by 
ELISA on the biopsy lysate. This will provide insight as to whether there is increased HGMB1 
expression in the SCC cohort and whether this correlates better with neutrophil influx specifically in 
SCC. 
There is increasing evidence that TAN infiltration during early stages of cancer is beneficial. 
Increased infiltration of ROS-producing neutrophils in early stage hepatocellular carcinoma 
dampened the production of the pro-tumourigenic IL-17-secreting γδ T cells 170. In our study, survival 
analysis identified that patients with a greater proportion of TANs relative to TAMs (NMRhigh) in SCC 
alone were associated with a more favourable clinical outcome following surgical resection. The 
relationship between TANs and TAMs in the tumour environment is not well understood and one of 
the limitations of our study is that we have not yet characterised the phenotype of the TANs and 
TAMs in the NMRhigh and NMRlow groups to determine whether these leukocyte infiltrates are 
polarised towards a pro- or anti-tumourigenic state. The expression of CSF1 however, may provide a 
possible link. Production of CSF1 by various cell types including epithelial and stromal cells plays an 
important role in the regulation of macrophage populations. Activation of its tyrosine kinase 
receptor (CSF1-R) by CSF1 can contribute to macrophage proliferation, recruitment and polarisation 
towards an M2 immunosuppressive phenotype 171. It has been shown that overexpression of CSF1 in 
a murine model of mammary cancer was closely associated with increased TAM density and 
accelerated disease progression 172. However, in our study we found a negative association between 
CSF1 transcription and increasing NMR which was not directly associated with neutrophils or 
macrophages alone. Further studies are needed to determine whether CSF1 is a contributing factor 
of increased M2-type macrophages in the NMRlow group or whether it is a secondary consequence of 
the low tumour burden potentially present in the NMRhigh group.  
Another important factor that can influence the immune cell landscape is tobacco smoke exposure. 
In our SCC cohort, 39/40 patients had a history of smoking. Consistent with previous studies, our 
univariate Cox regression analysis identified smoking status (current vs former) and increasing 
pathological stage as important predictors of survival in SCC. Additionally, multivariate analysis 
demonstrated an interaction between NMR and smoking. NMRlow patients that were current 
smokers at the time of surgery were associated with the greatest increase risk in death. In our biopsy 
cohort, pack year data was available but incomplete in a small proportion of patients. One of the 
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limitations of our study was the lack of non-smokers and current/former smokers with <30 pack 
years to be able to accurately assess the effect of cumulative smoke exposure on overall survival. 
Previous studies have identified smoking as an independent prognostic factor associated with poorer 
overall survival in NSCLC. Smoking status (current >15pack years, former/current <15pack years, 
never smokers <100 cig/day) was evaluated in large cohort (n=2010) of NSCLC patients with stage 
III/IV exclusively 173. It was shown that increasing pack years was associated with decreased overall 
survival in patients with advanced disease. Moreover, the effect of continued smoking may itself 
promote tumour progression due to stimulating a chronic inflammatory response that can support 
tumour growth and increasing the genetic heterogeneity of the tumour. In our study, it was unclear 
whether continued smoking promotes tumour recurrence because the proportion of patients that 
died from Lung cancer or secondary cancers were similar in the low and high NMR groups. A 
systematic review of predominately early stage lung cancer patients found that continued smoking 
following diagnosis was associated with an increase risk in all-cause mortality and recurrence 174. 
While the mechanism has not been fully established, smoking cessation is critical in improving 
survival outcomes and reducing the risk of secondary illness and death.    
Smoking may also alter the phenotype of neutrophils within the tumour nest in the NMRlow group. It 
has been previously shown that prolonged cigarette smoke exposure induced necrosis of human 
neutrophils isolated from the peripheral blood 175.  In addition, the increased TAM infiltration in the 
NMRlow group may be skewed towards an M2 pro-tumourigenic phenotype as a result of continued 
smoking. In depth gene expression analysis of alveolar macrophages derived from healthy smokers 
and non-smokers found a downregulation of M1-related genes such as CXCL11 and CXCL9 and an 
upregulation of M2-related genes including MMP-2 and MMP-7 in healthy smokers 176. Neutrophils 
and macrophages dominate the immune composition in NSCLC 60 and therefore understanding their 
role at different stages of the disease could provide alternative strategies to improving progression-
free survival post-surgery. The idea that increased TAN infiltration may be protective in early stages 
of the disease is gaining recognition. Patients with stage II colorectal cancer, expressing h levels of 
TANs above the median count, were associated with a 3-fold benefit in overall survival 177. However, 
it is not well characterised whether the increased TAN and TAM density improves or worsens overall 
survival in NSCLC178, 179. Our findings identify a distinct role for TANs dictated by tumour type and 
stage. 
In summary, we have identified that the relationship between TANs and TAMS is an important 
prognostic predictor of overall survival in early stage SCC. TAN infiltration in combination with a 
reduction in TAMs may have a protective effect against tumour progression, however the underlying 
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mechanisms need to be further elucidated. NMR as a prognostic tool for Adeno was not found 
possibly due to the low number of patients in the Adeno NMRhigh group under the current threshold. 
Further investigation in a larger cohort of Adeno patients may be needed. Moreover, we have 
demonstrated that the chemokine landscape is altered in NSCLC and varies between tumour 
subtypes, indicative that alternative pathways are involved in TAN infiltration in Adeno and SCC. In 
our study, we evaluated only a select number of chemokines that are classically involved in 
neutrophil recruitment and that are associated with increased neutrophilic inflammation in COPD. 
Future studies could utilise the 96-well TaqMan™ Array Human Chemokines plate (Thermo Fisher) 
which would enable an in-depth RTqPCR expression analysis of 96 genes including receptors, 
corresponding ligands and related genes from the four classes of chemokines, CC, CXC, C, and CX3C. 
This includes assessment of CXC3CL1 and its receptor which has been shown to be associated with 
poorer prognosis in lung adenocarcinoma 180. 
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Chapter 6 – General Discussion 
Lung cancer continues to be a major global health burden as it contributes to the largest proportion 
of all cancer-related deaths. Accurate classification of the tumour stage and subtype during 
pathological assessment remains critical in guiding clinical management of the disease, as survival of 
up to 90% may be achieved in patients diagnosed with early stage I-II NSCLC 6. LDCT screening of 
high-risk individuals is showing some promise in improving early detection and reducing mortality 
rates 21. Yet, the rate of false positive nodule detection is high with CT screening and a definitive 
diagnosis can only be reached following the retrieval of resection tissue, small biopsies and/or 
cytology specimens for a tissue-based assessment. Minimally invasive EBUS Bronchoscopy is 
becoming the preferred method for tissue sampling and when combined with  rapid onsite 
evaluation (ROSE), has significantly improved the diagnostic accuracy of both central and peripheral 
pulmonary lesions 29. Nevertheless, following the initial evaluation, diagnosis may be inconclusive for 
approximately 25% of patients, resulting in further invasive tests.  
 MMP-9:TIMP3 ratio is a diagnostic molecular marker in NSCLC. 
In this thesis, we explored shared components of the underlying chronic inflammation in lung cancer 
and COPD. As a result, we identified novel inflammatory biomarkers with the potential to improve 
diagnostic accuracy of EBUS bronchial brushings. Neutrophilic inflammation dominates the immune 
environment in COPD and is associated with the release of neutrophil elastase and the matrix 
degrading enzyme MMP-9 that contribute to deleterious airway remodelling 75. In addition, PTEN is 
commonly downregulated in the airway epithelium of COPD patients as a result of chronic smoke 
exposure 181. This in turn can lead to enhanced activation of the PIK3/AKT/mTOR pathway involved 
in cell proliferation and survival.  Increased MMP-9 expression and loss of the tumour suppressor 
gene PTEN is associated with poorer prognosis in lung cancer 182, 183. In chapter 2, we assessed MMP-
9 and PTEN transcription in FFPE lung tissue specimens derived from a small cohort of lung cancer 
patients with concurrent COPD. We detected increased MMP-9 transcript levels and reduced PTEN 
transcript levels in malignant tissue relative to the matched tumour-free specimens. Tumour-
associated neutrophils and the transformed epithelium were identified as two important sources of 
elevated MMP-9 expression. Using siRNA knockdown of PTEN in the bronchial epithelial cell line 
BEAS-2B cells, we demonstrated that the loss of PTEN can contribute to the steroid resistant 
increase in MMP-9 transcript levels within the chronic inflammatory environment.  
While MMP-9 as a therapeutic target has failed in numerous clinical trials 56, the diagnostic potential 
of MMP-9 transcription had not yet been fully explored in lung cancer. In Chapter 3, using a larger 
biopsy cohort, we showed that gene expression of various proteases and their natural TIMP 
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inhibitors were altered. In particular, MMP-9 transcript levels was consistently upregulated in 
patients with NSCLC, irrespective of subtype, as well as in the matched malignant specimens. 
Evaluation of the ratio of MMP9:TIMP3 transcript outperformed MMP-9 or TIMP-3 alone in 
discriminating tumour biopsy and EBUS brushing specimens with improved sensitivity and specificity. 
The potential clinical utility of the MMP-9:TIMP3 ratio to confirm diagnosis during the initial 
evaluation was demonstrated in a case study. Preliminary pathological assessment of EBUS-derived 
cytology specimens confirmed that the suspect lung lesion was benign. However, molecular analysis 
of the MMP-9:TIMP3 ratio detected a 311-fold increase suggesting malignant disease, which was 
confirmed 9 months later following pathological assessment of an additional EBUS specimen. 
Therefore, complementary molecular testing of the MM-9:TIMP3 ratio with initial pathological 
assessment may improve diagnosis of difficult cases within a shorter time frame and reduce the 
need for additional testing. 
There are several treatment options available for patients with early stage NSCLC. Complete surgical 
resection of the primary tumour is considered to be the optimal treatment, with curative potential  
184. Radiotherapy is an alternative approach for the treatment of localised disease, particularly for 
those cases which are unsuitable for surgical resection. Compared to standard radiation, Stereotactic 
body radiation therapy can deliver higher doses of radiation with precision leading to greater local 
control of the tumour 185.  However, due to a lack of early signs and symptoms, most patients still 
present with advanced metastatic NSCLC. Historically, treatment options for this population have 
been restricted to chemotherapy with limited effectiveness. In the past decade, the development of 
targeted therapies has proven to be more effective than chemotherapy alone, in a subset of Adeno 
patients harbouring distinct genetic alterations or driver mutations 186. Identifying suitable 
candidates for targeted therapies relies on mutational testing of biopsy material. For patients 
deemed inoperable, EBUS derived cytology specimens, without supplementary biopsy material, may 
be the only specimens available for pathological assessment and molecular testing.  
Formalin fixed preparations of EBUS-derived specimens can provide adequate tissue for both 
pathology and mutational profiling, however fixed tissue is not always optimal for mutation testing. 
It was previously shown that molecular testing could not be performed in cytology and biopsy 
specimens prepared for pathological assessment in up to 35% of Adeno patients 187. Formalin itself 
causes significant fragmentation to the nucleic acids, therefore reducing the amount of high-quality 
intact RNA and amplifiable DNA available for RTqPCR and targeted Next Generation Sequencing 188. 
Fragmentated DNA can lead to sequencing artefacts that may be equivalent to clinically relevant 
variants. It has previously been shown that EBUS derived waste brush tips preserved in TRI reagent 
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without formalin provided sufficient RNA for EGFR genotyping by RTqPCR 189. A comparison of the 
EGFR variants detected in the EBUS brushings verses matched FFPE biopsy and surgical specimens 
demonstrated 88.7% concordance.  The detection of actionable mutations in EGFR, ALK, ROS1 and 
BRAF by stand-alone assays is currently the minimum requirement for mutational profiling of Adeno 
patients. As more targeted therapies emerge from clinical development, the number of genes to 
assess in cytology and small biopsy specimens will increase.  
To address this issue, we developed an alternative approach for the preservation of a single-pass 
EBUS bronchial brushing without formalin, as described in Chapter 3. Following ROSE evaluation, an 
additional single pass EBUS bronchial brushing was collected in RLT lysis buffer. With the integrity of 
the nucleic acids adequately preserved, both RNA and DNA were simultaneously extracted. In 
particular, each malignant specimen generated a median yield of 1.9 g of DNA, well-above the 
minimum requirement of 10ng for targeted sequencing using the Illumina platform. This approach 
identified clinically relevant variants in EGFR, KRAS and MET that may have the potential to guide 
treatment-based decisions. In addition, we demonstrated high concordance between sequencing 
platforms using the Thermofisher Ion Ampliseq panel for confirmatory analysis. A strength of this 
study is that a single EBUS brushing collected in RLT lysis buffer can provide ample high-quality RNA 
and DNA for large scale gene expression analysis and may also be suitable for alternative sequencing 
panels used to assess tumour mutational burden and microsatellite instability. This is particularly 
important in understanding the underlying mechanisms of SCC. Predominantly smokers, SCC is 
associated with a higher mutational load and therefore there are currently no targeted therapies 
available for this tumour subtype 190. Utilising the AllPrep DNA/RNA/Protein Mini Kit, future studies 
could involve a more in-depth gene and protein analysis of EBUS specimens, which may help identify 
novel therapeutic targets in SCC.  
Whether this approach can be applied to other EBUS-directed specimens, including EBUS-
transbronchial needle aspiration (TBNA), has not yet been validated. Sampling by EBUS-TBNA may 
be prioritised over brushings, BAL and forceps biopsies because it enables access to mediastinal 
lymph nodes 191. In patients with advanced disease, it is imperative to assess the status of 
mediastinal lymph nodes to determine the presence of distant metastasis 192. It has also been 
highlighted that EBUS-TBNA may achieve a higher diagnostic yield due to its ability to extract a 
higher proportion of tumour cells. A previous study has demonstrated the utility of a single pass 
EBUS-TBNA to provide sufficient DNA for mutational analysis of EGFR, KRAS, NRAS, BRAF and PIK3CA 
193. A single pass was defined as distinct entry and exit of the needle into the target lesion with 10 
needle excursions per pass. With each specimen snap-frozen in dry ice and stored at -20°C, a mean 
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DNA yield of 4µg was obtained, well over the threshold for multi-panel sequencing. The variants 
detected in the single pass EBUS-TBNA for each case were 100% concordant to the variants detected 
in the matched FFPE reference samples comprised of 3 TBNA passes. Integration of EBUS-TBNA into 
our workflow may advance its utility for both multiplex sequencing and molecular profiling of 
diagnostic biomarkers.  
 An alternative assay for quantifying PDL1 levels in NSCLC. 
Diagnostic evaluation and mutational testing can also exhaust the amount of tissue available for PD-
L1 assessment. PD-1 immunotherapies are improving progression-free survival in 20% of NSCLC 
patients 51, 194. IHC analysis of PD-L1 tumour expression has been integrated into routine practice to 
determine suitable candidates for immunotherapies as first and second line treatment. However, 
recent evidence has shown that clinical responses may still occur in a subset of patients classified as 
PD-L1 negative, suggesting that PD-L1 IHC biomarker analysis may be suboptimal in predicting 
response. A contributing factor is the lack of standardised assays and IHC thresholds used to 
determine PD-L1 status 195. For each FDA approved inhibitor, PD-L1 status has been validated using 
different antibody clones. Comparison of the four major PD-L1 antibody clones 22C3, 28-8, SP236 
and SP142 used to determine response to nivolumab, pembrolizumab, atezolizumab and 
durvalumab have demonstrated variability in tumour and immune cells staining and therefore 
should not be used interchangeably 196. Furthermore, IHC analysis of PD-L1 is subject to 
interobserver variability and must be performed by an experienced pathologist. In Chapter 3, we 
aimed to address these limitations and standardise PD-L1 assessment by utilising RTqPCR for PD-L1 
transcript. We demonstrated high concordance between PD-L1 transcription and PD-L1 IHC scoring 
of SCC biopsy specimens. Furthermore, PD-L1 transcription showed high sensitivity and specificity in 
discriminating PD-L1 tumour scores above and below the current clinical thresholds (>1% and >50%).  
In Chapter 4, we further refined our workflow by incorporating multiplex ddPCR for simultaneous 
assessment of MMP-9, TIMP3 and PD-L1 transcription. A comparison between RTqPCR and ddPCR 
platforms demonstrated high concordance of the MMP-9:TIMP3 ratio in confirming malignancy. 
Direct quantification also enabled us to establish new thresholds without normalising to house-
keeping genes and control specimens. These thresholds may have the potential to distinguish 
malignant from disease control EBUS-derived specimens with high accuracy and may be used in 
conjunction with pathological assessment. Our study has highlighted the ease of integrating ddPCR 
into clinical practise for rapid gene expression analysis at low cost. A limitation of the study is that 
we have not yet assessed the applicability of using these defined MMP-9:TIMP3 and PDL1:TIMP3 
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ratios in a blinded prospective cohort and whether gene expression analysis can reduce the false 
negative rate following the initial pathological evaluation. Further validation in a larger EBUS cohort 
is warranted to determine whether these same thresholds can be applied to all EBUS-directed 
specimens including bronchial brushings and/or TBNA specimens collected in RLT lysis buffer. 
Evaluating the MMP-9:TIMP3 gene ratio in a single EBUS-TBNA specimen may be a useful alternative 
during the initial evaluation if bronchial brushings cannot be obtained. In addition, we showed for 
the first time that the ratio of PD-L1:TIMP3 transcript may be an alternative approach for the 
assessment of PD-L1 status. More importantly, Tumour Mutation Burden (TMB) is emerging as a 
potential biomarker predictive of response to immunotherapies and may outperform PD-L1 IHC 
assessment. In a recent study, patients classified has having high TMB, (>10 mutations per 
megabase) showed significant improvements in progression-free survival in response to 
Nivolumab/ipilimumab combination therapy compared to the chemotherapy arm 197. With the 
release of tests such as the Oncomine Tumor Mutation Load Sequencing Assay (ThermoFisher), 
future studies are warranted to compare the clinical utility of TMB against PD-L1 IHC and PD-L1 
transcript determination by ddPCR in a single EBUS-directed specimen. Such a study would be 
focused on evaluating the performance of each biomarker in predicting response to currently 
available immunotherapies.  
For a large proportion of advanced NSCLC patients, without actionable mutations and positive PD-L1 
status, chemotherapy remains the only option, which highlights the need for developing new 
therapies. Inhaled corticosteroids can modulate inflammatory processes and are used to treat COPD 
patients with a history of frequent exacerbations. Moreover, inhaled corticosteroid use in patients 
with COPD was associated with a reduced risk of lung cancer 198. Daily treatment for a minimum of 5 
years with aspirin, a non-steroidal anti-inflammatory that modulates the COX-2 pathway, 
significantly reduced the risk of developing lung Adeno only 199. Current immunotherapies are 
improving progression-free survival by boosting the natural cytotoxic T cell response for tumour 
killing. Harnessing the protective actions of other inflammatory cells may also help improve survival 
in different subsets of patients. Aside from T cells, neutrophils also dominate the immune 
composition in NSCLC 60.  
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Figure: 6.2.1 Our new workflow for integrating advanced molecular testing of a single EBUS-
directed specimen into current clinical practises 
This flow chart demonstrates the capacity of a single EBUS-derived specimen for molecular testing and its 
integration into current clinical practise. Following ROSE evaluation, an additional single-pass EBUS bronchial 
brushing is immediately preserved in RLT lysis buffer for advanced molecular testing. Within a shorter time, 
sufficient amounts of high quality RNA and DNA can be extracted from the single EBUS specimen. Triplex 
ddPCR is performed using the isolated RNA to assess the MMP-9:TIMP3 ratio. Values above the current 
threshold (> 0.028) have demonstrated high sensitivity and specificity for distinguishing malignant 
specimens. This may complement histology by confirming malignant disease in patients falsely identified as 
pathologically negative. Simultaneous assessment of PD-L1 status by triplex ddPCR may have the potential 
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to identify lung cancer patients most likely to benefit from PD-L1 inhibitors. Furthermore, there is sufficient 
DNA remaining for multi-panel mutational profiling of pathologically confirmed Adeno patients that would 
benefit the most from currently available targeted therapies. In this way, advanced molecular profiling of a 
single EBUS specimen may improve diagnostic accuracy and help guide precise therapeutic management of 
the disease more quickly. Image adapted28, 200 
 
 The NMR is a novel biomarker for SCC prognosis. 
In chapter 5, we demonstrated a significant increase in tumour associated neutrophils (TANs) in 
early stage NSCLC patient biopsies. Particularly, in SCC patients, TANs were disproportionately 
increased relative to tumour-associated macrophages (TAMs) in a subset of patients. The role of 
TANs in promoting or suppressing tumour development is not well characterised in NSCLC, however 
there is evidence to suggest that the initial recruitment of neutrophils may be beneficial for the 
expansion of cytotoxic T cells 64. In order to investigate why neutrophils were more dominant in the 
SCC setting, we evaluated a panel of chemokines and cytokines to determine which factors are 
influencing the substantial recruitment of TANs in NSCLC. We showed that chemokine and cytokine 
expression was significantly altered between tumour subtypes and that the classic chemotactic 
factors including IL-8, CXCL1 and CXCL2 were strongly associated with TAN recruitment specifically in 
Adeno.  
In contrast, TANs were not associated with classic CXCL neutrophil chemokines in SCC. Rather, we 
propose that neutrophil recruitment may be driven by matrikines generated by the activity of 
increased MMP-9 expression, as neutrophil density in SCC biopsies was positively associated with 
the MMP9:TIMP3 ratio. Excess MMP9 activity is known to degrade extracellular matrix proteins such 
as collagen in COPD and this can result in the release of matrikines (eg. PGP), which are potent 
neutrophil chemokines 167. We propose that collagen breakdown products such as PGP are driving 
increased neutrophil trafficking in SCC, however this has not yet been addressed in this study. 
Further investigation is needed to determine the levels of collagenase activity in the SCC cohort. 
Alternatively, the increased presence of necrosis in SCC may be contributing to extracellular HMGB1 
expression, which in turn may be contributing to the increased neutrophilic inflammation. NSCLC 
patients with elevated HMGB1 gene expression have been shown to be associated with poorer 
prognosis 201. Furthermore, it has been shown that HMGB1 overexpression in two NSCLC cell lines 
was associated with enhanced tumour invasiveness and can induce MMP-9 gene expression through 
the PI3K/Akt and NF-κB signaling pathways. Future studies are needed to determine whether 
HMGB1 is increased in our biopsy cohort, is a useful prognostic predictor and is positively associated 
with the neutrophilic influx in SCC. Additionally, for the first time we demonstrated that high 
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neutrophil-to-macrophage ratio (NMR) may be associated with a better prognosis following surgical 
resection, specifically in SCC patients. The non-invasive assessment of the neutrophil-to-lymphocyte 
ratio the peripheral blood of NSCLC patients has previously been associated with poorer prognosis 
145. 
 It is not known whether assessment of the neutrophil-to-monocyte ratio in the peripheral blood of 
patients undergoing EBUS can be used as an alternative approach to identify the NMRhigh and NMRlow 
SCC subgroups. A limitation of our study is that we have not yet identified the neutrophil phenotype 
in each tumour subtype. This may provide insight as to whether the survival advantage of the 
NMRhigh group is associated with neutrophils eliciting an anti-tumoural effect. Further studies, 
involving immunohistochemical markers and cell culture assays to characterise the phenotype and 
function of TANs in early stage NSCLC are needed. Harnessing the protective effects of TANs may 
identify novel immunotherapies for patients with advanced disease.   
In conclusion, molecular profiling of the chronic inflammatory environment in NSCLC revealed novel 
diagnostic and prognostic biomarkers. Previous studies have demonstrated MMP-9 as predictor of 
poorer prognosis in NSCLC. Our study identified an underlying link between NSCLC and COPD that 
TANs and the loss of PTEN are contributing factors for increased MMP-9 expression. For the first 
time, our study identified the diagnostic potential of the MMP-9:TIMP3 ratio. Using a select 
threshold, gene expression analysis of MMP-9:TIMP3 in a single EBUS bronchial brushing via ddPCR 
may improve diagnostic accuracy in conjunction with pathological assessment. Additionally, we were 
able to simultaneously assess PD-L1 gene expression, which was highly concordant with PD-L1 
tumour scoring. Similarly, assessment of PD-L1;TIMP3 expression by ddPCR offers an alternative and 
rapid approach in determining suitable patients for immunotherapies. Immunohistochemical 
staining of the major immune cell types, neutrophils and macrophages that dominate the lung 
tumour environment, identified distinct genetic signatures between the two main histological 
subtypes, Adeno and SCC. Our study identified NMR as a novel prognostic predictor, which showed 
that a high NMR in post-operative early stage SCC patients were associated with better overall 
survival.  Future studies are warranted to understand the factors influencing neutrophil influx and 
establish the mechanism by which high NMR is beneficial in early stage SCC.
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